Infected Biomaterials by Matl, Florian


Dissertation 
zur Erlangung des Doktorgrades der Fakultät für 
Chemie und Pharmazie der Ludwig-Maximilians-Universität 
München 
 
 
 
Infected Biomaterials 
New Strategies For Local Anti-Infective Treatment 
 
 
 
 
 
 
 
Florian Matl 
aus München 
2008 
 
Bibliografische Information er Deutschen ibliothek 
Die Deutsche ibliothek verzeichnet diese Publikation in der Deutschen 
Nationalbibliografie; detaillierte bibliografische Daten sind im Internet über 
http://dnb.ddb.de abrufbar. 
 
 
  
 
 
 
 
     Nonnenstieg 8, 37075 Göttingen 
      Telefon: 0551-54724-0 
      Telefax: 0551-54724-21 
      www.cuvillier.de 
 
Alle Rechte vorbehalten. Ohne ausdrückliche Genehmigung  
des Verlages ist es nicht gestattet, das Buch oder Teile 
daraus auf fotomechanischem Weg (Fotokopie, Mikrokopie) 
zu vervielfältigen. 
Gedruckt auf säurefreiem Papier 
 
1. Auflage, 200  
  CUVILLIER VERLAG, Göttingen 2009 
1. Aufl. - Göttingen : Cuvillier, 2009 
Zugl.: , Univ., Diss., 2008
978-3-86727-871-3
978-3-86727-871-3
d Nationalb
Nationalb
9
Erklärung 
 Diese Dissertation wurde im Sinne von § 13 Abs. 4 der Promotionsordnung vom 29. Januar 
1998 von Herrn Prof. Dr. Dr. Axel Stemberger vom Institut für Experimentelle Onkologie 
betreut und von Herrn Prof. Dr. Wolfgang Frieß von der Fakultät für Chemie und Pharmazie 
vertreten.  
 
 
 
 
Ehrenwörtliche Versicherung  
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
  
München, am 25.07.08  
 
 
 
 
 
 
Dissertation eingereicht am 25.07.08 
1. Gutachter: Prof. Dr. Dr. A. Stemberger 
2. Gutachter: Prof. Dr. W. Frieß 
Mündliche Prüfung am: 29.09.08 
 München
Acknowledgements 
 
 
The presented thesis was written at the Institute of Medical Engineering at the Technical 
University of Munich and at the Department of Pharmacy, Pharmaceutical Technology and 
Biopharmaceutics at the Ludwig-Maximilians-University in Munich under supervision of 
Prof. Dr. Dr. Axel Stemberger and Prof. Dr. Wolfgang Friess. 
 
First of all I want to express my gratefulness to Prof. Dr. Dr. Axel W. Stemberger for the 
possibility to be part of his research group and especially for his scientific guidance, 
professional input and fruitful discussions throughout my work. I very much appreciate that 
he offered me the opportunity to stay in Texas for a scientific project for three months and to 
take part in many conferences throughout Europe. Thank you for the fantastic working 
climate that made it a pleasure to be part of your group.  
 
My special thanks go to Prof. Dr. Wolfgang Friess, who guided me through the 
pharmaceutical part of my work with great engagement and supported me whenever questions 
came up. Thank you for giving me the possibility to be part of your group and to write my 
thesis at the Pharmaceutical Department at the Ludwig-Maximilians University Munich. It 
has been a pleasure to work with you.   
 
I want to thank Prof. Dr. Gross from the University of North Texas, USA for the outstanding 
time in Denton, the tremendous support he gave me personally as well as professionally. It 
was a great time for me – thank you very much. 
 
Many thanks to Prof. Dr. Gerhard Winter for his enthusiastic and dedicated leadership of the 
chair of Pharmaceutical Technology and Biopharmaceutics.  
 
Special thanks go to my colleague Dipl.-Ing. Andreas Obermeier who shared most of the time 
here at the IMETUM with me. Without his active support in setting up the experimental 
constructions as well as organizing and planning things, this work would not have been 
possible. Thanks for our fruitful and personal discussions and the fantastic working climate. 
 
Many thanks to Katharina Seiffe, Julia Zlotnyk, Simone Repmann and Teissa Köhler who did 
a great job during their student time in our working group. It was a pleasure to work with you.  
Special thanks to Tobias Pirzer for his parents and great support in all questions concerning 
computer programs used for this thesis. 
 
Thanks to Tiffany Kinney for reviewing parts of my thesis and Jochen Mayer for his 
cooperation in the neuroscience project.  
  
Thanks to Prof. Dr. Frank Böckler, Dr. Olga Mykhaylyk and Chemicell in Berlin for their 
advice and contributions to the magnetic drug targeting project. 
 
The microbiological investigations would not have been possible without the tremendous help 
of Ms V. Vatou, Institute for Medical Microbiology at the Klinikum rechts der Isar, Technical 
University, Munich – many thanks to you. 
 
Many thanks go to Dipl. Phys. W. Kraus and Dipl.-Ing. H. Stephan for their engagement, and 
the entire staff of the Neue Magnetodyn GmbH for their professional support and for 
providing the equipment. 
 
Special thanks to the entire staff of the Pharmaceutical Technology and Biopharmaceutics as 
well as my colleagues at the IMETUM especially Susanne Schnell-Witteczek and Ursula 
Hopfner for their professional support and the others for all the enjoyable dinners and night 
sessions we had. We had a wonderful time together. 
 
Furthermore I would like to thank the ITEM GmbH for the providing of laboratory space for 
carrying out the series of bacteriological experiments and, in particular, Mr J. Hintermeier for 
his very kind support. 
 
My aunt Dr. Ingrid Hofmann and my uncle Dr. Hans Hofmann for their support at the 
beginning of this thesis. Thank you very much. 
 
My parents, my sister Saskia and my brother Mark and Corinna, I want to thank you all for 
the support and the encouragement you gave me in all the years.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For mom and dad 
 
 
 
 
 
 
 
 

List of Abbreviations  
 
a.c.   Alternating current 
AHL   Acylated Homoserine Lactone 
ATCC®  American Type Culture Collection 
cfu   Colony-forming units 
CP   Chlorhexidine dipalmitate  
CL   Chlorhexidine dilaurate 
d.c.   Direct current 
DG   Diglyceride 
EF   Electric field 
EMF   Electro-magnetic field 
EMF+ ind. EF  Electro-magnetic field with additional a.c. electrical field 
ePTFE   Expanded PTFE 
ICR   Ion-Cyclotron-Resonance 
MIC   Minimal inhibitory concentration  
MRSA   Methicillin-resistant Staphylococcus aureus 
OH   Octenidine hydrochloride 
PDLLA  Poly(D,L)lactide 
PET   Polyethyleneterephtalate 
PTFE   Polytetrafluoroethylene 
RIP   RNA III Inhibiting Peptide 
TA   Tocopherole acetate 
TG   Triglyceride 
TRAP   Target of RNA III-Activating Peptide 
USPIO  Ultra-small superparamagnetic iron oxide 

Introduction and Objectives of the Thesis 
Table of Contents 
 
Chapter 1 
 
Introduction and Objectives of the Thesis 
 
1 INTRODUCTION ....................................................................................................................................... 2 
2 BIOMATERIALS........................................................................................................................................ 3 
2.1 VASCULAR GRAFTS ............................................................................................................................... 3 
2.2 SUTURES ............................................................................................................................................... 6 
3 INFECTIONS............................................................................................................................................... 7 
3.1 POST-OPERATIVE INFECTIONS ............................................................................................................... 8 
3.2 POST-OPERATIVE INFECTIONS IN VASCULAR SURGERY.......................................................................... 8 
3.2.1 Pathogenesis of post-operative infections after vascular reconstructive interventions................... 9 
3.2.2 Time point of vascular graft infections .......................................................................................... 10 
3.2.3 Localisation of vascular graft infections ....................................................................................... 10 
3.2.4 Infection risk of different grafts ..................................................................................................... 11 
3.2.5 Diagnosis of infectious complications after vascular reconstructive    interventions.................... 11 
3.2.6 Bacteriology of septic complications in vascular grafts................................................................ 12 
3.2.7 Sutures in infected areas................................................................................................................ 12 
3.3 NEURONAL INFECTIONS ...................................................................................................................... 13 
3.4 MEDICAL DEVICE INFECTIONS ............................................................................................................. 13 
3.5 BIOFILMS ............................................................................................................................................ 14 
3.5.1 Bacterial adhesion to surfaces....................................................................................................... 14 
3.5.2 Biofilm formation........................................................................................................................... 15 
3.5.3 Strategies of biofilm prevention..................................................................................................... 16 
3.6 THERAPEUTIC METHODS ..................................................................................................................... 17 
3.6.1 New tactics in surgery and local wound management................................................................... 17 
3.6.2 Antiseptics in wound care.............................................................................................................. 18 
3.6.3 Antibiotics in wound care .............................................................................................................. 18 
3.6.4 Prosthesis explantation.................................................................................................................. 19 
3.7 IMPLANTS AS DRUG DELIVERY SYSTEMS ............................................................................................. 19 
3.8 BIOCOMPATIBILITY ............................................................................................................................. 20 
3.9 HAEMOCOMPATIBILITY ....................................................................................................................... 20 
3.10 NEW APPROACHES FOR PROTECTION OF BIOMATERIAL INFECTIONS .................................................... 21 
3.10.1 Electro-magnetic field influence ............................................................................................... 21 
3.10.2 Antimicrobial coatings.............................................................................................................. 23 
3.10.3 Magnetic drug targeting systems .............................................................................................. 23 
3.10.4 Neuronal networks.................................................................................................................... 24 
4 CONCLUSIONS ........................................................................................................................................ 27 
5 OBJECTIVES OF THE THESIS............................................................................................................. 28 
6 FIGURE CAPTIONS ................................................................................................................................ 30 
7 REFERENCES........................................................................................................................................... 31 
 
 
 
 
 
 
 
New anti-infective coatings of medical implants based on lipid-like drug carriers 
_________________________________________________________________________________________________________________ 
Chapter 2 
  
New anti-infective coatings of medical implants based on lipid-like drug 
carriers 
 
1 INTRODUCTION ..................................................................................................................................... 38 
2 MATERIALS AND METHODS.............................................................................................................. 39 
2.1 MEDICAL IMPLANT ............................................................................................................................. 39 
2.2 THE ANTI-INFECTIVE COATING............................................................................................................ 39 
2.2.1 Drug carriers ................................................................................................................................ 39 
2.2.2 PDLLA .......................................................................................................................................... 39 
2.2.3 Softisan® 649................................................................................................................................. 39 
2.2.4 Dynasan® 118................................................................................................................................ 40 
2.2.5 Tocopherol acetate........................................................................................................................ 40 
2.2.6 Antibiotics ..................................................................................................................................... 40 
2.3 COATING PROCESS .............................................................................................................................. 40 
2.4 PARTICLE SIZE .................................................................................................................................... 41 
2.5 MORPHOLOGICAL ANALYSIS-SEM ..................................................................................................... 41 
2.6 ANTIBIOTIC RELEASE.......................................................................................................................... 41 
2.7 TEST BACTERIUM................................................................................................................................ 42 
2.7.1 Growth curve................................................................................................................................. 42 
2.7.2 Antibacterial characteristics ......................................................................................................... 42 
2.7.3 Adhesion of viable bacteria and antimicrobial potency after 24 hours elution ............................ 43 
2.8 CELL CULTURE ................................................................................................................................... 43 
2.9 IN VITRO CYTOTOXICITY STUDIES ....................................................................................................... 43 
2.10 HAEMOCOMPATIBILITY STUDIES......................................................................................................... 44 
3 RESULTS................................................................................................................................................... 45 
3.1 MORPHOLOGICAL ANALYSIS............................................................................................................... 45 
3.2 ANTIBIOTIC RELEASE.......................................................................................................................... 45 
3.3 ANTIBACTERIAL CHARACTERISTICS.................................................................................................... 47 
3.3.1 Adhesion of viable bacteria and antimicrobial potency after 24 hours elution ............................ 48 
3.4 IN VITRO CYTOTOXICITY STUDIES ....................................................................................................... 49 
3.5 HAEMOCOMPATIBILITY STUDIES......................................................................................................... 50 
3.5.1 Monoclonal enzyme immunoassay for plasma F1+2 values............................................................ 50 
3.6 AMIDOLYTIC SUBSTRATE ASSAY FOR FACTOR XIIA-LIKE ACTIVITY ................................................... 50 
3.6.1 Thromboelastography ................................................................................................................... 50 
3.6.2 Complement C3a-desArg ELISA................................................................................................... 51 
4 DISCUSSION............................................................................................................................................. 51 
5 CONCLUSIONS........................................................................................................................................ 53 
6 ACKNOWLEDGEMENTS ...................................................................................................................... 53 
7 FIGURE AND TABLE CAPTIONS........................................................................................................ 54 
8 REFERENCES .......................................................................................................................................... 55 
 
 
Chapter 3 
 
New anti-infective coatings of surgical sutures based on a combination of 
antiseptics and fatty acids  
 
1 INTRODUCTION ..................................................................................................................................... 58 
2 MATERIALS AND METHODS.............................................................................................................. 58 
2.1 MEDICAL IMPLANT ............................................................................................................................. 58 
2.2 THE ANTI-INFECTIVE COATING............................................................................................................ 59 
2.3 MORPHOLOGICAL ANALYSIS-SEM ..................................................................................................... 59 
2.4 DRUG RELEASE ................................................................................................................................... 59 
2.5 TEST BACTERIUM................................................................................................................................ 60 
2.5.1 Antibacterial characteristics ......................................................................................................... 60 
2.5.2 Adhesion of viable bacteria and antimicrobial potency after 24 hours elution ............................ 60 
2.6 CELL CULTURE ................................................................................................................................... 61 
2.7 IN VITRO CYTOTOXICITY STUDIES ....................................................................................................... 61 
3 RESULTS................................................................................................................................................... 62 
3.1 MORPHOLOGICAL ANALYSIS............................................................................................................... 62 
3.2 DRUG RELEASE ................................................................................................................................... 62 
3.3 ANTIBACTERIAL CHARACTERISTICS.................................................................................................... 64 
3.4 ADHESION OF VIABLE BACTERIA AND ANTIMICROBIAL POTENCY AFTER 24 HOURS ELUTION.............. 65 
3.5 IN VITRO CYTOTOXICITY STUDIES ....................................................................................................... 66 
4 DISCUSSION............................................................................................................................................. 67 
5 CONCLUSIONS........................................................................................................................................ 69 
6 ACKNOWLEDGEMENTS ...................................................................................................................... 69 
7 FIGURE CAPTIONS................................................................................................................................ 70 
8 REFERENCES .......................................................................................................................................... 71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Growth inhibition of Staphylococcus aureus induced by low-frequency 
electric and electro-magnetic fields 
 
1 INTRODUCTION ..................................................................................................................................... 74 
2 MATERIALS AND METHODS.............................................................................................................. 75 
2.1 TEST BACTERIUM................................................................................................................................ 75 
2.2 GROWTH CURVE ................................................................................................................................. 75 
2.3 BACTERIA ON GEL-LIKE MEDIUM ........................................................................................................ 76 
2.4 BACTERIA IN FLUID MEDIUM............................................................................................................... 77 
2.5 SINUSOIDAL LOW-FREQUENCY ELECTRO-MAGNETIC FIELD................................................................. 78 
2.6 ELECTROMAGNETIC FIELD COMBINED WITH AN ADDITIONAL ELECTRIC ALTERNATING FIELD ............ 79 
2.7 SINUSOIDAL ELECTRIC ALTERNATING FIELD....................................................................................... 81 
2.8 DIRECT CURRENT ELECTRIC FIELD ...................................................................................................... 81 
2.9 CALCULATIONS AND STATISTICAL METHODS...................................................................................... 82 
3 RESULTS................................................................................................................................................... 83 
4 DISCUSSION............................................................................................................................................. 85 
5 CONCLUSIONS........................................................................................................................................ 89 
6 ACKNOWLEDGEMENTS ...................................................................................................................... 89 
7 FIGURE AND TABLE CAPTIONS........................................................................................................ 90 
8 REFERENCES .......................................................................................................................................... 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Augmentation of antibiotic efficacy by low-frequency electric and electro-
magnetic fields examining Staphylococcus aureus 
 
1 INTRODUCTION ..................................................................................................................................... 95 
2 MATERIALS AND METHODS.............................................................................................................. 95 
2.1 TEST BACTERIUM................................................................................................................................ 95 
2.2 GROWTH CURVE ................................................................................................................................. 95 
2.3 ANTIBIOTIC......................................................................................................................................... 96 
2.4 GENTAMICIN TEST CONCENTRATION................................................................................................... 96 
2.5 BACTERIA ON GEL-LIKE MEDIUM ........................................................................................................ 97 
2.6 BACTERIA IN FLUID MEDIUM............................................................................................................... 97 
2.7 SINUSOIDAL LOW-FREQUENCY ELECTRO-MAGNETIC FIELD................................................................. 98 
2.8 ELECTRO-MAGNETIC FIELD COMBINED WITH AN ADDITIONAL ELECTRIC ALTERNATING FIELD ......... 101 
2.9 SINUSOIDAL ELECTRIC ALTERNATING FIELD..................................................................................... 101 
2.10 DIRECT CURRENT FIELD.................................................................................................................... 102 
2.11 CALCULATIONS AND STATISTICAL METHODS.................................................................................... 103 
3 RESULTS................................................................................................................................................. 103 
3.1 BACTERIA ON GEL-LIKE MEDIUM ...................................................................................................... 103 
3.2 BACTERIA IN FLUID MEDIUM............................................................................................................. 104 
3.2.1 Gentamicin test concentration..................................................................................................... 104 
3.2.2 Low - frequent electromagnetic field........................................................................................... 104 
3.2.3 Electro-magnetic field combined with an additional electric field.............................................. 107 
3.2.4 Sinusoidal alternating electric field ............................................................................................ 107 
3.2.5 Direct current field...................................................................................................................... 107 
4 DISCUSSION........................................................................................................................................... 107 
5 CONCLUSIONS...................................................................................................................................... 110 
6 ACKNOWLEDGEMENTS .................................................................................................................... 110 
7 FIGURE AND TABLE CAPTIONS...................................................................................................... 111 
8 REFERENCES ........................................................................................................................................ 113 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
Magnetic drug targeting for biomaterial infections  
 
CHAPTER 6 ...................................................................................................................................................... 115 
1 INTRODUCTION ................................................................................................................................... 116 
2 MATERIALS AND METHODS............................................................................................................ 117 
2.1 NANOPARTICLES............................................................................................................................... 117 
2.2 PARTICLE SIZE AND ZETA POTENTIAL ............................................................................................... 118 
2.3 DRUG LOADING................................................................................................................................. 118 
2.4 COATING TECHNOLOGY.................................................................................................................... 119 
2.5 ANTIBACTERIAL CHARACTERISTICS.................................................................................................. 120 
2.5.1 Test bacterium............................................................................................................................. 120 
2.5.2 Calibration curve ........................................................................................................................ 120 
2.5.3 Antimicrobial potential ............................................................................................................... 120 
2.5.4 Pathologically relevant bacterial concentrations ....................................................................... 121 
2.5.5 Gentamicin efficacy..................................................................................................................... 121 
2.6 GENTAMICIN RELEASE FROM NANOPARTICLES ................................................................................. 121 
2.7 IN VITRO CYTOTXICITY STUDIES ....................................................................................................... 122 
2.7.1 Cell culture.................................................................................................................................. 122 
2.7.2 Ferrofluid toxicity ....................................................................................................................... 122 
2.7.3 Gentamicin toxicity ..................................................................................................................... 122 
2.8 CIRCULATORY EXPERIMENTS............................................................................................................ 123 
2.9 IRON CONTENT DETERMINATION....................................................................................................... 124 
3 RESULTS................................................................................................................................................. 125 
3.1 LOADING OF MAGNETIC NANOPARTICLES WITH GENTAMICIN ........................................................... 125 
3.2 ANTIBACTERIAL CHARACTERISTICS.................................................................................................. 126 
3.3 PERCENT SURFACE COVERAGE.......................................................................................................... 128 
3.4 IN VITRO CYTOTOXICITY STUDIES ..................................................................................................... 128 
3.5 CIRCULATORY EXPERIMENTS............................................................................................................ 130 
4 DISCUSSION........................................................................................................................................... 132 
5 CONCLUSIONS...................................................................................................................................... 135 
6 ACKNOWLEDGEMENTS .................................................................................................................... 135 
7 FIGURE AND TABLE CAPTIONS...................................................................................................... 136 
8 REFERENCES ........................................................................................................................................ 137 
 
 
 
 
 
 
 
Chapter 7 
 
Functional neurotoxicity of individual antibiotics investigated with 
mammalian neuronal networks grown on microelectrode neuroarray  
 
1 INTRODUCTION..................................................................................................................................... 141 
2 MATERIALS AND METHODS ............................................................................................................. 142 
2.1 COMPOUNDS ...................................................................................................................................... 142 
2.2 MICROELECTRODE ARRAYS (MEAS)................................................................................................. 142 
2.3 CELL CULTURE................................................................................................................................... 143 
2.4 EXPERIMENTAL SETUP ....................................................................................................................... 146 
2.4.1 Recording station.......................................................................................................................... 146 
2.4.2 Chamber Setup ............................................................................................................................. 146 
2.4.3 Data recording ............................................................................................................................. 148 
2.4.4 Data analysis ................................................................................................................................ 149 
2.4.5 Dose Response curves .................................................................................................................. 150 
2.5 EXPERIMENTAL DESIGN ..................................................................................................................... 150 
3 RESULTS .................................................................................................................................................. 151 
3.1 SUPPRESSION OF ACTION POTENTIAL PRODUCTION ............................................................................ 151 
3.1.1 Dose-response curves ................................................................................................................... 151 
3.1.2 IC50 Determination ....................................................................................................................... 152 
3.2 BURST PARAMETER............................................................................................................................ 156 
3.3 DROP OUT OF INDIVIDUAL CELLS ....................................................................................................... 158 
3.3.1 Bursting neurons........................................................................................................................... 158 
3.3.2 Active neurons .............................................................................................................................. 158 
3.3.3 Active neurons versus bursting neurons....................................................................................... 159 
4 DISCUSSION ............................................................................................................................................ 160 
5 CONCLUSIONS ....................................................................................................................................... 161 
6 ACKNOWLEDGEMENTS ..................................................................................................................... 162 
7 APPENDIX................................................................................................................................................ 163 
7.1 ACTIVITY PATTERN OF ANTIBIOTICS .................................................................................................. 163 
7.1.1 Penicillin G................................................................................................................................... 163 
7.1.2 Penicillin G/Streptomycin............................................................................................................. 165 
7.1.3 Streptomycin ................................................................................................................................. 166 
7.1.4 Gentamicin.................................................................................................................................... 168 
7.1.5 Vancomycin .................................................................................................................................. 169 
8 FIGURE AND TABLE CAPTIONS ....................................................................................................... 171 
9 REFERENCES.......................................................................................................................................... 174 
 
 
 
Chapter 8 
SUMMARY OF THE THESIS ......................................................................................................................... 175 

Chapter 1 
 
 
Introduction and Objectives of the Thesis 
 
Abstract 
In the general introduction the classification for medical applied biomaterials with the focus 
on vascular grafts and surgical sutures is discussed. The complex process of infection in 
particular post-operative infections, neuronal infections and medical device-associated 
infections are highlighted. Biofilm formation on the surface of biomaterials and the associated 
increase of antibiotic and host immune resistance is a challenge for patients and physicians. 
Graft explantation and the pre-, peri and postoperative administration of antibiotics and 
antiseptics is the common procedure for implant infection therapy. The utilization of devices 
as drug delivery systems is described. Furthermore biocompatible and haemocompatible 
requirements for devices are specified. Various new approaches for the prevention and on 
demand therapy of implant infections are presented in Chapter 1.   
 
Keywords: Biomaterials, vascular grafts, surgical sutures, biofilm, infection  
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1  Introduction 
 
In 1986 the European Society for Biomaterials, realizing that terms in this very interdisciplinary 
field of science are often being confused, organized a congress with the aim of harmonizing the 
terminology of “Definitions in Biomaterials”. According to these definitions, a prosthesis is a 
device that “replaces, in part or in whole, the function of one of the organs of the body”. An 
implant is named as “any medical device made from one or more materials that is intentionally 
placed within the body, either totally or partially buried beneath an epithelial surface”. A 
biomaterial is defined as a “non-viable material, used in a medical device, intended to interact 
with biological systems” (107). 
Biomaterials have accompanied human life since early civilizations. While the Mayan people 
used nacre teeth from sea shells in 600 A.D. (76), an iron dental implant four hundred years later 
was found in a corps dated 200 A.D. in Europe (22). Particular sutures were manufactured and 
applied for thousands of years (1).  
A reasonable chronological classification of modern biomaterials is the allocation into first-
generation, second-generation and third-generation biomaterials. The declared goal of all 
developed biomaterials of the first-generation during the 1960s and 1970s was to “achieve a 
suitable combination of physical properties to match those of the replaced tissue with a minimal 
toxic response in the host” (47). The requirements for the second-generation during the 1980s 
and 1990s shifted from a bioinert tissue response to “instead producing bioactive components 
that could elicit a controlled action and reaction in the physiological environment” (49). This 
new mindset to utilize the biomaterial rather than to hide it, opened up new vistas in the 
interaction of foreign material with the biological system of the host. The compositions of a great 
variety of bioactive glasses, ceramics or glass ceramics reached clinical use in the mid-1980s in 
orthopaedic and dental applications. Bioactive glasses (composed of Na2O-CaO-P2O5-SiO2) for 
instance were demonstrated to cause a sequence of 11 reaction steps in the creation of a strong 
bond between tissue and biomaterial surface finally resulting in a formation of new bone (46). 
The development of resorbable biomaterials with a defined chemical breakdown and resorption 
marked another progress in this second-generation of biomaterials. This innovation solves the 
interface problem, as the regenerating tissue replaces the foreign material and provides a basis 
for the application of controlled-release drug delivery systems. Biodegradable sutures consisting 
of a composition of polylactide and polyglycolic acid as well as resorbable screws or fracture 
plates became an important pillar in wound management and orthopaedic treatment (43). 
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However the irrevocable success of first and second generation biomaterials cannot hide the fact 
that the clinical application of bioinert, bioactive and resorbable biomaterials is connected with 
many problems. The endurance for instance of skeletal prostheses and artificial heart valves is 
limited to 10 to 25 years (50, 89, 109) and already small improvements of failure rates require an 
enormous financial and experimental effort (50). This limitation, based on the fact that synthetic 
materials, in contrast to living tissues, can never respond to changing physiological loads or 
biochemical stimuli, has directed the focus of interest toward a more biological solution for a 
new generation of biomaterials.  
The declared aim of third-generation biomaterials is the stimulation of specific cellular responses 
at the molecular level. The originally separately considered approaches of bioactive materials 
and resorbable materials have been combined and transferred to the cellular level. The 
inducement of cell proliferation, differentiation or gene activation in order to stimulate tissue 
regeneration is the target of third-generation resorbable materials such as polymers, alloys or 
bioactive glasses (48). Thereby two concepts are tracked, the tissue engineering and in situ tissue 
regeneration. For tissue engineering, biomaterial surfaces are modified outside the body with 
cellular networks imitating naturally occurring tissue and implanted into the patient. The 
scaffolds are resorbed and replaced by a fully functionalized host tissue.  
For in situ tissue regeneration, biomaterials are thought to release biological active drugs like for 
example growth factors to stimulate tissue regeneration inside the body.  
However coming along with innovations and new ideas in the field of biomaterials, it is obvious 
that only an effective cooperation between the different disciplines of science and a yielding 
dialogue between physicians, engineers and natural scientists will not only result in fruitful 
concepts but also in realizable products for future implants and will help patients to regain a 
better quality of life.   
 
2  Biomaterials 
 
2.1  Vascular grafts 
 
Biomaterials applied in the cardiovascular system, the so-called cardiovascular medical devices, 
play a key role in the life-saving treatment of patients. Particularly the enhancement of survival, 
besides an improvement of quality of life, makes them unique among all other medical devices. 
Cardiovascular medical devices include a broad spectrum of devices from heart valves, 
3
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pacemakers, implantable cardioverter-defibrillators, cardiac assist and replacement devices to the 
area of stents and vascular grafts.  
Reconstructive vascular surgery dates back to the nineteenth century when the first animal 
experiments were carried out testing different sewing techniques and vascular replacements 
using aluminium, silver, glass or Lucite® tubes (9, 62). These experiments paved the way for the 
first surgical intervention in a human being in 1897 by the american surgeon John B. Murphy 
who redissected a traumatized femoralis segment and reconstructed the vessel via a special 
sewing technique (9).  
In contemporary vascular surgery, the application of autogenous, allogenous, xenogenous or 
alloplastic vascular replacements is standard practice. The accidental observation of a 
pseudointima formation around a silk suture gave the impulse to develop vascular grafts out of 
alloplastic material (104). The requirement of biological indifference and porosity led to the 
invention of a pool of different biocompatible alloplastic grafts consisting of materials like 
Nylon®, Orlon®, Ivalon®, Marlex®, Teflon® and Dacron® (24, 106).  
Teflon® (Polytetrafluoroethylene) and Dacron® (Polyethylenterephtalate) showed the most 
suitable and superior properties (42) and represent the gold standard of synthetic vascular grafts 
nowadays. Variations of the texture (knitted or woven) and unilateral or bilateral velour 
trimming, as well as crimping and the invention of expanded PTFE (ePTFE), improved the 
physiological characteristics of alloplastic grafts (27). While Dacron® prostheses are more 
commonly used for “larger vessel applications”, Teflon® grafts are preferred to bypass “smaller 
vessels” (up to 4 mm diameter) leaving the decision of size to the surgeon`s discretion (76). 
Before application, porous alloplastic Dacron® grafts are impregnated with connective tissue 
proteins or preclotted with the patient`s blood in order to reduce blood loss, aid clotting and 
stimulate tissue ingrowth.  
After implantation the inner surface of a vascular graft becomes covered with a so-called 
pseudointima developed from the interaction of plasma proteins, in particular fibrinogen, and 
thrombocytes aggregating into a platelet-fibrin layer. A neointima is formed when endothelial 
cells cover this layer (Figure 1). This desirable as nonthrombogenic formation of a neointima is 
unfortunately limited to a small area adjacent to the anastomosis, nevertheless efforts are being 
made in the area of tissue engineering to find solutions (72). 
From the outside, the surrounding connective tissue encapsulates the vascular graft within 
normal tissue and develops a foreign-body reaction. The exterior surface is mantled with giant 
cells covered by a mixture of collagen, fibroblasts, extracellular and cellular tissue elements as 
well as blood vessels (76). 
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The great advantages of alloplastic vascular grafts such as short operation times, availability of 
each required size and large numbers as well as facile operation techniques, are overshadowed 
by several unsatisfying observations. The short-term and long-term patency is dependant on the 
size of interposition, the graft diameter and the flow resistance in such a way that an increase in 
interposition size and a decrease of vessel diameter, associated with an increase in resistance to 
flow, leads to a decrease in both the short-term and long-term patency rates. Five to ten years 
patency rates of 90 % for grafts used for aortofemoral bypass are reduced to 50 % for small 
vascular grafts (< 8 mm diameter) (17). The common most frequently occurring complications of 
vascular grafts are thrombosis, thromboembolism, periprosthetic fluid collection, 
pseudoaneurysm, intima hyperplasia, structural degeneration and infection. The problem of 
infection of PTFE grafts will be elaborated in chapter 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Vascular graft healing. A) Pannus formation, smooth muscle cells migrate from the media to the 
intima of the adjacent artery and proliferate on the graft surface. B) Possible sources of endothelium on the 
blood-contacting surface of the vascular graft (76).  
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2.2  Sutures 
 
Sutures are known to be one of the oldest applied biomaterials in human history traceably 
appearing for the first time in 32000 B.C. (16). Several developments and acquired knowledge 
about polymers, sterilization, toxicology, immunology and inflammation or biodegradation lead 
to an array of modern suture forms which shall be highlighted in the following.  
Sutures can be described by three different characteristics – the material (synthetic or natural), 
absorption profile (absorbable or nonabsorbable) and fiber construction (monofilament or 
multifilament). Materials with natural origin are based on plant or animal fibers of cellulose or 
protein structure, for instance catgut or silk spun whereas synthetic sutures are made of metal or 
polymers like PET, PTFE and those based on α-hydroxy acids. The original borderline between 
nonabsorbable and absorbable sutures associated with the property to maintain mechanical 
strength for more than 2 months (94) has been obliterated since the time period of mechanical 
strength was enhanced up to one year for newly developed sutures (15, 40). The profile of 
mechanical strength loss is an important parameter for the choice of the right suture as it is an 
effective support during wound-healing process. Sutures of natural origin degrade enzymatically, 
whereas the absorption of synthetic sutures is predominantly caused by hydrolysis (4, 13, 80) 
and enzymes are presumed to play more of a role in degradation and elimination of hydrolysis 
by-products (80).  
The basis of the fabrication of sutures as monofilaments or multifilaments is the requirement for 
an adequate suppleness. Materials with a high tensile modulus are more likely manufactured into 
a multifilament suture. The tensile modulus range for the fabrication of a monofilament is at 
about 500 kpsi or less. Multifilament braids are generally coated to increase the tissue lubricity 
(76).  
The most common suture types on the market are absorbable synthetic sutures which represent 
almost 42 % of total suture usage worldwide (76). The five different cyclic monomers, glycolide 
(GA), L-lactide (LLA), ε-caprolactone (CL), p-dioxane (DO) and trimethylene carbonate (TMC), 
mark the basic building blocks for absorbable polymers.  
This broad range of different types of suture material demonstrates that the selection of the right 
suture material depends on several parameters, such as the tissue type or the surgeons preference 
(97). Multifilament sutures for instance provide a higher comfort for knotting technique, 
however the fabrication is complex. They have to be coated in order to minimize tissue trauma, 
and the danger of bacterial colonization and the risk of infection, due to the so-called “wicking “, 
can not be trivialized (36).  
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3  Infections 
 
Pus bonum et laudabile – This expression in medicine of the nineteenth century reflects the 
involuntary togetherness of surgical intervention and infection in former times. Infection was 
even considered as part of the normal wound healing process as the alternatives – wound 
phlegmons or gangrenes – led to a predetermined death of the patient. The history of wound 
management is linked to the care of infection and goes back to the Egyptians who realized that a 
suppurating wound needed drainage (25). However mismanagement over hundreds of years of 
introducing substances into wounds to encourage suppuration must have added to the risk of 
infection and killed many patients (90). The introduction of personal hygiene, for instance the 
simple act of hand washing, and the discovery and knowledge of asepsis and antisepsis marked 
an important advance in infection prevention and treatment. At the beginning of the twentieth 
century antiseptic surgery was replaced by aseptic techniques. The simultaneous discovery of 
antibiotics and their targeted application during and after the Second World War resulted in 
better infection handling and prophylaxis care (29).  
The immune response of the body is the natural guard to prevent infection. It is classified into 
the specific (recognition of antigens) and the non-specific (not directed against specific 
antigens). The physical and chemical environment of the body surface presents the major barrier 
for microorganisms. When this host defence is modified, opportunists, normally considered to be 
harmless, become pathogenic. This depression of host defences is caused by systemic factors like 
shock, immunosuppression and poor nutrition or local factors like ischaemia, trauma, or 
implantation of prosthetic grafts. Primary pathogens unite a number of attributes which allow 
them to enter the host, multiply in vivo, interfere with the host defence mechanisms, and cause 
damage to the host and are therefore dangerous in case of a depressed host defence. 
The dimension of infection is determined by the size of the inoculum of microorganisms and the 
degree of pathogenicity. It is not only a high risk for the patient to delay healing after operation 
or tissue damage, but also of economical interest of hospitals, to prevent and treat infections as 
effectively as possible. The unchecked application of antibiotics has resulted in an increase of 
resistance and emergency. Particular nosocomial infections have recently become a great 
challenge for infection treatment.  
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3.1  Post-operative infections 
 
In a formative clinical study in 1980, where over 60,000 post-operative wounds were analysed in 
a time period of 10 years for occurrence and their etiopathogenesis, Cruse et al. demonstrated a 
total post-operative infection rate of 4.7 % (23). In order to determine such infection rates more 
precisely, it is unavoidable to classify the conditions under those which the operations are 
performed. There are four categories, which lead as expected to different infection rates. If the 
operative intervention is elective under sterile conditions without opening contaminated hollow 
organs like in heart, vascular, orthopaedic, respiratory, intestinal or urogenital surgery, the 
intervention is characterized as clean intervention. Other categories are clean-contaminated, 
contaminated and infected. Clean interventions represent 75 % of all operations. The infection 
occurrence in clean interventions is widely dependent on exogenous factors. The duration of 
preoperative hospitalisation for instance increases the infection risk from 1.2 % for a one day of 
hospital inhabitation up to 3.4 % for a hospital stay of two weeks. A second exogenous influence 
is the duration of the surgical intervention itself. Because of a higher risk of bacterial 
contamination, as well as a decreased resistance of the operation field and a weakening of the 
patient the infection risk rises hourly from 1.3 % up to 4 %. The time point of operations also 
plays an important role in the risk management of operations. Operation performed after 
midnight showed twice as high infections rates than day time interventions. A last important fact 
which influences the risk of infection is the age and therefore the actual condition of the patient. 
Infection risk, averaging 1.5 % for a 20 year old patient, increases up to 3.2 % for patients older 
than 66 years of age (23).  
 
3.2  Post-operative infections in vascular surgery 
 
The invention and application of synthetic biomaterials for graft replacements present a boon and 
bane in vascular surgery. Post-operative infections give rise to an unexpected challenge for 
surgeons as severe complications can result in amputations and death. In order to react in an 
appropriate and therapeutically sensible way, it is important to classify graft infections under 
specific characterizations. In 1972, Szilagyi et al. published a classification of different grades of 
graft infections predominantly under morphological aspects (95). The differentiation between 
superficial and deep graft infection is essential for the prognosis and therapy. Especially the 
stadium of a deep infection, subdivided by Koning and van Dongen, with an involvement of the 
implant actively threatens extremity or life of patients (57). Under consideration of the 
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application of modern alloplastic grafts, a subdivision into deep graft infections after Zühlke and 
Harnoss copes with present conditions (111). It has been recognized that the localisation of 
infection as well as the local complications are of decisive importance for therapy.  
The infection rate for vascular reconstructive interventions is influenced by many parameters 
such as intra-operative contamination, the stadium of pathogenesis, the localization and 
dimension of the intervention, the operation technique, used prosthetic material and infection 
prophylactic regimen. Different clinical studies demonstrate that deep post-operative wound 
healing disorders average from about 1.2 % to 6 % (74). A pronounced tendency of a higher 
infectious sensitivity of alloplastic grafts in comparison to autogenous grafts is stated in several 
studies (110), however the comparison of different patient groups must be viewed critically.  
 
3.2.1 Pathogenesis of post-operative infections after vascular reconstructive 
interventions 
 
In general, during every graft reconstructive intervention, independent of the applied operation 
technique or used graft material, post-operative infection can occur. Thereby the virulence of the 
pathogen as well as the constitution of host immune defence determine the ability of 
microorganism to cause infection. Fry and Lindenauer demonstrated that the quantity and 
intensity of bacterial contamination in the operation wound are the key parameters to induce 
infection in each performed graft reconstruction in animal experiments independent of the type 
of operation (31). Thereby infection can be caused by the patient himself through locoregional 
ways, for instance the surgical margin of the operation wound and haematogene factors like 
intra-operative concomitant infection of the patient in the area of the urogenital tract. The 
constitution of the host immune defence can be influenced by exogenous factors like intensive 
therapy or blood loss and endogenous factors like age or comorbidity of the patient.  
Bacterial infection is abetted through the structure of allografts and their initiated reactions inside 
the host. The porous architecture of Teflon® grafts or the fibrin network of pre-clotted knitted 
Dacron® prostheses enables pathogens to immigrate into areas where the host immune cells can 
not follow. Through unspecific foreign body reactions, pathogens can be activated which 
promotes infection. The ability of pathogens to adhere to the implant surface depends on the type 
and structure of bacteria, the ability to secrete muzin, the endurance and point in time of 
contamination and the physical and chemical characteristics of the graft. In a comparative study, 
a significantly higher affinity of enterobacteria to Dacron® grafts was demonstrated by 
Sugerman. In in vitro experiments, the lowest adherence of Staphylococcus aureus was assessed 
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at PTFE grafts followed by umbilical-venious prostheses and Dacron® grafts. This specific 
behaviour of pathogens leads to different infection rates for different vascular grafts (7, 8). In 
chapter 3.5 the mechanism of bacterial adherence to surfaces and biofilm formation is further 
discussed. 
 
3.2.2 Time point of vascular graft infections 
 
In patients with implants, infection can occur at any point in time. In general, the differentiation 
between early and late manifestations can be made, whereas the limitation of four weeks induced 
by operation for early infections by Vollmar makes sense (103). An estimated 60 % of all graft 
infections after reconstructive graft intervention manifest between one and four weeks. Late graft 
infections can be observed after more than seven years. The integration of the biomaterial into 
the host plays a key role in infection occurrence. Only in fully integrated vascular grafts, a 
haematogene and lymphogene perfusion is the precondition for host defence mechanism assured. 
After integration, late manifestations can only occur as consequences of an incompletely 
developed neointima, injuries such as punctuations, or as so-called dormant infections. Thereby 
an intraoperative bacterial contamination persists over a longer time period in the perivascular 
tissue of the implant and becomes clinically relevant months or years later. Symptoms of early 
infections are characterized by abscess development, bleeding or purulent secretion through the 
operation wound, and are mostly manifested in the groin. Late manifestations are predominantly 
abdominally localized and cause fever, shivering or septic complications.  
 
3.2.3 Localisation of vascular graft infections 
 
The probability of post-operative infectious complications is dependant on the location of the 
intervention. The axillo-femorale bypass shows the highest infection risk at 4.7 %, whereas at the 
carotids an infection risk of only 0.5 % is quoted. In general the natural pathogenic flora, the 
possibility of complicated surgery and a nominal amount of stress because of a minimization of 
graft stress as well as the selection between autogenous and allogenous grafts can influence the 
probability of graft infection. 
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3.2.4 Infection risk of different grafts 
 
Different types of vascular grafts - autografts, xenografts and allografts - demonstrate a different 
infection risk. Autografts show the lowest rate of deep infections in clinical studies. Depending 
on the location, rates of infection were between 0.2 % for thrombarteric excision or patchplastic  
and 0.5 % for a graft reconstruction with an autogenic vein (81). In the last ten years a total 
infection rate of 1.36 % for autogenic vein replacement and, as consequence of deep infections, 
an amputation rate of 54 % and a lethality of 20 % was observed. The application of xenografts 
is widely obsolete because of the decisive disadvantage of being dissolved. Allografts represent 
the most infection susceptible graft, resulting in hardly avoidable intra-operative contamination. 
Simultaneously the immune defence is suppressed as a consequence of insufficient perfusion and 
capillarization. This is also the reason for the bad prospects of antibiotic treatment. According to 
Vollmar, risks for deep infections average at 2.6 % which is almost double that of the occurrence 
for autogenic grafts (102). Within allografts a slight tendency for a lower incidence of infection 
for knitted, primary non-sealing Dacron-Velour prostheses is presumed (105), however this 
could not be significantly proven. In fact in a study by Lorentzen no advantages of individual 
materials could be demonstrated (66).   
 
3.2.5 Diagnosis of infectious complications after vascular reconstructive   
 interventions 
 
Every patient with an implanted alloplastic graft bears the risk of implant infection. The reason 
can be a transitoric bacteriaemie, an incomplete or through shear force damaged pseudointima. 
Different types of diagnosis are used when there is a hint of graft infection. Clinical inspections 
of the operation scars for signs of inflammatory processes or the opening of the wound in the 
early post-operative stage, provide further evidence of a possible infection. Sonography, x-ray 
diagnostic, computer tomography, magnetic resonance tomography, szintigraphy, wound smear 
and blood cultures provide insight into possible vascular graft infections. The modern diagnostic 
possibilities, the acknowledgement of symptoms, and the omnipresent possibility of infection 
should be deep-seated in the consciousness of surgeons.   
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3.2.6 Bacteriology of septic complications in vascular grafts 
 
There is a broad spectrum of pathogens responsible for vascular implant infection. 
Staphylococcus aureus unquestionably represents the most frequently occurring pathogen in 
mono and mixed infections. In 1962 Javid showed that S. aureus can be assessed in every 
infection after graft reconstructive interventions (52). In an overview of five clinical studies Bunt 
et al. demonstrated the average occurrence of S. aureus at 43 %, followed by S. albus and E. coli 
each at 14 % (12). However, there is a detectable downward tendency in the appearance of S. 
aureus to 25 % and a simultaneous increase of S. albus. Comparing early and late manifestations, 
high virulent pathogens like S. aureus, E. coli or P. aeruginosa can mostly be found within the 
first month whereas gram-negative germs are often detected in later manifestations. Particularly 
coagulase-negative staphylococci such as S. epidermidis play a certain role in later 
manifestations. A possible answer may be the low virulence of this pathogen and the endurance 
to establish an infection against host immune response. 
 
3.2.7 Sutures in infected areas 
 
In general the requirements for surgical sutures used for vascular reconstruction are the same as 
for vascular grafts. In several studies, synthetic monofilic non-resorbable sutures 
(Polypropylene) have proven their value (44, 82). However in traumatology, paediatric and 
septic surgery, the application of suture material may result in complications. Particularly, in the 
application to infected areas there is a risk of a non healing infection (100). Sandmann and 
Schmitz-Rixen demonstrated that non-resorbable sutures lead to an additional and permanent 
foreign body reaction and can obstruct infection healing (83, 88). The requirements for a suture 
material in infected areas is therefore a predictable, but enhanced and reproducible loss of tensile 
strength, a  smooth surface, no capillarity, a minimum of induced tissue reaction and good 
management by the surgeon. In many areas of surgery, medium-term monofilic resorbable suture 
materials have replaced the non-resorbable ones. Giessler demonstrated that resorbable sutures 
are particularly suited for healing anastomoses (33). The reconstruction with respect to anatomic 
layers of artery walls and a healing promotion between two blunt vessels are only two of several 
advantages of resorbable suture materials. 
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3.3  Neuronal infections 
 
Neuronal infections like bacterial meningitis, pathogen caused meningoencephalitis, brain 
abscess, neuroborreliosis or neurosyphilis require antibiotic therapy. For neuro-surgical 
interventions the additional antibiotic prophylaxis is a common method for pre-operative 
treatment. The choice of applied antibiotics is geared to the diagnosed bacterial species and 
covers the broad spectrum of available antibiotics. Most applied antibiotics show sufficient 
infection protection, however in some cases for instance inflammatory meningitis therapy failure 
is not uncommon as a consequence of pathogen - or resistance change during therapy. 
Insufficient penetration into the liquor can also be considered as a reason for therapeutic failure. 
Therefore an adequate effective high drug level in devitalized brain tissue or in the area of 
inserted implants and foreign bodies like dura mater replacement, or fibrin glue has to be 
assured. The local application of antibiotics (intrathekal or intraventricular) for instance   10 mg 
to 50 mg vancomycin i. th. for infections caused by staphylococci is indicated in complicated 
neuronal infections. Applied antibiotic concentrations are mostly based on clinical experience. 
The systematic investigation of the influence of antibiotics on neuronal tissue, particularly the 
dose response and functional toxicity of antibiotics, is of basic interest in the area of neuronal 
infections and may improve antibiotic therapy. 
 
3.4  Medical device infections 
 
The “classic” device-related infection observed by surgeons for the first time could not be 
explained properly, as it did not seem to follow a logical pattern. In many cases symptoms 
caused by medical device-related infections showed up almost immediately, sometimes months 
or years after device implantation, inflammation was bordered locally in the area of medical 
device or spread systemically. To get to the bottom of these observations a glance over the fence 
to environmental microbiology was very helpful. In this scientific area Costerton et al. developed 
and articulated the theory of the biofilm concept in 1978 (20). Four years later Tom Marrie 
introduced this concept into medical microbiology (69). The theory is based on the assumption 
that bacteria grow in matrix-enclosed communities adhered to surfaces in nutrient-deprived 
ecosystems (21). In medicine this assumption was soon confirmed by observations made by 
scanning and transmission electron microscopy investigating hundreds of failed medical devices 
(76). The highest bacterial colonization appeared in intrauterine contraceptives and dental 
devices. The sealable way of introducing pathogens to the normally sterile environment is the 
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channel from the skin to the device. Common environmental and skin pathogens like 
staphylococci are the most frequently detected germs in device-related infection. Large and 
complicated operations also enhance the risk of pathogenic manifestation on the implant surface. 
A surface colonization however, does not automatically lead to infection. In many cases the 
pathogenic change of surrounding tissue causes a loosening or detachment of the implant and 
therefore the loss of function (51). Symptoms may not be elicited immediately as only the 
release of planktonic cells and toxins from the biofilm community causes an inflammatory 
response. Furthermore a biofilm formation protects bacterial cells from both humoral and cell-
mediated immunity (61). 
The constitution of the patient therefore does not influence the occurrence of device-related 
infections since the key event is the discharge of single bacterial cells from the community. Only 
released pathogens can be antagonized by the immune response or applied antibiotics leading to 
the alleviation of symptoms, however the infection itself persists and the fear of severe and life- 
threatening consequences always looms over the patient.  
 
3.5  Biofilms 
 
3.5.1  Bacterial adhesion to surfaces 
 
Wild natural bacteria are necessary to study adhesion of pathogens on the surface of biomaterials 
as lab-adapted strains do not reproduce conditions inside the body. The DLVO theory constituted 
by van Loodsrecht et al. in 1990 is based on the comparison of bacterial cells with smooth 
colloid particles that interact with a surface as a result of an electrostatic attraction (99). 
However several studies showed that this theory is of limited application in terms of bacterial 
adhesion as the bacterial cells are not smooth-surfaced particles. The surface is rather covered by 
hydrophobic exopolysaccharide and sometimes a highly structured protein shell. There are 
different mechanisms of adherence ranging from utilization of flagella or pili to the point of 
producing windrows of cells (58). In general, pathogens show reversible and irreversible patterns 
of adherence (70), meaning that bacterial cells are able to adhere to the surface as well as to 
detach and leave the area again before attaching irreversibly and initiating the process of biofilm 
formation. Physical properties of the biomaterial surface seem to play an inferior role for 
adherence procedure as several studies have demonstrated. Pathogens seem to adhere equally 
well to hydrolphilic and hydrophobic, and to rough as well as to smooth surfaces (68, 91) even in 
systems with very a high shear flow rate (14). Scientists are still searching for new solutions.   
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Figure 2. Interaction between pathogens, tissue and implant (37). 
 
3.5.2 Biofilm formation  
 
The irreversible attachment of bacterial cells at a biomaterial surface is accompanied by a 
genetic switch which implicates a phenotypic change, in some cases up to 70 % (84). The 
phenotype of planktonic cells of Pseudomonas aeruginosa for instance, shows a higher 
agreement with planktonic cells of other species in the same genus than their biofilm 
counterparts (85). The production of exopolysaccharides by up-regulated genes is thereby one of 
the first activities of the bacterial cell with a differing phenotype (84, 93). These 
exopolysaccharides attach the cell irreversibly to the biomaterial surface and form the matrix of 
the biofilm. Binary fission or further attachment increases the number of phenotypically 
modified bacterial cells on the biomaterial surface resulting in a community of matrix and 
bacterial colonies of varying shape. These entities are separated by open water channels and 
water moves through these complex microcolonies in a convective pattern. A balance between 
multiplication and detachment of planktonic cells adjusts. Approximately one week after the 
initiation of colonization, a stable community structure has formed and can remain so for years. 
Observed resistance to antibiotics or to uptake by phagocytes can also be attributed to the 
upregulation of genes, as for example the gene fmt C is responsible for antibiotic resistance of 
staphylococcal species. The clinical consequence is that antibiotics can be used for treating acute 
infection occurrence caused by planktonic cells, but not for biofilm clearance. Biofilm-covered 
devices therefore have to be removed in many cases by surgery.  
The complex structure and organization of these bacterial microcolonies lead to the conclusion 
that pathogens within these entities are able to communicate with each other via signals like 
15
                                                                                         Introduction and Objectives of the Thesis 
_____________________________________________________________________________ 
 16 
hormones or pheromones. The assumption of this so-called quorum sensing was first confirmed 
in 1998 by Davis et al. who demonstrated that biofim formation in Pseudomonas aeruginosa is 
controlled by an acylated homoserine lactone (AHL) quorum sensing signal. This AHL signal is 
only one of many signals which control the organization of pathogens in biofilm communities.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Staphylococcus aureus accumulation A) without B) with slime production (41). 
 
3.5.3 Strategies of biofilm prevention 
 
The most common way to prevent biofilm formation on medical devices is the incorporation of 
antibiotics into surface material in order to kill incoming planktonic cells before they can adhere 
and start biofilm formation. After complicated and longer operations, in particular, device-
related infections can occur because skin and environmental bacteria have enough time to adhere 
and initiate biofilm formation. An antibiotic-modified surface is therefore a helpful and 
established strategy. The problem is that after the initial drug release, which guarantees effective 
protection against planktonic bacteria for a short period of time, the delivered sublethal antibiotic 
concentrations after months or years as well as the application of highly specialized drugs like 
ciprofloxacin can cause resistant strains. A switch to multitarget antiseptics like chlorhexidine 
has improved the situation, however, most are not approved yet for systemic use in humans. 
Another method of resolution is the development of intelligent coatings mimicking skin 
consisting of a self-assembled surface layer that contains molecules loaded into an underlying 
plastic. The advantage is the delivery of antimicrobial drugs in controlled impulses by ultrasonic 
waves post-operatively or any time preliminary signs of device-related infection show up. Other 
studies show that the application of ultrasonic energy itself (71, 77) or weak direct current fields 
(19) are promising strategies to render pathogens susceptible to antimicrobial agents.  
    A                       B 
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A more focused method to prevent biofilm formation is the utilization of biofilm signal blockers, 
for instance the RNA III-inhibiting peptide (RIP) analogue blocking the target of RNA III-
activating protein (TRAP) receptor in gram-positives or brominated furanones targeted on the 
acylated homoserine lactone (AHL) system of gram-negative bacteria (6). This method is based 
on the idea to inhibit the genetic switch between planktonic cells and their biofilm counterparts 
and is derived from observations of plants that protect themselves from biofilm colonization by 
the use of signal blockers (92). This lock of pathogens in the planktonic phenotype makes them 
susceptible to conventional antibiotic therapy.  
The new development from Westaim Biomedical Inc. for burn bandages uses a galvanic 
combination between silver and copper along with a simultaneous release system of silver and 
copper ions. This may have an effect on pathogen adhesion, biofilm formation and susceptibility 
to antibiotics. The synthesis of different concepts may be the best way for the development of 
new antimicrobial devices or so-called antifouling materials. 
 
3.6  Therapeutic methods 
 
3.6.1 New tactics in surgery and local wound management 
 
Wound management is based on knowledge of the wound healing process. This process proceeds 
in four stages, the inflammatoric phase, followed by the resorptive, the proliferative and the 
reparative phase (64). Within the inflammatory phase, the wound can be opened and 
inflammation can be battled through surgical cleaning and if necessary local application of 
antibiotic or antiseptic agents. Additionally the systemic application of antibiotics is 
recommended in order to prevent recontamination of the vascular graft in revision surgery. In the 
resorptive phase, the surgical cleaning of the wound, bandage changing, and removal of necrotic 
tissue provide the basis for the later replenishment of the wound in the proliferative phase. A 
necessary prerequisite in starting wound healing is the physical and enzymatic wound cleaning. 
The following reparative phase leads to a completely closed wound which may result in a scar. 
The application of different dressings with and without drugs, like autogenous skin transplants or 
poly-urethane dressings, may prevent wound re-infection. The management of an infected 
wound after vascular graft infection differs from wound management in other areas of surgery 
due to the fact that spread of infection from the wound to the vascular graft may lead to severe 
complications like sepsis, sometimes with lethal consequences for the patient. An early diagnosis 
of infection is therefore as important as the correct classification into superficial or deep, as well 
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as into early and late manifestation. The probability of limiting infection and avoiding severe 
complications is higher when surgical intervention and the appropriate therapy is performed 
quickly. 
 
3.6.2 Antiseptics in wound care 
 
Antiseptics are predominantly applied for external use and sterilization of instruments or 
surfaces. The application of antiseptics in open wound management is regarded sceptically as 
they are inactivated by body fluids or pus (34, 75). Different types of antiseptics are used for skin 
preparation and instrument cleaning in surgery and wound management. These drugs are not 
approved for i.v. administration. Particular hypochlorite solutions are controversially discussed 
as the doubtless bactericidal effect is accompanied by a clear toxicity to healing tissue. 
Nevertheless their use is historically widespread for skin grafting. Povidone-iodine, a 
polyvinylpyrrolidine iodophor presented with a detergent as Betadine, is used as a topical 
antimicrobial for skin preparation or hand-washing (63). It should be used with caution in open 
wounds as it may have an effect on thyroid function when absorbed as well as a delay on healing 
(28, 101). Due to side reactions concerning fibrin formulation, application of fibrin glue and 
betadine is a contraindication. Chlorhexidine is known to have a prolonged broad spectrum of 
activity against gram-positive and gram-negative pathogens and has been demonstrated to have 
superior antimicrobial effectiveness compared with other antiseptics (73). Another advantage is 
its smaller interaction with body fluids and the fact that it is not absorbed through intact skin. 
Although the evidence of antimicrobial activity of hydrogen peroxide is missing (11), it is widely 
used as wound irrigant. Though toxicity to fibroblasts has been proven when properly used, it 
does not appear to interfere with healing (65).  
 
3.6.3 Antibiotics in wound care 
 
Antibiotics in wound management are applied as prophylactic therapy as well as for diagnosed 
infections. The choice of resorbable and non-resorbable antibiotics is empirical and defined by 
drug approval (60, 96). The parenteral application (i.v. or i.m.) is often preferred to achieve 
necessary peak levels. The duration of antibiotic treatment differs between prophylactic 
application and therapeutic demand. Furthermore the application has to be oriented to biological 
resistance of the diagnosed pathogen and application has to be focused on the patient. In the 
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following, the most commonly proven antibiotics in wound care are briefly described. Penicillins 
are the first choice for streptococcal or clostridial wound infections, however their narrow 
spectrum of activity, the risk of sensitivity and a short half life limit their application for internal 
use only. The combination with clavulanic acid in newer formulations prevents agents from ß-
lactamase degradation. The cephalosporines are used in general prophylaxis and therapy of 
broadband infections. Because of their higher potency, third generation agents like cefotaxime 
are applied, usually in combination, in serious infections. This enhanced potency, however, is 
limited to a narrowed spectrum. Aminoglycosides like gentamicin are effective against 
staphylococci and aerobic gram-negative bacilli and safe for prophylactic therapy with a 
prolonged post-antibiotic effect. In high risk patients, side effects like renal and oto-toxicity can 
be avoided by close drug monitoring. Tetracyclines and sulphonamides play an inferior role in 
wound infection managment and are used for special indications like abdominal or colorectal 
surgery. To avoid resistance, the responsible application of antibiotics and the compliance of 
hygienic guidlines in hospital is still of high priority. 
 
3.6.4 Prosthesis explantation 
 
Implants and infected biomaterials for instance an infected vascular prosthesis need surgical 
excision. Notable are involvement of the pseudo-intima by infection, danger of rupture, 
incidence of distale septic emboli or a septic thrombosis. The surgical intervention covers the 
exposure and excision of prosthesis and suture material, follow-up resection of the vessel wall 
and the occlusion of the vessel by suture or the maintenance of the vessel axis with the help of an 
interponat. In primary operations long term results are focused upon, whereas in secondary 
reconstructions in an infected area life maintenance and infection palliation are the main targets. 
Therefore, autogenic material is the gold standard, however in consideration of the danger of 
rupture in autogenic graft, the application of alloplastic material like Dacron® or Teflon® as 
bypass graft in non infected areas is also common (98). In vessel lesions alloplastic grafts are 
only used in the case of emergency, as for instance when a patient`s life is threatened. 
 
3.7 Implants as drug delivery systems 
 
Biomaterials have altered modern medicine and improved life of patients. Strategies to utilize the 
artificial surfaces of biomaterials for local drug delivery are developed to improve tissue 
compatibility, control infection, prevent thrombogenity and improve tissue integration. These 
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artificial surfaces can also be utilized to locally insert defined drug delivery systems (DDS) that 
release drugs in a controlled manner. These DDS are commonly used to maintain low blood 
plasma levels for a long period of time below the therapeutic index as well as to obtain high local 
drug concentrations in the area of the device. An approved technology in orthopaedic and trauma 
surgery is the anti-infective coating of osteosynthesis material for the prevention of biofilm 
colonization. In device coatings drugs are often dispersed in biodegradable matrix systems as for 
instance poly(lactic acid) or poly(lactic-co-glycolic acid). These polymers play a decisive role 
among biodegradable drug delivery systems as they are hydrolysed to the natural metabolites L-
lactide acid and glycolic acid (45). In thick coatings the erosion of poly(L-lactic acid) follows 
four steps beginning at the outer perimeter of the device and gradually moving into the interior, 
thereby releasing the incorporated drug and preventing the device for instance from a possible 
bacterial colonization.  
 
3.8  Biocompatibility 
 
The biocompatibility of a medical device is defined as the tolerance between the implant and the 
organism and can be subdivided into structure compatibility and surface compatibility (108). 
Structure compatibility is characterized by mechanical adaptation of the implant to the recipient 
tissue with the aim to take structure properties of the biological system. Surface compatibility 
means an adaptation of the chemical, physical, biological and morphological properties of the 
implant surface to the recipient tissue. The surface structure of an implant is the key to improved 
biocompatibility as the body is confronted with this surface and responds with inflammatory or 
allergic reactions in case of an limited compatibility. It is the subject of an entire scientific field 
to improve biocompatibility. For the clinical application of new materials or surface 
modifications, like device coatings, evidence of safety for the patient has to be investigated 
according to ISO (DIN) standards. 
 
3.9  Haemocompatibility 
 
The implantation of artificial surfaces like cardiovascular medical devices and the blood contact 
initiate haemostatic mechanisms originally designed to arrest bleeding from injured blood 
vessels. This haemostatic process involves a complex system of reactions between the 
biomaterial surface, thrombocytes, coagulation and the complement system as well as the 
20
                                                                                         Introduction and Objectives of the Thesis 
_____________________________________________________________________________ 
 21 
fibrinolytic system. It is the task of biomaterial engineers to assure that this interaction between 
activation and inhibition systems on the biomaterial surface is balanced in a way that blood flow 
in the circulation is maintained and the danger of thrombosis or exaggerated inflammatory 
response is minimized. Many interactions of participating cells and proteins with artificial 
surfaces, including polymer coatings as drug delivery systems have not yet been defined and it is 
difficult to standardize haemocompatibility requirements for biomaterials. Increased haemostatic 
procedures still limit the utilizability of many cardiovascular devices and require the system 
application of anticoagulants such as heparin or coumarines (76). 
 
3.10  New approaches for protection of biomaterial infections 
 
3.10.1  Electro-magnetic field influence 
 
The Magnetodyn® procedure is based on the influence of electro-magnetic fields on bone healing 
and infection palliation (Figure 4). The non-invasive magnetic-field therapy is clinically applied 
in case of loosening of prostheses and non-union in the fracture zone. The involved body parts 
are inserted in a magnetic field coil and exposed to a low-frequency sinusoidal magnetic field.  
 
 
 
 
 
 
Figure 4. Extracorporal magnetic-field coils of the Magnetodyn
®
 procedure. 
A) pelvis and thorax B) hip and shoulder C) extremities D) medical device M80 
(Source: Neue Magnetodyn GmbH) 
 
A frequency in the range of 0 Hz up to 20 Hz, a magnetic flux density of 0.5-10 mT, and the 
wave form of the signal can be adjusted individually. The invasive magnetic-field therapy is 
performed in the same way with the difference that via implanted secondary coils, an additional 
electro-magnetic field is induced over the fracture gap (Figure 5). This additional field has a 
considerably stronger electric field part and can extend over larger fracture areas. A sinusoidal 
current, similar to the "leakage current" of a condenser, flows over the cross-sectional area of the 
fracture. Investigations of the therapeutic benefit of the invasive Magnetodyn® procedure in the 
treatment of avascular defects and pseudo arthrosis in association with bone transplants 
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demonstrate superior healing rates (5, 59, 86, 87). The possible mechanisms of the influence of 
low frequency electro-magnetic fields on biological systems are based on different theories 
which are the object of several studies. The radical pair effect constitutes the generation of free 
radicals during high-energy photonic or electro-magnetic irradiation in biological systems. These 
free radicals can damage cell membranes or modify ionic channel conductivity. However the 
energy of low-frequency systems used in the Magnetodyn® therapy with frequencies between 10 
and 30 Hz are too weak to result in radical formation. Although the energy is not sufficient for 
stimulation, quantum electrodynamics predicts magnetic effects in the case that resonant 
stimulation conditions occur simultaneously. 
The mechanism of the ion-cyclotron resonance (ICR) constitutes that the Lorentz force effects 
ions and ion-protein complexes because of their intrinsic movements and their charges within a 
static magnetic field. This diverts the ions from circular orbits and causes a precession 
movement, according to Lamor (32). The resonant stimulation is the stimulation of a biological 
system by electro-magnetic fields of defined orbital frequency. The resonance frequency for Ca2+ 
ions is in the range of extremely low-frequency fields like those used in the Magnetodyn® 
procedure which could be a possible explanation for a bactericidal effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Principle of the invasive Magnetodyn
®
 procedure. 
(Source: Neue Magnetodyn GmbH) 
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3.10.2 Antimicrobial coatings 
 
Biofilm formations and haemostatic reactions on the surface of allografts lead to the 
modification of graft surfaces. For the improvement of physical and mechanical properties and 
the adaptability to the target vessel Intervascular® has developed a polyester vascular graft 
coated with collagen (InterGard Knitted UltraThin®). SEALPTFE® is a gelatine coating of PTFE 
provided by VASCUTEK® with the advantage that gelatine closes the branch canels and 
bleeding is stopped quickly. In order to avoid the formation of thrombi, an antithrombotic lumen 
surface was developed by JOTEC® (FlowLine Biopore® Heparin). The lumen surface of this 
ePTFE prosthesis is coated with a synthetic protein where heparin is attached via covalent bonds 
and ionic interactions. VASCUTEK® offers a system of rifampicin powder that can be used for 
preoperative graft coating in order to avoid adherence of bacterial cells. An antimicrobial coating 
for vascular grafts is provided by Intervascular®, Intergard® is a polyester graft coated with a 
combination of collagen and silver and claims to be effective against post-operative infections. 
In the area of surgical sutures, Vicryl® Plus (Ethicon®), an absorbable synthetic braided suture is 
antimicrobially coated with triclosan. This technology represents the current development to 
predominantly focus on the equipment of biomaterial surfaces with drug release systems 
consisting of antibiotics or antiseptics incorporated in drug carriers in order to prevent bacterial 
colonization of medical devices like PTFE grafts or surgical sutures.  
 
3.10.3 Magnetic drug targeting systems 
 
Nanotechnology will play a decisive role in future technology for many areas such as medicine, 
material science and electronics. A combination of thin polymer layers at the nanoscale and 
inorganic hybrid materials, for instance, can prevent energy-saving organic illuminating diodes 
from faster aging. Many membranes in solar cells and facilities for water treatment to filter 
nanoparticles consist of nano structures. In building services engineering, barrier layers at the 
nanoscale are used for vacuum isolation panels. 
In medicine, nanotechnology opens up new possibilities as all important life processes in human 
cells happen at the nanoscale. Structures and customized particles of less than 100 nm in size are 
gaining interest in different medical disciplines. Ferries at the nanoscale are designed to carry 
molecules, genetic material, and drugs, selectively and well-dosed to diseased cells. This 
targeted drug transport especially raises hope in chemotherapy where only diseased cells should 
be destroyed. Different methods to direct nanoparticles to their targets are practical such as the 
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equipment with antibodies, sugars, enzymes and tensides which serve as identification molecules 
or enable the docking at the target cell via receptors. Polyethylene glycol coated particles in a 
range of 500 nm, for instance, still penetrate the mucous membrane, although the common 
opinion supposes that penetration can be performed only by particles in the range of a 
nanometer. Nanoparticles consisting of iron oxide (Fe3O4), better known as ultra-small 
superparamagnetic iron oxides (USPIO), are only one type of a wide range of different 
nanoparticle materials like stealth liposomes or polybutylcyanoacrylat particles. These USPIOs 
usually consist of the iron core and an organic shell like dextrans or fatty acids and are 
formulated as suspensions. A big advantage of those so called ferrofluids is the already proven 
biocompatibility as they are in clinical use as x-ray contrast agent. A second advantage is that 
these nanoparticles can be magnetized through an external magnetic field and concentrated after 
intra-venous or intra-arterial injection in the target tissue where a controlled release of the 
specific drug is desirable. This technique known as magnetic drug targeting has been 
successfully applied in several in vitro and in vivo studies for cancer treatment (2, 3). The first 
clinical approach in human patients was performed with epirubicin-loaded ferrofluids for 
advanced and unsuccessfully pre-treated cancers or sarcomas and opened the way for further 
clinical experiments (67). In consideration of this successful new concept in chemotherapy the 
switch to apply magnetic drug targeting in alternative indications by using different drugs seems 
to be a more than logical development.     
 
3.10.4 Neuronal networks 
 
Neural mechanisms are based on activities at the cellular and molecular level, however only the 
interaction between sub - and suprathreshold electrophysiological signals of neuronal networks 
determine perception and behaviour (26, 30). A good structural organization of such neuronal 
groups is a basic requirement for a system where transient information calls for a fast response. 
However the structural complexity of vertebral nervous systems becomes obvious in several 
observations. Even stable adult nervous systems show constant changes in their physical 
structure (53, 55) as well as in synaptic weights (10). Glasser showed that a specific morphology 
of neuronal circuits does not always predict specific electric properties (35). In consideration of 
these challenges simplified systems are unavoidable in order to gain a better insight of neuronal 
interaction.  
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Slice preparations (56) and invertebrate preparations have been established experimental systems 
(18), however most investigations have focused on input/output relationships which are 
informative about network responses but do not provide information about how responses are 
formed.  
An alternative and advanced development describes the cultivation of mammalian neuronal 
networks on beds of photoetched microelectrodes. The first recording of spike potentials with 
photoetched microelectrode surfaces was described by Gross et al. in 1977 and is nowadays a 
routine method for monitoring internal dynamics of mammalian networks (38, 39).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mammalian frontal cortex networks cultivated on microelectrode neuroarray (CNNS archives). 
 
This monitoring of spike activity from visible cells makes it possible to simultaneously gather 
statistical temporal and spatial data, as well as to select high signal-to-noise ratio of 
representative spike activity. Several applications are conceivable. The electrical stimulation of 
networks (79) as well as optical measurements of ionic fluxes in the living state in monolayer 
networks (54) or the development of tissue based biosensors can be performed. Disease models 
like epilepsy can be established as cultures are maintained in specific states of activity for long 
periods of time without signs of excitotoxicity (78).  
An interesting application field for pharmacological studies is the screening of compounds. In 
the focus is the question how networks react to certain agents and the investigation of 
acclimatization effects, and receptor – agent interactions. Functional compound toxicity of novel 
agents can be studied, and generated dose response data are helpful markers for further studies in 
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animal models. The combination of all these applications shed light into the inner life of 
neuronal networks and enables the extraction of general principles of the organization of 
neuronal networks.   
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4  Conclusions 
 
Various approaches to prevent and treat device-associated infections are part of our research 
activities. The development of biodegradable drug delivery systems on the surface of 
biomaterials highlight the most important requirements for an effective as well as biocompatible 
anti-infective equipment of implants such as PTFE grafts and surgical sutures for the prevention 
of post-operative infection.  
The application of low-frequency electromagnetic fields to S. aureus cultures corroborated 
observations of infection palliation in clinical situations of bone infections during magnetic field 
therapy and could be used for new developments in the treatment of biomaterial associated 
infections.  
A new perspective in the on demand treatment of vascular graft infection is presented in the 
development of biomaterial oriented magnetic drug targeting systems. With the help of a strong 
external magnetic field, drug-functionalized nanoparticles are concentrated at the surface of 
infected grafts ensuring high drug levels to destroy biofilm embedded pathogens.  
The utilization of mammalian neuronal networks on microelectrode neuroarray will provide new 
concepts regarding the functional toxicity of antibiotics locally applied with resorbable and non-
resorbable implants during brain surgery.    
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5  Objectives of the thesis 
 
The key events in biomaterial-associated infection are the pathogen adherence on the surface of 
biomaterials and the subsequent biofilm formation coming along with a genetic switch and a 
change of the planktonic phenotype of pathogens into the biofilm phenotype. This genetic switch 
of pathogens leads to an increased antibiotic and host defence resistance which is the major 
problem for a successful clinical treatment. The most frequently occurring pathogens in 
biomaterial-associated infection belong to S. aureus and S. epidermidis.  
The concept of this thesis was to find new ways to prevent post-operative medical device-
associated infections and new perspectives for the on demand treatment of already manifested 
medical device-associated infections.  
For post-operative device protection our intention was to develop individual biodegradable drug 
delivery systems on the surface of PTFE prostheses based on lipid-like drug carriers like 
PDLLA, tocopherol acetate, a diglyceride (Softisan®) and a triglyceride (Dynasan®) with 
incorporated antibiotics like gentamicin and teicoplanin. The in vitro investigation and 
comparison of drug release, anti-infective characters, biocompatibility and haemocompatibility 
highlighted the most important requirements for effective as well as compatible anti-infective 
coatings of vascular grafts (Chapter 2).  
A second project for the prevention of post-operative infection presented the antimicrobial 
equipment of synthetic absorbable PGA surgical sutures with biodegradable drug delivery 
systems based on a combination of antiseptics like chlorhexidine or octenidine and fatty acids 
like palmitic acid and lauric acid. In vitro investigations for drug release, anti-infective 
characters and biocompatibility were performed and checked for realization (Chapter 3).  
For the on demand therapy of already existing device-associated infections various methods of 
resolution were taken into consideration.  
Clinical observations of bone infection palliation during magnetic field therapy gave reason to 
study the influence of low-frequency electromagnetic fields on S. aureus growth in vitro 
(Chapter 4). 
Furthermore we tried to increase antibiotic susceptibility of S. aureus by the application of low-
frequency electromagnetic fields in presence of an aminoglycoside. These data are the 
fundament for further investigations about the influence of low-frequency electromagnetic fields 
on susceptibility  of  pathogens  with increased antibiotic resistance in biofilms (Chapter 5). 
A further study for the on demand therapy of device-associated infections focused on the 
establishment of a magnetic drug targeting system to accumulate high antibiotic concentrations 
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on the surface of vascular grafts. The development and characterization of gentamicin coated 
ultra-small superparamagnetic iron oxides and the establishment of a circulatory model to imitate 
blood flow were in the focus of this investigation (Chapter 6). 
In a cooperation of the Technical University of Munich and the University of North Texas, the 
functional neurotoxicity of locally applied drugs in neurosurgery was investigated with 
mammalian neuronal networks grown on microelectrode neuroarray. Our intention therefore was 
to study the local application of antibiotics in combination with biomaterials used in brain 
surgery to predict functional neurotoxicity (Chapter 7).  
 
 
In summary the main objectives of the thesis were: 
 
1. The anti-infective equipment and characterization of PTFE grafts for the prevention of 
post-operative infection. 
2. The anti-infective equipment and characterization of PGA surgical sutures for the 
prevention of post-operative infection. 
3. The elucidation of the influence of low-frequency electromagnetic fields on 
Staphylococcus aureus growth in order to corroborate clinical observations about bone 
infection palliation during magnetic field therapy.  
4. The investigation of the influence of low-frequency electromagnetic fields on antibiotic 
susceptibility of Staphylococcus aureus. 
5. The development and characterization of anti-infective coated ultra-small 
superparamagnetic iron oxides and the establishment of a magnetic drug targeting system 
for biomaterial infections. 
6. The study of functional neurotoxicity of individual antibiotics investigated with 
mammalian neuronal networks grown on microelectrode neuroarrays. 
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6  Figure Captions 
 
Figure 1. Vascular graft healing. A) Pannus formation, smooth muscle cells migrate from the 
media to the intima of the adjacent artery and proliferate on the graft surface. B) Possible sources 
of endothelium on the blood-contacting surface of the vascular graft.  
 
Figure 2. Interaction between pathogens, tissue and implant. 
 
Figure 3. Staphylococcus aureus accumulation A) without B) with slime production. 
 
Figure 4. Extracorporal magnetic-field coils of the Magnetodyn® procedure. 
 
Figure 5. Principle of the invasive Magnetodyn® procedure. 
 
Figure 6. Mammalian frontal cortex networks cultivated on microelectrode neuroarrays. 
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Chapter 2 
 
 
New anti-infective coatings of medical implants based on lipid-
like drug carriers 
 
Abstract 
Objectives: Implantable devices are highly susceptible to infection and therefore a major risk 
in surgery. The present work presents a novel strategy to prevent formation of a biofilm on 
PTFE grafts. 
Methods: PTFE grafts were coated with gentamicin and teicoplanin incorporated in different 
lipid-like carriers under aseptic conditions in a dipping process. Poly-D, L-lactic acid, 
tocopherol acetate, the diglyceride Softisan®649 and the triglyceride  Dynasan®118 were used 
as drug carriers. Drug release kinetics, anti-infective characteristics, biocompatibility and 
haemocompatibility of developed coatings were studied.   
Results: All coatings showed an initial drug burst followed by a low continuous drug release 
over 96 hours. The dimension of release kinetics depended on the carrier used. All coated 
prostheses reduced bacterial growth even beyond pathologically relevant concentrations 
drastically over 24 hours. Different cytotoxic levels could be observed bringing up tocopherol 
acetate as the most promising biocompatible carrier. A possible reason for the highly 
cytotoxic effect of Softisan®649 could be assessed by demonstrating incorporated lipids in the 
cell soma with the oil red O staining. The performance of tromboelastography studies, ELISA 
assays and an amidolytic substrate assay could confirm haemocompatibility of individual 
coatings. 
Conclusions: The development and in vitro studies of described biodegradable drug delivery 
systems highlight the most important requirements for an effective as well as compatible anti-
infective equipment of PTFE grafts. Through continuous local release, high drug levels can be 
obtained at only the targeted area, physiological bacterial proliferation can completely be 
inhibited while at the same time biocompatibility as well as haemocompatibility can be 
ensured. 
Keywords: Vascular graft, antimicrobial coating, drug release, biocompatibility, 
haemocompatibility  
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1 Introduction 
 
A major risk associated with surgical placement of medical implants such as endoprostheses 
or vascular prostheses is their high infection rate (4, 8). This is not only of prime importance 
for the patient, but also presents a high financial factor for the economy (21). Synthetic 
vascular grafts like PTFE prostheses are easily accessible to pathogens mostly belonging to 
Staphylococcus aureus and Staphylococcus epidermidis. These pathogens colonize the 
implant by adhering to the patients own proteins located on the surface of the graft and form a 
biofilm (1, 14, 16, 23, 34). The formation of biofilms on biomaterials present challenging 
complications in the field of medical implants (2, 12, 24, 28, 30). In a biofilm bacteria are 
well protected from the host immune defence. An increase in antibiotic resistance is the 
consequence (6, 8, 35), even high local concentrations of antibiotics do not completely 
eradicate bacteria in biofilms (8, 10). It is therefore of high importance to prevent bacterial 
adhesion on vascular grafts (7). This can be achieved by antibiotic surface coatings. 
There have been several approaches to equip vascular grafts with anti-infective agents to 
avoid bacterial colonization. Different antimicrobial agents have been used (3, 5) as well as 
different ways to bind those drugs on the surface of a PTFE prostheses.  
A common method used to bind hydrophilic drugs on the lipophilic surface of  PTFE grafts is 
the use of surfactant-mediated agents e.g. benzalkonium chloride (15, 18) or 
tridodecylmethylammonium chloride (17). Another way of drug binding is the incorporation 
of drugs in biodegradable polymer carriers (13).  
The present work presents new lipid-based formulations to incorporate antibiotics for anti-
infective graft equipment. Through local release, high drug levels can be attained at only the 
targeted area and a pathogenic colonization of the graft can be avoided. PTFE grafts were 
coated with lipophilic agents like Poly-D,L-lactic acid (PDLLA), tocopherol acetate, the 
diglyceride Softisan®649 and the triglyceride Dynasan®118 as carriers for gentamicin and 
teicoplanin. An overall in vitro study assessing release kinetics as well as cytotoxicity, anti-
infective characters and haemocompatibility of the corresponding coatings was examined.  
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2 Materials and Methods 
 
2.1 Medical implant 
 
Commercially available PTFE grafts of 6 mm diameter (Alpha Graft® PTFE, Alpha Research 
Deutschland GmbH, Berlin, Germany) were studied. Sterile grafts were cut into 1 cm length 
under aseptic conditions in a laminar airflow. The average weight of four 1 cm samples was 
assessed by weighing each sample three times as weight standards are more accurate than 
length measurements. 
 
2.2 The anti-infective coating 
 
2.2.1 Drug carriers 
 
A defined mass of each of the following drug carriers was weighed out in a glass vial. 
 
2.2.2 PDLLA 
 
Resomer R203H purchased from Boehringer Ingelheim (Ingelheim, Germany) is a polymer of 
PDLLA of 29,000 Da molecular weight. It is a racemic mixture of D- and L-enantiomers of 
lactic acid and is well studied as a biodegradable coating for medical implants.  
 
2.2.3 Softisan® 649 
 
Softisan® 649 (Sasol Germany GmbH, Witten, Germany) is a partial ester of diglycerin 
containing medium chain fatty acids, isostearic acid, stearic acid 12-hydroxystearic acid and 
adipic acid. It can be sterilized by heat and has a stable viscosity from 25 °C to 75 °C similar 
to that of lanolin. In the following it is termed as DG for diglyceride. 
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2.2.4 Dynasan® 118 
 
Dynasan® 118 (Sasol Germany GmbH, Witten, Germany) is a tristearin and is often used in 
the pharmaceutical and cosmetic industry as adjuvants in preparations. Its melting range 
according to SOP 0540 (Sasol Germany GmbH, Witten, Germany) is 70 °C to 74 °C and it is 
stable against oxidation. In the following it is termed as TG for triglyceride. 
 
2.2.5 Tocopherol acetate 
 
Tocopherol acetate (Sigma-Aldrich AG, Deisenhofen, Germany) is termed as TA. 
 
2.2.6 Antibiotics 
 
Gentamicin sulfate (Fa. Heraeus, Holding GmbH, Hanau, Germany) and teicoplanin (Fa. 
Heraeus, Holding GmbH, Hanau, Germany) were lyophilized and suspended in chloroform 
(Sigma-Aldrich AG, Deisenhofen, Germany) in case of PDLLA, DG and TG and in 99 % 
ethanol (Sigma-Aldrich AG, Deisenhofen, Germany) in case of TA at a concentration of 22.9 
mg/mL. To decrease the particle size, suspensions were homogenized for five minutes (Hand 
homogenizer, Sartorius AG, Göttingen, Germany). The resulting suspension was added to the 
drug carriers building up a drug concentration of ten percent.  
 
2.3 Coating process 
 
Four different drug carriers were used for incorporating gentamicin sulfate as well as 
teicoplanin in a concentration of ten percent. The implants were coated by two dip-coating 
procedures ensuring a regular polymer coating and are termed in the following as drug-
carrier-coated PTFE prostheses. Dip-coating procedure was carried out in sterile sealable 
glass vials in presence of a magnetic stir bar on a magnetic stirrer (IKA, RET basic 
IKAMAG®) for 5 min following a drying period of 5 min between both coating procedures. 
All coating steps were carried out under aseptic conditions in a laminar air-flow hood. For 
cytotoxicity tests, grafts were additionally coated with the drug carriers without drug in the 
same way and are termed in the following as carrier-coated PTFE prostheses. The weight of 
each coating as well as the amount of incorporated drug was assessed by weight difference of 
PTFE grafts before and after the coating procedure. As the surface of PTFE prostheses is not 
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plane and regular and shows many pores, the thickness of individual coatings could not be 
reliably determined. In order to control reproducibility of the quantity of coating and the drug 
dose per sample and to minimize mistakes caused by 1 cm samples of PTFE prostheses 
inexact in length, the weights of PTFE prostheses before and after coating procedure were 
assessed and a coating quotient was established. The coating quotient is defined as the ratio 
between the weight of coating and the weight of 1 cm uncoated PTFE prostheses of this 
individual coating process: mcoating/ mPTFE prosthesis. The coating quotient is termed in the 
following as Qc. For each developed coating the Qc was obtained for 10 samples. 
 
2.4 Particle size 
 
The median particle size of untreated drug, lyophilized drug and drug after lyophilisation in 
combination with homogenization was determined by a particle size meter (Zetasizer Nano 
SZ, Malvern Instruments, Malvern UK). Particle size after lyophilisation and homogenization 
averaged 15.7 µm for gentamicin and 21.1 µm for teicoplanin. These data are confirmed by 
SEM studies. 
 
2.5 Morphological analysis-SEM 
 
Coated PTFE prostheses were prepared for SEM by sputtering with Gold (BAL-TEC MED 
020 coating system, Boeckeler Instruments, Arizona, USA) and examined with a high 
vacuum SEM (JSM 6060LV Scanning Electron Microscope, JEOL Ltd., Tokyo, Japan).  
 
2.6 Antibiotic release 
 
Drug release from drug-carrier-coated PTFE prostheses (n=3, length 1 cm, diameter 6 mm) 
was studied in phosphate-buffered saline (PBS) at 37 °C (pH 7.4) at 300 rpm in a 
Thermomixer (Fa. Eppendorf, Hamburg, Germany). The rotation was preferred to static state 
to simulate blood flow conditions in the vascular system. Uncoated PTFE prostheses served 
as control. At the time points 15 minutes, 1, 4, 8, 24, 48, 72 and 96 hours elution medium was 
completely changed. Sample drug solutions were assayed for gentamicin by spectroscopy. 
Therefore gentamicin was treated with 1.25 % aqueous ninhydrin solution at 95 °C for 15 min 
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and absorption was measured at 405 nm. Teicoplanin concentrations were determined by 
Innofluor Teicoplanin assay system (Opus Diagnostics, Fort Lee, USA). 
 
2.7 Test bacterium 
 
For in vitro studies a clinical isolate of S. aureus (strain ATCC® 49230) was used. The test 
strain was susceptible to both gentamicin (MIC 0.5 mg/l) and teicoplanin (MIC 0.25 mg/l). S. 
aureus was cultured on columbia agar plates (Becton Dickinson GmbH, Heidelberg, 
Germany) at 37 °C for 18 hours before testing.  
 
2.7.1 Growth curve 
 
In order to correlate the optical density at 600 nm (GeneQuant pro, biochrom, Cambridge, 
UK) of a S. aureus suspension with the colony forming units of the microorganism, a growth 
curve was recorded at different time points in Mueller-Hinton broth (No. 275730, BD 
Diagnostic Systems, Difco™, Heidelberg, Germany) at 37 °C. A logarithmic regression curve 
with the formula OD=0.0741 Ln(cfu)–0.2066 and a correlation coefficient of 0.91 resulted. 
 
2.7.2 Antibacterial characteristics 
 
In order to assess antibiotic efficacy at pathologically relevant concentrations (11), bacterial 
suspensions with 1 x 102, 1 x 103, 1 x 104 cfu/ml were prepared and incubated with 1 cm of 
drug-carrier-coated prostheses for 24 hours at 37 °C. 1 ml of each sample was added to 9 ml 
of Mueller-Hinton broth and incubated for another 24 hours at 37 °C. The optical density of 
the obtained suspensions and colony forming units on blood agar plates were determined for 
each sample and reference.  
In order to investigate the antimicrobial potential of drug-carrier-coated grafts, a hundredfold 
concentration of the commonly observed pathological concentration (1 x 104 cfu/ml) was 
chosen. Aseptically drug-carrier-coated PTFE prostheses (n=3, length 1 cm) as well as sterile 
uncoated PTFE prostheses as reference were added to 50 ml of S. aureus suspensions (2 x 106 
cfu/ml) and the optical density was measured at defined time intervals. 
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2.7.3 Adhesion of viable bacteria and antimicrobial potency after 24 hours 
elution 
 
After incubation of drug-carrier-coated PTFE prostheses in a suspension of S. aureus (2 x 106 
cfu/ml) for 24 hours, prostheses were removed and washed twice with isotonic NaCl. To 
determine the quantity of germs adsorbed, washed prostheses were placed into an ultrasonic 
bath of 1 ml of isotonic NaCl for ten minutes. 100 µl of the bacterial suspension obtained 
were plated on blood agar plates. For reference prostheses two dilution steps of 1 to 10 were 
carried out additionally expecting a high amount of adhered pathogens. Blood agar plates 
were incubated for 18 h at 37 °C and colony forming units were visually determined and 
extrapolated to the initial number of adsorbed pathogens. Uncoated reference prostheses were 
treated the same way.  
To determine whether drug-carrier-coated prostheses still retained anti-infective 
characteristics after the initial drug burst, drug–carrier-coated prostheses (n=3, length 1 cm) 
were eluted for 24 h in phosphate-buffered saline (PBS) at 37 °C (pH 7.4) at 300 rpm in a 
Thermomixer and placed on bacterial lawns cultured on Mueller-HintonII-agar plates (No. 
221177 BD Diagnostic System, Heidelberg, Germany).  
 
2.8 Cell culture 
 
Mouse connective tissue fibroblasts L929 were kindly provided by the ITEM GmbH – The 
Biotooling Company (Garching, Germany) and maintained in RPMI 1640 medium 
supplemented with 10 % fetal bovine serum, penicillin and streptomycin (100 U/ml and 0.1 
mg/ml, respectively), partricin (50 µg/ml) and stable glutamine at 37 °C in a humidified 
atmosphere containing 5 % CO2. 
 
2.9 In vitro cytotoxicity studies 
 
Cytotoxicity tests were carried out with L929 fibroblasts from mouse connective tissue. 
Developed drug-carrier-coated PTFE prostheses as well as carrier-coated PTFE prostheses 
were studied. In order to achieve the optimal ratio between the inner surface area of the grafts 
and the area of cell culture, grafts were cut into 0.33 cm pieces (n=3). Subsequently cells were 
cultured in 96-well microplates in presence of uncoated, carrier-coated and drug-carrier-
coated PTFE prostheses were immersed in 200 µl medium. Cells were cultured until 
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subconfluence, prostheses were taken out of the microplates and metabolic activity of viable 
cells was measured with the Roche cell proliferation reagent WST-1 (Roche Diagnostics 
GmbH, Mannheim, Germany).  
In order to analyze the toxicity of the drugs themselves, cells were cultured in 96-well 
microplates in presence of different concentrations of gentamicin and teicoplanin until 
subconfluence followed by a Roche cell proliferation reagent WST-1 test.  
For determination of fatty inclusions in the cell soma, cells were cultured in 96-well 
microplates in presence of coated PTFE prostheses (n=3, length 1cm) until subconfluence. 
Subsequently, cells were fixed with 50 % ethanol, treated with Oil Red O reagent (Sigma-
Aldrich AG, Deisenhofen, Germany) for 10 minutes at 4 °C and after washing with 50 % 
ethanol incubated in PBS. LM-micrographs were taken from sample and reference cells.  
 
2.10 Haemocompatibility studies 
 
Blood tests were carried out to study thrombogenic characteristics of individual coatings. 
Therefore 1 cm of sample and reference grafts were incubated for eight minutes in four ml 
freshly drawn non anticoagulated human whole blood in 15 ml conical centrifugal tubes (Carl 
Roth, Karlsruhe, Germany). Incubated blood was anticoagulated with trisodium citrate as well 
as EDTA and plasma was generated. In order to get information about a modified coagulation 
different coagulation factors were determined. Citrated blood plasma was examined with an 
amidolytic substrate assay for factor XIIa-like activity (Unitest™ FXIIA, Unicorn Diagnostics 
Ltd, Kent, UK) as well as by a monoclonal enzyme immunoassay for plasma F1+2 values 
(Enzygnost F1+2 micro, Behring, Marburg, Germany). EDTA blood plasma was tested for 
C3a-desArg (Complement C3a-desArg ELISA, Progen Biotechnik GmbH, Heidelberg, 
Germany). A thromboelastography for whole blood was carried out with a roTEG 
Coagulation Analyser (Pentapharm GmbH, Munich, Germany) using the in-TEM® 
(Pentapharm GmbH, Munich, Germany) for analysing the intrinsic pathway of blood 
coagulation. 
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3 Results 
 
3.1 Morphological analysis 
 
Stable and regular coatings could be observed through SEM after dip-coating. All coated 
grafts kept their flexibility and open pores for both side penetrations (Figure 1A – D). 
 
A B 
C D 
 
Figure 1. SEM pictures of the inner surface of a PTFE prostheses coated with gentamicin 10 % in 
tocopherol acetate: A) magnification 500; B) magnification 1500 and uncoated PTFE prostheses:  
C) magnification 500; D) magnification 1500. 
 
3.2 Antibiotic release 
 
The weights of used PTFE prostheses of a size of 1 cm averaged 76.80 mg and varied by 
more than ten percent concluding that measuring 1 cm lengths of PTFE prostheses is less 
accurate than weighing. Coatings consisting of PDLLA with incorporated gentamicin showed 
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an average Qc of 0.52 corresponding to a coating weight of 39.94 mg relating as the following 
given coating weights to the average 1 cm PTFE prostheses,  whereas the Qc of coatings 
consisting  of  PDDLA with  incorporated  teicoplanin  averaged  at  0.32  corresponding  to  a 
coating weight of 24.58 mg. Tocopherol acetate based coatings showed a Qc of 0.25 (coating 
weight of 19.2 mg) in case of incorporated gentamicin and 0.23 (coating weight of 17.67 mg) 
in case of teicoplanin. Qc of coatings with DG averaged at 0.24 (coating weight of 18.43 mg) 
for  incorporated  gentamicin  and  at  0.25  (coating  weight  of  19.2  mg)  for  incorporated 
teicoplanin.  The coatings consisting of TG with gentamicin showed a Qc of 0.29 (coating 
weight of 22.72 mg) and in case of teicoplanin a Qc of 0.31 (coating weight of 23.81 mg) 
(Figure 2). Reliable reproducibility of coating procedure was demonstrated with TA, DG and 
TG. Average Qc of PDLLA with incorporated gentamicin is statistically different than average 
Qc of PDLLA with incorporated teicoplanin.
Figure 2. Individual coating quotients Qc defined as the ratio between the weight of coating and the weight 
of a 1 cm uncoated PTFE prosthesis of this individual coating process: mcoating/ mPTFE prosthesis.
G1 ^= gentamicin 10 % in PDLLA, G2 ^= gentamicin 10 % in tocopherol acetate, G3 ^= gentamicin 10 % in  
Softisan® 649,  G4  ^=  gentamicin  10  %  in  Dynasan® 118,  T1  ^=  teicoplanin  10  %  in  PDLLA,  T2  ^= 
teicoplanin 10 % in tocopherol acetate, T3 ^= teicoplanin 10 % in Softisan® 649, T4 ^= teicoplanin 10 % in 
Dynasan® 118
To obtain information about time - dependant drug kinetics, the release rates (defined as the 
total amount of released drug in microgram per hour) of gentamicin/teicoplanin present in the 
respective  carriers  were  plotted  against  time.  Continuous  drug  release  kinetics  could  be 
demonstrated over 96 hours for the four individual carriers (PDLLA, TA, DG, TG). In the 
first  hour  an  initial  drug  burst  was  observed  followed  by  a  low  continuous  release  of 
0
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gentamicin for the rest of the testing interval. The carriers TA and DG showed comparable 
release rates for incorporated gentamicin after 15 minutes between 2403.1 µg/h and 2121.6 
µg/h. For gentamicin in PDLLA, a much higher release rate after 15 minutes of 4528.0 µg/h 
could be assessed whereas the lowest release rate of 1167.0 µg/h was detected for gentamicin 
in TG. After 96 hours, release rates for all four individual carriers varied between 0.5 µg/h in 
case of PDLLA and 0.1 µg/h in case of TG.  
For Teicoplanin an initial drug burst in the first hour was detected following a continuous 
drug release for the rest of the testing time. Release rates after 15 minutes of the four 
individual carriers varied between 6090.0 µg/h for PDLLA and 1477.7 µg/h for TA 
decreasing almost exponentially. 
Continuous drug release over 96 hours fulfils the primary aim of developing an effective anti-
infective method for post-operative protection against infection. The total amount of the drug 
is expected to be released as the lipid-based carrier degrades over one to six months which 
implies an extended protection for this period of time.   
Gentamicin and teicoplanin each showed a distinct pattern of drug release using the four 
different lipid-based carriers. Gentamicin and teicoplanin were stable in PBS in experiments 
for at least 96 hours. 
 
3.3 Antibacterial characteristics 
 
Continuous antibiotic release for more than one day after a surgical procedure is one 
important aspect, but the key characteristic is the antibacterial effect. Individual coatings 
showed a highly effective potency against pathologically relevant S. aureus concentrations in 
a range of 102 to 104 cfu/ml. There was no difference between OD values from samples and 
sterile Mueller-Hinton medium. Colony growth on agar plates incubated with sample medium 
could not be observed with each of the individual coatings concluding a total germ eradication 
caused by individual coatings.  
Bacterial growth in highly concentrated bacterial suspensions of 2 x 106 cfu/ml could be 
reduced by all developed drug-carrier-coated PTFE prostheses. In all cases using gentamicin, 
a pathogen reduction of over 99 % after 24 hours was observed. After 5 hours of incubation a 
decrease in colony forming units compared to uncoated prostheses was observed. While the 
number of S. aureus colonies in reference tubes increases in the following incubation time, 
drug-carrier coated samples show no additional growth. The best growth inhibition effect 
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after 24 hours was observed with the combination of PDLLA and gentamicin resulting in a 
colony reduction of 99.42 % (Table 1). 
Coatings with teicoplanin showed a reduction in S. aureus concentration after 24 hours of at 
least 93.14 % with TA up to 99.43 % using PDLLA as drug carrier (Table 1). First growth 
inhibition effects can also be detected after 5 hours of incubation.  
 
 
Type of coating Colony reduction [%] 
G1 99.42 
G2 99.35 
G3 99.36 
G4 99.31 
T1 99.43 
T2 93.14 
T3 99.48 
T4 94.53 
Uncoated PTFE prostheses 0 
 
Table 1. S. aureus colony reduction of drug-carrier-coated PTFE prostheses in [%] compared to uncoated 
PTFE prostheses after 24 hours of incubation in S. aureus suspension (initial S. aureus concentration:  
2 x 106 cfu/ml, S. aureus concentration after 24 hours in presence of uncoated PTFE prostheses: 5381.06 x 
106 cfu/ml). 
 
G1 ^= gentamicin 10 % in PDLLA, G2 ^= gentamicin 10 % in tocopherol acetate, G3 ^= gentamicin 10 % in 
Softisan® 649, G4 ^= gentamicin 10 % in Dynasan® 118, T1 ^= teicoplanin 10 % in PDLLA, T2 ^= 
teicoplanin 10 % in tocopherol acetate, T3 ^= teicoplanin 10 % in Softisan® 649, T4 ^= teicoplanin 10 % in 
Dynasan® 118 
 
3.3.1 Adhesion of viable bacteria and antimicrobial potency after 24 hours 
elution 
 
Bacterial adhesion on 1 cm coated grafts after 24 hours of incubation in a S. aureus 
suspension was determined. All gentamicin and teicoplanin coatings showed a visible reduced 
number of adhered pathogens on the surface. The lowest number of pathogens on gentamicin 
coatings was observed on the surface of DG based coatings with average counts of 67 cfu 
whereas PDLLA based coatings showed the highest counts at an average of 5433 cfu. 
Reference pathogen numbers could not be assessed being far beyond visual determination 
building up a bacterial mat even after carrying out two dilution steps of 1 to 10 (Table 2). 
Inhibition zones on S. aureus lawns could not be detected for all four gentamicin coatings. For 
tested coatings with incorporated teicoplanin, the lowest number of adsorbed bacteria was 
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found on the surface of PDLLA based coatings at an average of 120 counts whereas TA based 
coatings averaged 14956 counts. Inhibition zones could not be detected for all four 
teicoplanin coatings. 
 
 
 
Coating type Averaged counts of adhered cfu 
G1 5433 ± 9411 
G2 1967 ± 3748 
G3 67 ± 58 
G4 600  ± 1039 
T1 123 ± 70 
T2 14956 ± 8735 
T3 1450 ± 190 
T4 1706 ± 1951 
Uncoated PTFE prostheses Bacterial lawn/ total coverage 
 
Table 2. Averaged numbers of S. aureus colonies adsorbed on the surface of drug-carrier-coated PTFE 
prostheses after 24 hours of incubation in 2 x 106 cfu/ml suspension. 
 
G1 ^= gentamicin 10 % in PDLLA, G2 ^= gentamicin 10 % in tocopherol acetate, G3 ^= gentamicin 10 % in 
Softisan® 649, G4 ^= gentamicin 10 % in Dynasan® 118, T1 ^= teicoplanin 10 % in PDLLA, T2 ^= 
teicoplanin 10 % in tocopherol acetate, T3 ^= teicoplanin 10 % in Softisan® 649, T4 ^= teicoplanin 10 % in 
Dynasan® 118 
 
3.4 In vitro cytotoxicity studies 
 
The WST-1 assay shows high metabolic activity of viable cells in presence of PTFE 
prostheses coated with a combination of TA with 10 % teicoplanin (91 % of reference cell 
proliferation) followed by PDLLA (79 % of reference cell proliferation) and TG with 10 % 
teicoplanin (77 % of reference cell proliferation). Cells in presence of gentamicin 10 % 
incorporated in TA, PDLLA and TG maintain a sufficient but lower metabolic activity (32 % 
to 67 % of reference cell proliferation). Prostheses coated with gentamicin 10 % in DG as 
well as teicoplanin 10 % in DG in contrast show a very low metabolic activity concluding a 
higher cytotoxic potential (≤ 15 % of reference cell proliferation). The Oil Red O assay gives 
a possible explanation for this observation. Under the microscope, red stained lipid inclusions 
were only detected in cells cultured in presence of prostheses coated with DG and gentamicin 
respectively teicoplanin.  
The WST-1 assay for pure drug carriers shows results with a similar tendency. A high cell 
proliferation in presence of PDLLA, TA and TG could be demonstrated whereas cells in 
presence of DG show a low metabolic activity and lipid inclusions.  
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In concentrations of 200 µg to 1000 µg per well teicoplanin showed no cytotoxic effect on 
mouse fibroblasts whereas gentamicin showed increased cytotoxic properties at 
concentrations beyond 200 µg.  
 
3.5 Haemocompatibility studies 
 
3.5.1 Monoclonal enzyme immunoassay for plasma F1+2 values 
 
The incubation of individual drug-carrier-coated PTFE prosthese in human blood caused the 
formation of a smaller degree of human prothrombine fragment F1+2 compared to uncoated 
PTFE prostheses. The concentration of F1+2 fragments varied between 204 pmol/l and 272 
pmol/l. The range of citrated plasma for healthy adults averages from 69 pmol/l to 229 pmol/l. 
Uncoated PTFE prostheses however showed a much higher F1+2 fragment concentration at 
350 pmol/l. 
 
3.6 Amidolytic substrate assay for factor XIIa-like activity 
 
The assessment of factor XIIa-like activity in human blood showed that all individual 
coatings activated factor XIIa in the same range as uncoated prostheses. Developed coatings 
showed a factor XIIa-like activity between 11.25 u/l and 12.06 u/l whereas uncoated PTFE 
prostheses caused a slightly higher factor XIIa-like activity of 13.37 u/l.  
 
3.6.1 Thromboelastography 
 
The roTEG coagulation study provides two important parameters the clotting time (CT) and 
maximal clot firmness (MCF). CT describes the time interval from the start of the 
measurement until initiation of clotting whereas MCF is a dimension of the firmness of a clot. 
All lipid-based coatings besides teicoplanin 10 % in TG showed median CT values in a range 
of 102.63 seconds to 146.13 seconds. The coating type of teicoplanin 10 % in TG caused a 
CT of 62.50 seconds similar to those of uncoated PTFE prostheses of 63.31 seconds. These 
data confirm results from F1+2 value assessment indicating a delayed blood coagulation for 
almost all individual coatings. MCF values of all lipid-based coatings are situated in the 
normal range of 53 mm to 72 mm and do not differ from uncoated PTFE values.  
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3.6.2 Complement C3a-desArg ELISA 
 
The quantitative assessment of C3a-desArg showed different results depending on the used 
lipid-based coating. Prostheses coated with gentamicin sulfate incorporated in PDLLA 
showed very low C3a-desArg concentrations at 189 ng/ml whereas TA with incorporated 
gentamicin and teicoplanin as well as DG in combination with teicoplanin activated a higher 
amount of C3a-desArg in a range between 406 ng/ml and 442 ng/ml. All other coatings 
activated C3a-desArg fragments between 241 ng/ml and 351 ng/ml whereas uncoated 
prostheses caused a median C3a-desArg fragment concentration of 179 ng/ml.  
 
4 Discussion 
 
In the present work new anti-infective surface coatings using lipid-based drug delivery 
systems were studied. Used PDLLA, TA, DG and TG carrier give the possibility to bring 
hydrophilic antibiotics on the surface of hydrophobic implants building up a slow release drug 
delivery system independent of drug charge. Further important characteristics of individual 
carriers are a melting point above body temperature and the possibility of sterilization.  
There is a great diversity of used antibiotics for a reasonable graft protection in literature 
using penicillins (18), fluoroquinolons (29) or aminoglycosides (27).  
Okahara et al. (29) impregnate PTFE grafts with ofloxacin, Prahlad et al. (31) use (14)C-
penicillin for antimicrobial PTFE graft protection while Modak et al. (25) claim to achieve a 
less toxic and less thrombogenious effect by binding antibiotics directly or in combination 
with a metal such as silver to the surface of a graft, however this sets a limitation both in the 
quantity of drug on the graft surface as well as in the development of a slow drug release 
system.  
Another way for an anti-infective equipment of grafts is the use of cationic surfactants like 
benzalkonium chloride (19), but both cytotoxicity studies have demonstrated that these 
surfactants often used in pharmaceutical preparations as preservatives show a high cytotoxic 
potential in already low concentrations (9, 22) and there is a limitation of drug choice because 
of charge dependency. Haverich et al. (20) and Ney et al. (27) use a fibrin sealant while 
Moore et al. (26) developed a collagen-release system as antibiotic carrier for anti-infective 
graft protection, however a decreased haemocompatibility could be the consequence. 
In this study the coverage of a broad spectrum of pathogens was the crucial factor for 
antibiotics of choice. Gentamicin was chosen as it is a basic antibiotic for treating implant 
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infection (33) whereas teicoplanin is clinically applied in more pronounced infections and  
MRSA treatment (32) which is of increasing importance for nosocomial infections.  
In the present work a coating process was developed and received coated PTFE prostheses 
were studied in vitro for drug release, biocompatibility, anti-infective character and 
haemocompatibility. Reproducibility of the coating process could be ensured in case of TA, 
DG and TG, however coating procedure with PDLLA showed fluctuation in terms of coating 
weights. Developed coatings ensure a continuous drug release over 96 hours and guarantee a 
high local antibiotic concentration around the graft. In comparison to systemic drug 
application side effects for the host organism can thereby be reduced.  
As gentamicin and teicoplanin do not dissolve in used organic solvents, samples were coated 
in drug/carrier suspensions. As a result coatings consisted of antibiotic particles which are 
incorporated in the polymer. An initial drug burst in the first hour of elution is the 
consequence as antibiotic particles from the surface of the coating dissolve rapidly after 
contact with elution buffer. Particles located deeper inside the lipid-based polymer will only 
be released after polymer degradation or diffusion through the polymer.  
In pathologically relevant bacterial concentrations as demonstrated by Elek and Conen (11), 
developed drug-carrier coatings achieved a bacterial eradication rate of 100 %. This shows a 
highly effective potency against S. aureus colonization. Even in a concentration hundredfolds 
beyond maximal pathologically relevant bacterial concentration, S. aureus growth could 
highly be reduced after 24 hours by each of the developed drug-carrier coatings. Coatings 
with incorporated teicoplanin showed an insignificant smaller growth inhibition effect than 
coatings with gentamicin. Bacterial adhesion after 24 hours of incubation in a 2 x 106 cfu/ml 
S. aureus suspension could also highly be reduced by drug-carrier-coated prostheses 
compared to uncoated ones. Drug-carrier coatings after 24 hours of drug elution could not 
show inhibition zones on bacterial lawns assuming that the contact area to agar plates is too 
small and drug diffusion into agar medium is not as easy as in fluid media. However the 
antibacterial effects in fluid media are closer to physiological conditions. All coatings besides 
DG showed small but functionally acceptable cytotoxic levels (≤ 22.8 % cell proliferation 
decrease). Tests with oil red O reagent show that DG is incorporated in the cell soma which 
apparently leads to cell death.  
Haemocompatibility of individual coatings could be confirmed by several experiments. Data 
of activated human prothrombin fragement F1+2 and FXIIa activity in plasma as well as 
clotting time and maximal clot firmness from roTEG tests show an even lower thrombogenic 
effect of individual lipid-based coatings in comparison to uncoated PTFE grafts. Increased 
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C3a-desArg concentrations were caused by some of the coatings, nevertheless tolerable C3a-
desArg concentration limits have to be discussed.  
 
5 Conclusions 
 
In this study we could demonstrate the development of a drug delivery system consisting of 
lipid-based polymers with incorporated gentamicin and teicoplanin to locally release high 
drug concentrations in the area of implant infection. Developed coatings with PDLLA, 
tocopherol acetate and Dynasan® 118 as drug carriers completely inhibited the proliferation of 
S. aureus in pathologically relevant concentrations while preserving biocompatible and 
haemocompatible characteristics. If these results can be confirmed in vivo, developed drug 
delivery systems could have a high interest in vascular surgery. 
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7 Figure and Table Captions 
 
Figure 1. SEM pictures of the inner surface of a PTFE prostheses coated with gentamicin  
10 % in tocopherol acetate and uncoated PTFE prostheses.   
 
Figure 2. Individual coating quotients Qc defined as the ratio between the weight of coating 
and the weight of a 1 cm uncoated PTFE prostheses of this individual coating process: 
mcoating/ mPTFE prosthesis.
 
Table 1. S. aureus colony reduction of drug-carrier-coated PTFE prostheses in [%] compared 
to uncoated PTFE prostheses after 24 hours of incubation in S. aureus suspension. 
 
Table 2. Averaged numbers of S. aureus colonies adsorbed on the surface of drug-carrier-
coated PTFE prostheses after 24 hours of incubation in 2 x 106 cfu/ml suspension. 
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Chapter 3
New  anti-infective  coatings  of  surgical  sutures  based  on  a 
combination of antiseptics and fatty acids 
Abstract
Objectives: Wound infection is a feared complication in surgery. The aim of this study was to 
develop  new anti-infective  coatings  of  surgical  sutures  and  to  compare  the  antimicrobial 
effectiveness and biocompatibility to the well-established Vicryl Plus®. 
Methods: Synthetic  absorbable  PGA  surgical  sutures  were  coated  with  three  different 
chlorhexidine concentrations and two different octenidine concentrations in combination with 
palmitic acid and lauric acid. Drug release kinetics lasting 96 hours was studied in phosphate 
buffered saline  at  37 °C. Anti-infective  characteristics  were determined by measuring  the 
change in optical density of Staphylococcus aureus suspensions charged with coated sutures 
over time. Microorganisms adsorbed at the surface of sutures were assessed on blood agar 
plates  and coated sutures eluted for 24 hours were placed on bacterial  lawns cultured  on 
Mueller-Hinton plates to prove retained antimicrobial potency. A cell proliferation assay was 
performed  to  assess  the  degree  of  cytotoxicity.  Anti-infective  characteristics  and 
biocompatibility were compared to Vicryl Plus®. 
Results: A coating technology for slow-release drug delivery systems  on surgical  sutures 
could  be  developed.  All  coatings  showed  a  continuous  drug  release  within  96  hours. 
Individual chlorhexidine  and  octenidine  coated  sutures  showed  superior  anti-infective 
characteristics but inferior biocompatibility in comparison to Vicryl Plus®.
Conclusions: We conclude that developed anti-infective suture coatings consisting of lipid 
based  drug  delivery  systems  in  combination  with  antiseptics  are  highly  effective  against 
bacterial  colonization in vitro,  however drug doses for human use have to be adjusted to 
comply with biocompatibility.
 
Keywords: Surgical sutures, antimicrobial coating, drug delivery system, biocompatibility, 
fatty acids
New anti-infective coatings of surgical sutures 
_________________________________________________________________________________________________________________ 
 58
1 Introduction 
 
Wound infection is a feared complication in post-operative treatment leading to severe health 
burden for the patient and high medical costs for society (1, 3). One of the most common 
pathogens in wound infections is Staphylococcus aureus colonizing surgical implants or 
sutures (8, 20). It is of high importance to avoid those infections as good as possible. A new 
technology is the equipment of surgical sutures with antimicrobial drugs like antiseptics (11, 
25). In order to fix hydrophilic agents on the surface of biomaterials, a lipophilic mediator 
agent is needed.  
Beyond its character to equip the surface of biomaterials with hydrophilic antimicrobial 
agents, this mediator agent should fulfil the function of a retarded drug release in order to 
achieve anti-infective protection during wound healing after surgery. Furthermore the 
mediator agent should decrease the surface roughness and consequently reduce mechanical 
stress during sewing. In order to give considerations to all of these requirements, the mediator 
agent has to be chosen advisedly. In this work the fatty acids palmitic acid and lauric acid are 
used as mediator agents to build up a slow release system in anti-infective coatings on PGA 
sutures. The present work presents newly developed lipid-based drug delivery systems in 
combination with antiseptics for anti-infective suture equipment and the evaluation of drug 
release, anti-infective characters and biocompatibility compared to Vicryl Plus®. 
 
2 Materials and Methods 
 
2.1 Medical Implant 
 
Commercially available synthetic absorbable PGA surgical sutures (3 metric) (PGA 
Resorba®, Resorba, Nürnberg, Germany) and Vicryl Plus® (3 metric) (Ethicon GmbH 
Deutschland, Norderstedt, Germany) were applied. Sterile sutures were cut into defined 
length (1 cm, 3 cm) under aseptic conditions in a laminar airflow and used for further 
experiments. 
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2.2 The anti-infective coating 
 
PGA sutures were antimicrobially equipped with one type of chlorhexidine dipalmitate (CP) 
(Heraeus, Hanau, Germany) coating, two types of chlorhexidine dilaurate (CL1 and CL2) 
(Heraeus, Hanau, Germany) coatings and two types of octenidine hydrochloride (OH1 and 
OH2) (Dishman Pharmaceutical, NJ, USA) coatings. For octenidine hydrochloride the fatty 
acid palmitic acid (Carl Roth, Karlsruhe, Germany) was used as drug carrier. Within one 
coating type, coatings differed only in the drug weight per unit length. Methanol was used as 
solvent for individual coatings. Drug concentrations (w/v) in methanol differed for each 
coating. (CP: 2 %, CL1: 5 %, CL2: 15 %, OH1: 10 %, OH2: 21 %). In preliminary 
experiments the influence of ethanol and methanol as bath solvent was elucidated. During 
coating procedure with ethanolic solvents, a delamination of the commercial coating of the 
PGA Resorba® can occur, the application of methanol is practical in this respect. Sutures (50 
cm length) were coated by a dip-coating procedure carried out in sterile sealable one neck 
flasks in presence of a magnetic stir bar on a magnetic stirrer (RCT basic IKAMAG®, IKA, 
Staufen, Germany) at room temperature (23 °C). Therefore sutures were pulled through the 
coating bath within few seconds. This procedure was followed by a drying process for 24 
hours under the laminar air-flow hood. Coated sutures were packed in PE bags and sterilized 
with ethylenoxide. Coating weights were gravimetrically determined and a standardized drug 
weight per unit length massdrug/lengthsuture (µg/cm) was assessed for each coating type. 
 
2.3 Morphological analysis-SEM 
 
Individual coated sutures were prepared for SEM by sputtering with gold (BAL-TEC MED 
020 coating system, Boeckeler Instruments, Arizona, USA) and examined with a high vacuum 
SEM (JSM 6060LV Scanning Electron Microscope, JEOL Ltd., Tokyo, Japan).  
 
2.4 Drug release 
 
Drug release kinetics lasting 96 hours was studied in phosphate-buffered saline (PBS) at 37 ° 
C (pH 7.4) in a thermomixer (Fa. Eppendorf, Hamburg, Germany). Therefore one thread of 1 
cm length was placed in 750 µl PBS in a 1.5 ml flask (Eppendorf Cap, Fa. Eppendorf, 
Hamburg, Germany). Three experiments per coating type were performed. At time points 1 h, 
4 h, 8 h and 24 h, 48 h, 72 h and 96 h elution medium was completely changed. Octenidine 
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was assessed by spectroscopic measurement at 280 nm. Chlorhexidine was assessed by 
derivatize with bromcresol and measuring the optical density at 410 nm.  
 
2.5 Test bacterium 
 
For in vitro studies a clinical isolate of S. aureus (strain ATCC® 49230) was used. The test 
strain was susceptible to both gentamicin (MIC 0.5 mg/l) and teicoplanin (MIC 0.25 mg/l). S. 
aureus was cultured on columbia agar plates (Becton Dickinson GmbH, Heidelberg, 
Germany) at 37 °C for 18 hours before testing.  
 
2.5.1 Antibacterial characteristics 
 
In order to assess antibiotic efficacy at pathologically relevant concentrations, S. aureus was 
resuspended in normal saline and adjusted to 1 x 108 cfu/ml by visual comparison with a 0.5 
McFarland standard. Based on this stock suspension, bacterial suspensions (1 ml) with 1 x 
102, 1 x 103, 1 x 104 cfu/ml were prepared and incubated with individual sutures (length: 3 
cm, n=3) in sealed glass capillaries. Samples were incubated for 24 hours at 37 °C. 100 µl of 
each sample was plated on blood agar plates and incubated for 24 hours at 37 °C. Colony 
forming units were determined for each sample and reference. In order to investigate the 
maximal antimicrobial potential of coated sutures, a hundredfold concentration of the 
maximal pathologically relevant concentration (1 x 104 cfu/ml) was chosen. Sterile coated 
sutures (length: 3 cm, n=3) were added to 50 ml of S. aureus suspensions. The optical density 
was measured every 60 minutes within the first eight hours and after 24 hours again. Optical 
density was plotted against time. With the aid of a calibration curve, bacterial concentrations 
in colony forming units (cfu/ml) of sample and reference at different investigation times could 
be obtained. A reference was established by investigating Vicryl Plus® and uncoated sutures 
the same way.  
 
2.5.2 Adhesion of viable bacteria and antimicrobial potency after 24 hours 
elution 
 
In order to determine the number of germs adsorbed, sutures were incubated in 1 x 106 cfu/ml 
for 24 hours. Subsequently sutures were washed twice with NaCl and placed into an 
ultrasonic bath of 1 ml of isotonic NaCl for ten minutes. 100 µl of the bacterial suspension 
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obtained were plated on blood agar plates. For reference sutures two dilution steps of one to 
ten were carried out additionally expecting a high amount of adhered pathogens. Blood agar 
plates were incubated for 18 h at 37 °C and colony forming units were visually determined 
and extrapolated to the initial number of adsorbed pathogens. Sutures (length 3 cm, n=3) were 
eluted for 24 h in PBS at 37 °C and placed on bacterial lawns cultured on Mueller-HintonII-
agar plate (BD Diagnostic System, Heidelberg, Germany). Bacterial lawns were produced by 
adding cultured S. aureus in isotonic NaCl, adjusted to 1 x 108 cfu/ml by visual comparison 
with a 0.5 McFarland standard.  
 
2.6 Cell culture 
 
Mouse connective tissue fibroblasts L929 were kindly provided by the ITEM GmbH – The 
Biotooling Company (Garching, Germany) and maintained in RPMI 1640 medium 
supplemented with 10 % fetal bovine serum, penicillin and streptomycin (100 U/ml and 0.1 
mg/ml, respectively), partricin (50 µg/ml) and stable glutamine at 37 °C in a humidified 
atmosphere containing 5 % CO2. 
 
2.7 In vitro cytotoxicity studies 
 
Cytotoxicity tests were carried out with L929 fibroblasts from mouse connective tissue. In 
order to prove biocompatibility, L929 fibroblasts (IMETUM, Garching, Germany) were 
cultured in presence of 1 cm of individual sutures until subconfluence. To assess the degree of 
cytotoxicity, the Roche cell proliferation assay (Roche Diagnostics GmbH, Mannheim, 
Germany) was performed. The Oil Red O staining was used for detecting incorporated lipids 
in the cell soma.  
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3 Results 
 
3.1 Morphological analysis 
 
Coatings could be observed through SEM after dip-coating. All coated sutures kept their 
flexibility (Figure 1A - D). 
 
 
Figure 1. SEM pictures of PGA Resorba® sutures coated with A) chlorhexidine dipalmitate (CP) and B) 
octenidine hydrochloride (OH2), C) Vicryl Plus® and D) clinically used PGA Resorba® (magnification 
450). 
 
3.2 Drug release 
 
The drug weight per unit length was assessed for the CP coating at 90 µg/cm, for CL1 at 70 
µg/cm and CL2 at 190 µg/cm and for OH1 at 6 µg/cm and OH2 at 28 µg/cm (Figure 2). All 
developed coatings showed a continuous drug release within 96 hours. CP was released 
continuously within 96 hours ending up in a concentration of 4.1 µg/ml. The concentration of 
A B
C D
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CL1 was assessed at 10.4 µg/ml after 96 hours, for CL2 concentrations of 31.1 µg/ml within 
96 hours were determined. OH1 showed a released concentration of 0.7 µg/ml after 96 hours 
whereas for OH2 a concentration after 96 hours of 0.5 µg/ml was assessed (Figure 3).  
 
 
 
Figure 2. Released concentration of antiseptic drugs (weight/volume) from PGA sutures after 96 hours 
into PBS buffer, related to antiseptic drug charge (weight/unit length). 
 
CP ^= chlorhexidine dipalmitate (90 µg/cm), CL1 ^= chlorhexidine dilaurate (70 µg/cm), CL2 ^= 
chlorhexidine dilaurate (190 µg/cm), OH1 ^= octenidine hydrochloride (6 µg/cm), OH2 ^= octenidine 
hydrochloride (28 µg/cm) 
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Figure 3. Elution profiles of different drugs into PBS from A) chlorhexidine coated PGA sutures and B) 
octenidine coated PGA sutures.  
 
CP ^= chlorhexidine dipalmitate (90 µg/cm), CL1 ^= chlorhexidine dilaurate (70 µg/cm), CL2 ^= 
chlorhexidine dilaurate (190 µg/cm), OH1 ^= octenidine hydrochloride (6 µg/cm), OH2 ^= octenidine 
hydrochloride (28 µg/cm) 
 
3.3 Antibacterial characteristics 
 
Individual coatings showed a highly effective potency against physiological S. aureus 
concentrations in a range of 102 to 104 cfu/ml. Colony growth on agar plates incubated with 
sample medium could not be observed with each of the individual coatings concluding a total 
germ eradication caused by all tested individual coatings. 
Bacterial growth in highly concentrated bacterial suspensions of 2 x 106 cfu/ml could be 
reduced by all developed suture coatings. CP, CL1, CL2 and OH2 coated sutures showed a 
cfu/ml reduction after 24 hours in comparison to uncoated reference of over 99 % whereas 
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OH1 coated sutures only reduced pathogen concentration in a range of 17 % after 24 hours in 
comparison to uncoated sutures. Vicryl Plus® reduced bacterial growth in a range of 34 % 
after 24 hours (Figure 4). 
 
 
 
Figure 4. S. aureus growth cultured in sterile Mueller-Hinton broth for 24 hours in the presence of 
individual antimicrobially coated sutures: A) chlorhexidine dipalmitate, B) octenidine hydrochloride, C) 
octenidine hydrochloride, D) Vicryl Plus®. 
 
CP ^= chlorhexidine dipalmitate (90 g/cm), CL1 ^= chlorhexidine dilaurate (70 g/cm), CL2 ^= 
chlorhexidine dilaurate (190 g/cm), OH1 ^= octenidine hydrochloride (6 g/cm), OH2 ^= octenidine 
hydrochloride (28 g/cm) 
 
3.4 Adhesion of viable bacteria and antimicrobial potency after 24 
hours elution 
 
Bacterial adhesion on coated PGA sutures was reduced depending on the coating type. The 
lowest number of adhered pathogens was observed on the surface of PGA sutures coated with 
CL2 at an average of 5326 cfu/ml ± 7048 cfu/ml. CP and CL1 showed adhered bacterial 
concentrations of 163392 cfu/ml ± 87402 cfu/ml and 121434 cfu/ml ± 86770 cfu/ml. Adhered 
bacterial concentration on the surface of OH1 and OH2 were assessed at 5772 cfu/ml ± 2141 
cfu/ml and 8214 cfu/ml ± 11920 cfu/ml. The highest amount of adsorbed germs on coated 
sutures was detected on Vicryl Plus® suture surfaces at 273060 cfu/ml ± 52016 cfu/ml. 
Uncoated reference sutures showed  an average pathogen adhesion of 273948 cfu/ml ± 35694 
B
C
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cfu/ml. Inhibition zones on bacterial lawns were only developed by CL2 coated sutures and 
Vicryl Plus® sutures (Figure 5).  
 
 
Figure 5. Numbers of S. aureus colonies adsorbed on the surface of coated PGA sutures after 24 hours of 
incubation in 2 x 106 cfu/ml suspension. 
 
CP ^= chlorhexidine dipalmitate (90 µg/cm), CL1 ^= chlorhexidine dilaurate (70 µg/cm), CL2 ^= 
chlorhexidine dilaurate (190 µg/cm), OH1 ^= octenidine hydrochloride (6 µg/cm), OH2 ^= octenidine 
hydrochloride (28 µg/cm) 
 
3.5 In vitro cytotoxicity studies 
 
Cells in presence of coated sutures showed a metabolic activity in a range of 16 % and 17 % 
for coating types CP, CL1, OH1 and OH2 and a relative metabolic activity of 25 % for CL2 in 
comparison to reference. Cells in presence of Vicryl Plus® showed a comparable metabolic 
activity to uncoated sutures. The oil red O test demonstrates high amounts of fatty inclusions 
inside the cell soma of cells in presence of palmitic acid which is a possible reason for the 
high cytotoxic level of fatty acid coated sutures (Figure 6). 
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Figure 6. Metabolic activity of viable cells incubated with individual coated sutures measured with the 
Roche cell proliferation assay. Uncoated PGA sutures as well as Vicryl Plus® sutures served as reference. 
 
CP ^= chlorhexidine dipalmitate (90 µg/cm), CL1 ^= chlorhexidine dilaurate (70 µg/cm), CL2 ^= 
chlorhexidine dilaurate (190 µg/cm), OH1 ^= octenidine hydrochloride (6 µg/cm), OH2 ^= octenidine 
hydrochloride (28 µg/cm) 
 
4 Discussion 
 
Post-operative infections are feared complications in surgery (5). One of the most common 
pathogens in wound infections and implant-associated infections is Staphylococcus aureus 
colonizing foreign surfaces like surgical implants, sutures and the surrounding tissue (6, 24, 
26). In presence of implants, a smaller amount of pathogens is necessary to cause infection. 
The formation of biofilms on biomaterials protects bacteria from host immune defence and 
increases antibiotic resistance so that even high local concentrations of antibiotics do not 
completely eradicate bacteria in biofilms (7, 10, 17). It is therefore of high importance to 
prevent bacteria from surface adhesion (11). A promising therapeutical approach is the anti-
infective equipment of sutures in order to release locally high amounts of antimicrobial drugs 
(12, 13, 15, 16). Antiseptics like chlorhexidine and octenidine have shown high anti-infective 
efficacy in several studies about orthopaedic and dental applications however no literature is 
available concerning suture coatings (9, 14, 23). 
In this work PGA sutures were coated with antiseptics to achieve an effective protection 
against bacterial colonization during wound healing. A coating technology for PGA sutures 
was developed and coatings were characterized by drug release, anti-infective effectiveness 
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and biocompatibility. Morphological analysis by SEM showed that developed anti-infective 
coatings are partly integrated into the multifilament structure of PGA sutures, a delamination 
of coatings could not be assessed macroscopically. Therefore, when applied in vivo, no 
delamination is expected during sewing. The evaluation by surgeons in animal experiment 
under standardized conditions could shed light on this regard (22). 
In order to fix the used antiseptics chlorhexidine and octenidine on the suture surfaces and to 
build up a retarded drug release system for long-term anti-infective characters, chlorhexidine 
and octenidine were combined with the fatty acids palmitic acid and lauric acid. These lipid-
based formulations furthermore decrease the surface roughness of sutures and consequently 
reduce mechanical stress during sewing. The newly developed anti-infective coatings using 
the antiseptics chlorhexidine and octenidine were compared to the already well established 
suture Vicryl Plus® using triclosan as anti-infective compound.  
Biocompatibility as well as the anti-infective effectiveness of Vicryl Plus® have been 
corroborated in several in vitro and in vivo studies. Rothenburger et al. have evaluated a 
coated polyglactin 910 suture with triclosan for its antibacterial effectiveness against 
staphylococci (19). They report a sufficient antimicrobial effect to prevent in vitro 
colonization caused by S. aureus and S. epidermidis. A significant in vitro efficacy of 
Poliglecaprone® 25 suture with triclosan against several strains of bacteria was assessed by 
Ming at al. (18). Storch et al. studied the effect of the effect of coated polyglactin 910 suture 
with triclosan to tissue response and wound healing over a 28 day period on full-thickness 
linear wounds in the hairless guinea pig model and assessed no evidence of impedance to 
wound healing (21). In a review about the safety of triclosan and the biocompatibility of 
coated polyglactin 910 suture with triclosan, Barbolt could demonstrate the safety of this 
suture and triclosan for clinical use (2). However it is of fundamental importance to have a 
choice between different antimicrobial agents on surgical sutures primarily due to an 
increased pathogen resistance, but also to parameters like tissue compatibility or drug 
stability. Yazdankhah et al. confirmed the occurrence of triclosan resistance amongst dermal, 
intestinal, and environmental microorganisms of clinical relevance and assume that the 
widespread use of triclosan lead to the development of concomitant resistance to clinically 
important antimicrobials (27). The increased triclosan susceptibility of clinical isolates of 
MRSA assessed by Brenwald and Fraise corroborates these observations (4). 
Drug release studies showed a continuous drug release within 96 hours which is a basic 
requirement for an effective anti-infective protection. The gap between the amount of released 
drug after 96 hours and the remaining drug amount on the surface of developed sutures 
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revealed a high potential for a long-term anti-infective protection (Figure 1). The 
controversial result that OH1 (6 µg/cm) released slightly more octenidine than OH2 (28 
µg/cm) is obvious and needs further investigation. 
A reduction of the number of adhered pathogens on the suture surface as well as the inhibition 
of S. aureus growth in suspension was assessed by all investigated coating types. All 
chlorhexidine and octenidine coated sutures showed superior anti-infective characteristics in 
comparison to the clinically well-established Vicryl Plus®.  Biocompatibility studies revealed 
a higher cytotoxic potential of developed suture coatings than Vicryl Plus®. One possible 
reason for this effect is the inclusion of palmitic acid in the cell soma assessed by the Oil Red 
O staining. The balance between an adequate drug concentration and the biocompatibility of 
developed coatings is under elucidation. As the anti-infective potential is superior to Vicryl 
Plus®, a drug concentration decrease is conceivable contributing to a lower cytotoxicity. 
  
5 Conclusions 
 
In this study we demonstrated the development of novel anti-infective suture coatings 
consisting of lipid based drug delivery systems in combination with antiseptics to avoid post-
operative wound infections. Continuous drug release kinetics and superior anti-infective 
characteristics were assessed. Enhanced tissue compatibility is under development rendering 
these coatings of high interest in surgery.  
 
6 Acknowledgements 
 
We would like to thank Josef Hintermair (ITEM-GmbH, The Biotooling Company, Garching, 
Germany) for his great assistance in microbial testing. The authors did not receive any 
payments or benefits from a commercial party related directly or indirectly to the subject of 
this article. This study was partly supported by the Arbeitsgemeinschaft industrieller 
Forschungsvereinigungen (AiF).  
 
 
 
 
 
 
69
New anti-infective coatings of surgical sutures 
_________________________________________________________________________________________________________________ 
 70
7 Figure Captions 
 
Figure 1. SEM pictures of PGA Resorba® sutures coated with A) chlorhexidine dipalmitate 
(CP) and B) octenidine hydrochloride (OH2), C) Vicryl Plus® and D) uncoated PGA 
Resorba® (magnification 450). 
 
Figure 2. Release concentration of drugs (weight/volume) from PGA sutures after 96 hours 
into PBS buffer, related to drug charge (weight/unit length). 
 
Figure 3. Elution profiles of different drugs into PBS from A) chlorhexidine coated PGA 
sutures and B) octenidine coated PGA sutures.  
 
Figure 4. S. aureus growth cultured in sterile Mueller-Hinton broth for 24 hours in the 
presence of individual antimicrobially coated sutures: A) chlorhexidine dipalmitate,  
B) octenidine hydrochloride, C) octenidine hydrochloride, D) Vicryl Plus®. 
 
Figure 5. Numbers of S. aureus colonies adsorbed on the surface of coated PGA sutures after 
24 hours of incubation in 2 x 106 cfu/ml suspension. 
 
Figure 6. Metabolic activity of viable cells incubated with individual coated sutures measured 
with the Roche cell proliferation assay. Uncoated PGA sutures as well as Vicryl Plus® sutures 
served as reference. 
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Chapter 4
Growth inhibition of Staphylococcus aureus induced by low-
frequency electric and electro-magnetic fields
Abstract
Objectives: Magnetic  field  therapy  is  an  established  technique  in  the  treatment  of 
pseudarthrosis. In cases of osteomylitis, palliation is also observed. This study focuses on the 
impact of different electric and electromagnetic fields on the growth of Staphylococcus aureus 
by in vitro technologies.
Methods: Cultures of S. aureus in fluid and gel-like media were exposed to a low-frequency 
electromagnetic field, an electromagnetic field combined with an additional electric field, a 
sinusoidal electric field and a static electric field.
Results: In gel-like media no significant difference between colony-forming units of exposed 
samples and non-exposed references was detected.  In contrast,  S. aureus concentrations in 
fluid media could clearly be reduced under the influence of the four different applied fields 
within 24 hours of experiment.  The strongest effects  were observed for the  direct  current 
electric field which could decrease cfu/ml of 37 %, and the low-frequency electro-magnetic 
field  with  additional  induced  electric  alternating  field  with  a  decrease  of  staphylococci 
concentration by 36 %.
Conclusions: The  effects  of  the  electromagnetic  treatment  on  staphylococci  within  fluid 
media  are  significantly  higher  than  in  gel-like  media.  The  application  of  low-frequency 
electromagnetic fields corroborates clinical situations of bone infections during magnetic field 
therapy.
Keywords: Electro-magnetic field, Staphylococcus aureus, growth inhibition, infection, low-
frequency
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1 Introduction 
 
Magnetic fields are in use in medicine, for example in the magnet resonance tomography, the 
magnetic stimulation of brain areas and for magnetic drug targeting. Several studies in 
literature attest magnetic fields a therapeutic benefit. Sharrard performed a double-blind trial of 
pulsed electromagnetic fields for delayed union of tibial fractures and concluded that pulsed 
electromagnetic fields significantly influence healing in tibial fractures with delayed union 
(30). Borsalino et al. reported in a double-blind treatment of 32 consecutive patients treated 
with femoral intertrochanteric osteotomy for hip degenerative arthritis a statistically significant 
difference between controls and patients treated with low-frequency pulsing electromagnetic 
fields (5).  In a double blind study about the effect of electromagnetic fields on patients 
undergoing massive bone graft following bone tumor resection, Capanna et al. observed a 
decrease in the healing time from 9.4 months in the control group to 6.7 months in the active 
stimulated group when adjuvant postoperative chemotherapy was not employed (6). Trock et 
al. assessed pulsed electromagnetic fields the potential as an effective method of improving 
symptoms in patients with osteoarthritis (35). In the area of wound healing Stiller et al. 
assessed the clinical efficacy and safety of pulsed electromagnetic limb ulcer therapy in the 
healing of recalcitrant, predominantly venous leg ulcers by a portable pulsed electromagnetic 
field device (31). 
Magnetic field therapy is often used as a therapeutic procedure to improve fracture healing 
(34). Heckman et al. claimed the effectiveness in the treatment of ununited fractures by 
noninvasive, pulsed  electromagnetic fields  after three  months of intensive use in more than 
85 % of 149 patients (16). Bassett et al. demonstrated that the surgically noninvasive, 
outpatient method of pulsing electromagnetic fields induce weak electric currents in bone and 
produced confirmed end results in 1,007 ununited fractures and 71 failed arthrodeses, 
worldwide (3).  
The so-called Kraus-Lechner procedure is based on the interaction of low-frequency 
nonthermal sinusoidal electro-magnetic fields with bone and cartilage tissue and it is often 
applied to purely healing bone fractures of non-unions (19). Clinical observations have shown 
that in infected pseudarthrosis this technology improves bone healing and decreases bone 
infections (20, 21). Nowadays there are no data of low-frequent electromagnetic fields based 
on the Kraus-Lechner techniques and similar electric fields on the influence on bacterial 
growth. Methodical investigations of the effect of different kinds of applied fields on bacterial 
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growth have not been elucidated before as previous studies mostly focused on one specific 
electric or electromagnetic field effect.
The purpose of this study was to determine whether an application of different electric and 
electromagnetic fields could influence the growth of S. aureus since it is the main cause of 
bone and implant-associated infections.
2 Materials and Methods
2.1 Test bacterium
A clinical isolate of S. aureus (strain ATTC® 49230) was provided by the Institute of Clinical 
Microbiology (Department of Clinical Hygiene, Klinikum rechts der Isar, Munich, Germany). 
The  germ  was  plated  on  columbia  agar  plates  (No.  254071,  BD  Diagnostic  Systems 
Heidelberg, Germany) and incubated at 37 °C for 24 hours. After 24 hours, several colonies 
were gathered with a sterile one-way inoculation loop, plated on a fresh agar plate and placed 
in an incubator at 37 °C. This procedure was repeated every other day for life maintenance 
and 24 hours before experimental performance.  
2.2 Growth curve
In order to correlate the optical density at 600 nm of S. aureus suspension with the colony 
forming units of the microorganism, a calibration curve was recorded. A bacterial suspension 
was produced by resuspending about 100 colonies of S. aureus from columbia agar plates in 
750  ml  of  sterile  Mueller-Hinton  broth  (No.  275730,  BD  Diagnostic  Systems,  Difco™, 
Heidelberg, Germany).  The homogeneous suspension was incubated at 37 °C for 24 hours 
under static conditions. In time intervals of 60 minutes within the first eight hours and again 
after  24  hours  both  the  optical  density  (GeneQuant  pro,  biochrom,  Cambridge,  UK)  of 
obtained suspension at 600 nm was measured and different dilutions of each sample were 
plated  on  columbia  agar  plates.  The  degree  of  dilution  was  assessed  in  preliminary 
experiments  and  conformed  to  the  number  of  obtained  colony  forming  units  visually 
countable. 
75
Electromagnetic treatment of staphylococci  
_________________________________________________________________________________________________________________ 
 
 76
After incubating for 24 hours at 37 °C the colony forming units were visually determined, 
extrapolated to the initial concentration in suspension and correlated to the measured value of 
optical density. This experiment was repeated three times and all values were combined as 
optical density values as well as cfu/ml can not be reproduced to defined values. A 
logarithmic regression curve with the formula OD=0.0741 Ln(cfu)–0.2066 and a correlation 
coefficient of 0.91 resulted. 
 
2.3 Bacteria on gel-like medium 
 
Experiments on gel-like medium were performed on columbia agar plates with 5 % sheep 
blood. This highly nutritious medium is used for the isolation and cultivation of nonfastidious 
and fastidious microorganisms (10). Bacteria from columbia agar plates were resuspended in 
normal saline and adjusted to 1x108 cfu/ml by visual comparison with 0.5 McFarland 
standard. This suspension was diluted with normal saline to an inoculum of 1x103 cfu/ml. For 
each of the four applied electric or electromagnetic fields the same volume of the suspension 
was plated on seven sample and seven reference columbia agar plates. The sample plates were 
then exposed to one of the four applied electromagnetic fields in a sample incubator at 37 °C 
for 24 hours. The reference plates were placed in a reference incubator at 37 °C for 24 hours 
(Figure 1). These experiments were performed thrice for each of the four applied electric or 
electromagnetic fields.  
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 Figure 1. Experimental equipment: A) Solenoid with cooling jacket to generate a sinusoidal electro-
magnetic field (5 mT, 20 Hz), B) Electric field applicator with rod-like electrodes to expose bacterial 
suspensions, C) Electric field applicator for standard Petri dishes, D) Secondary coil to induce an 
additional electric field. 
 
2.4 Bacteria in fluid medium 
 
Staphylococcus aureus suspension was produced as already described. Eight sterile 50 ml 
tubes were filled with 50 ml bacterial suspension (1x103 cfu/ml). Four reference tubes were 
placed in the reference incubator. Four sample tubes were then exposed to one of the four 
applied electromagnetic fields in the sample incubator. Field exposure took place in the 
sample incubator at 37 °C within the first eight hours in respectively 40 minutes intervals 
following 20 minutes breaks. After this samples were then incubated at 37 °C for further 16 
hours. Four references were placed in the reference incubator at 37 °C for 24 hours. In a time 
interval of 60 minutes within the first eight hours and again at a time point of 24 hours of 
incubation at 37 °C the optical density at 600 nm of bacterial suspension was measured. A 
bacterial growth curve of sample and reference was determined. The bacterial concentrations 
of sample and reference at different points in time could be compared with the aid of the 
calibration curve.  
 
77
Electromagnetic treatment of staphylococci  
_________________________________________________________________________________________________________________ 
 
 78
2.5 Sinusoidal low-frequency electro-magnetic field  
 
A sinusoidal low-frequency electromagnetic field was generated by a solenoid (FA-P6-K, 
Neue Magnetodyn®, Munich, Germany) (Figure 1A and 2A, 2C) combined with a frequency 
generator (M80, Neue Magnetodyn®, Munich, Germany). This setup is clinically established 
as magnetic field therapy in bone fracture healing using sinusoidal frequencies between 0 and 
30 Hz and magnetic flux densities between 0.5 mT and 10 mT. Test tubes containing bacteria 
in fluid medium as well as agar plates inoculated with bacteria were placed inside the 
solenoid. The solenoid was constructed in a manner that it was possible to insert seven agar 
plates as well as four 50 ml test tubes. A cooling system was built to prevent the solenoid 
from overheating by connecting a circulation water bath including a thermostat (F3, Haake, 
Vreden, Germany). A stable incubation temperature of the bacteria at 37 °C ± 0.1 °C was 
assured by placing the coil in a sample incubator (CB150, Binder, Tuttlingen, Germany). 
Culture temperature was monitored by a calibrated temperature meter (VC306/K202, Conrad 
Electronic, Hirschau, Germany) located close to bacteria cultures and recorded online. A 
reference incubator was placed at 3 meter distance to the sample incubator. The stray field of 
the coil was measured in radial and axial direction to make sure that the reference incubator 
(CB150, Binder, Tuttlingen, Germany) is not influenced by the electro-magnetic stray field. 
By measuring the spatial distribution of the magnetic flux density inside the coil with a Gauss 
meter (Bell640, F.W. Bell Inc.), the homogeneity of the magnetic field was assured (Figure 
3). In this experimental setup a low-frequency electro-magnetic field with a frequency of 
20 Hz and a flux density of 5 mT by using a current of 1.2 A was applied. The electric field 
strength of the solenoid itself at a radial distance r = 4.5 cm from the coil axis is about 
17 mV/cm and was neglected because of its low amplitude. The geomagnetic field was 
measured at 60 µT. 
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Figure 2. Spatial distribution of the magnetic flux density inside the coil - during action at 5 mT, 20 Hz - 
along the cross section beginning at the central axis. Measurements were carried out in each Petri dish 
layer to make sure that the cultures are exposed to a defined region of flux density.  
 
2.6 Electromagnetic field combined with an additional electric 
alternating field  
 
The same experimental setup as already described for low-frequency electromagnetic field 
was applied (2B and 2D). Additionally, secondary coils (SI-FE, Neue Magnetodyn®, Munich, 
Germany) (Figure 1D) were placed inside the primary solenoid in order to establish an 
additional electric alternating field. Especially designed lids for standard Petri dishes were 
used containing two plane electrodes at a distance of 5.7 cm, which were dipping inside the 
agar (Figure 1C). An alternating voltage which can be gripped at the secondary coil is induced 
by the alternating magnetic field from the primary solenoid. An additional voltage of 0.8Veff 
at 20 Hz is induced in the secondary coil running the primary coil with 20 Hz and 5 mT which 
results in an effective alternating electric field strength of 140 mV/cm. This homogeneous 
electric field is applied as an additional electric field between the electrodes across the agar 
medium inside the Petri dishes directed perpendicular to the magnetic field. For S. aureus 
suspensions, the secondary coils were connected to electric field applicators made of surgical 
steel rods placed at a distance of 1.7 cm inside the tubes attached to the lids (Figure 1B). In  
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this experimental setup an additional voltage of 0.8 Veff at 20 Hz resulting in a maximal 
induced alternating electric field strength of 470 mV/cm by the alternating magnetic field 
from the primary solenoid at 5 mT and 20 Hz.  
The electric field strength is the quotient of the applied voltage (0.8 Veff) and the electrode 
distance (5.7 cm for gel-like medium, 1.7 cm for bacterial suspensions). 
 
 
Figure 3. Scheme of experimental setups to apply low-frequency electro-magnetic fields (20 Hz, 5 mT: 
only Solenoid) and electro-magnetic fields with additional electric fields for S. aureus cultures on Mueller-
HintonII agar and in suspensions. A sample incubator with A) Low-frequency electro-magnetic fields 
(5 mT, 20 Hz) exposed to gel-like medium and similar with B) Electro-magnetic field (5 mT, 20 Hz) 
combined with an additional electric field of 140 mV/cm on gel-like medium, C) Low-frequency electro-
magnetic field (5 mT, 20 Hz) in fluid medium, D) Electro-magnetic field (5 mT, 20 Hz) combined with an 
additional electric field of 470 mV/cm in fluid medium.  
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2.7 Sinusoidal electric alternating field  
 
Bacteria colonies on agar plates as well as in fluid medium were exposed to a pure sinusoidal 
electric field. Electric field applicators already described were connected to a frequency 
generator (PM 5131, Phillips, Hamburg, Germany) to apply an electric alternating field 
without using a primary or secondary coil. In agar plates sinusoidal voltages of 0.707 Veff 
were applied which results in an electric field strength of 124 mV/cm. A sinusoidal voltage of 
0.8 Veff and a field strength with a maximum of 470 mV/cm in case of bacteria suspension 
were applied (Figure 1 and 4A, 4C).  
 
2.8 Direct current electric field  
 
A direct current field was applied by connecting the electrodes already described to a 
frequency generator (PM 5131, Phillips, Hamburg, Germany). Bacteria colonies on agar 
plates as well as in fluid medium were exposed to this field. Bacteria on agar plates were 
affected by a direct voltage of 1.0 V and an electric field strength of 175 mV/cm. Bacteria in 
fluid medium were exposed to a direct voltage of 1.0 V resulting in a maximal field strength 
of 470 mV/cm. For the calculation of the direct current electric field strength, the direct 
current voltage corresponds to the peak voltages already used (Figure 1 and 4B, 4D). 
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Figure 4. Scheme of experimental setups to apply sinusoidal and direct current electric fields for S. aureus 
cultures on columbia agar and Mueller-HintonII suspensions: A) Sinusoidal electric alternating field 
(124 mV/cm, 20 Hz) in gel-like medium, B) Direct current field of 175 mV/cm in gel-like medium, C) 
Sinusoidal electric alternating field (470 mV/cm, 20 Hz) in fluid medium, D) Direct current field of 
588 mV/cm in fluid medium. 
 
2.9 Calculations and statistical methods 
 
Data from bacterial growth studies were compared for statistical significance using a two 
tailed student t-test with P < 0.05 considered significant. 
 
 
 
 
 
A            B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C            D 
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3 Results 
 
An application of the four different electromagnetic fields on S. aureus cultured on columbia 
agar plates showed no significant effect regarding the stimulation or inhibition of colony 
forming (Figure 5). A tendency of growth inhibition was detected by exposing the pathogen 
cultures to a low-frequency electromagnetic field (5 mT, 20 Hz) as well as to an 
electromagnetic field combined with an additional electric field (5 mT, 140 mV/cm, 20 Hz). 
The application of a sinusoidal electric field (124 mV/cm, 20 Hz) as well as a constant electric 
field (175 mV/cm) to S. aureus on columbia agar plates shows a weak but not statistically 
significantly stimulating effect of colony forming. The absolute hights of cfu differ from 
experiment to experiment due to various amounts of bacterial suspension used to inoculate the 
agar plates. However within one experimental setup the used cfu are identical for samples and 
references. Samples and reference can therefore be compared and the field effect evaluated.  
 
 
Figure 5. Gel-like medium containing S. aureus: Influence of electric and electro-magnetic fields on 
colony-forming units. 
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In fluid medium, a faster bacterial growth compared to reference of S. aureus under the 
influence of a low-frequency electromagnetic field (5 mT, 20 Hz) within the first eight hours 
was observed. However, at the end of the experiment after 24 hours, bacteria concentration in 
low-frequency electromagnetic sample showed a significantly lower cfu/ml than in the 
reference. A significant microorganism concentration reduction of 29 % could be 
demonstrated under the influence of the applied low-frequency electromagnetic field 
(Figure 6A). 
Treatment of S. aureus in fluid medium with an electromagnetic field (5 mT, 20 Hz) 
combined with an additional electric field (470 mV/cm) showed during field application a 
decrease of bacterial growth until the end of the experiment. At the end of the experiment 
after 24 hours a cfu/ml reduction of 36 % compared to reference could be observed (Figure 
6B). 
Exposing staphylococci suspensions to a sinusoidal electric field (470 mV/cm, 20 Hz), 
revealed an increase of cfu/ml compared to reference during exposure time intervals within 
the first 8 hours. Bacterial growth within the following 16 hours is delayed in comparison to 
reference. The application of a sinusoidal electric field reduces cfu/ml of 18 % compared to 
reference (Figure 6C). 
The application of a constant electric field (588 mV/cm) on staphylococci in fluid medium 
showed an increase of microorganism concentration within the first 8 hours of treatment 
compared to untreated reference. In the following time period between eight and twenty four 
hours, a clear reduction of pathogen growth was detected resulting in a decrease of cfu/ml in a 
range of 37 % (Figure 6D). 
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Figure 6. Fluid medium containing S. aureus: Influence of electric and electro-magnetic fields on bacterial 
concentration (cfu/ml). Mediumn cfu/ml of sample (n=4) and reference (n=4) from S. aureus cultured in 
sterile Mueller-Hinton broth under the influence of different electro-magnetic-fields. A) Low-frequency 
electro-magnetic field (5 mT, 20 Hz), B) Electro-magnetic field (5 mT, 20 Hz) combined with an additional 
electric field of 470 mV/cm, C) Sinusoidal electric alternating field (470 mV/cm, 20 Hz), D) Direct current 
field of 588 mV/cm. 
 
EMF ^= electromagnetic field, a.c. EF ^= alternating electrical field, d.c. EF ^= direct current electrical field 
 
4 Discussion 
 
Medical implants like orthopaedic implants are highly susceptible to pathogens and therefore 
feature high infection rates. Common environmental and skin pathogens like Staphylococcus 
aureus and Staphylococcus epidermidis are the most frequently detected germs in device-
related infection. These pathogens colonize the implant by adhering to the patients own 
proteins located on the surface of the graft and form a biofilm (1, 13, 14). The biofilm 
formation on biomaterials present challenging complications in the field of medical implants. 
In a biofilm bacteria are well protected from the host immune defence. The consequence is an 
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increase in antibiotic resistance so that even high local concentrations of antibiotics do not 
completely eradicate bacteria in biofilms (8, 9). A technology that offers considerable promise 
in the field of device-related infections is the application of weak electric and electromagnetic 
fields.  
Several studies are focusing on the effect of electromagnetic fields on growth of bacteria like 
S. aureus. Strasak et al. report a decrease of optical densities for different bacteria strains 
exposing to a 50 Hz electro-magnetic field at room temperature (33). Fojt et al. observed a 
decrease of the number of viable bacteria by low-frequency electromagnetic fields at 50 Hz 
(11). Using sinusoidal low-frequency weak magnetic fields of 60 and 600 Hz at 3 mT for 
more than 50 hours, Ramon et al. could show an decrease of bacterial colonies of E. coli (28). 
The influence of static magnetic fields was also investigated. Gerencser et al. demonstrated 
reduced bacterial growth of staphylococci and Serratia marsecens by static magnetic fields 
(12). However, Kohno et al. could not detect any inhibition on E. coli exposed to static 
magnetic fields (18).  Nevertheless, they observed a decreased growth rate and growth 
maximum number of S. mutans and S. aureus under anaerobic conditions. Grosman et al. 
detected no significant influence caused by a static magnetic  field in the range of 0.5 to 4 
Tesla on growth and biochemical activity on S. aureus and E. coli (15). These findings could 
not be corroborated by Zhang et al. investigating E. coli (37). Piatti et al. reported a growth 
inhibitory effect and a decrease of the pathogen virulence using Serratia marcescens in the 
presence of a static magnetic field (26). Studies of Pareilleux and Sicard about the influence 
of static electric fields on bacteria revealed a lethal activity of low-voltage alternating currents 
in the presence of chlorid ions in tested E. coli suspensions (23). An inactivation of 
microrganisms by strong pulsed electric fields in the range of 4.5 kV/cm is reported by 
Kermanshahi and Sailani (17). Recently Cellini et al. demonstrated that the exposure of E. 
coli to a 50 Hz electromagnetic field acts as a stressing factor leading to phenotypical and 
transcriptional changes (7).  
In previous studies only one type of field was investigated. However, in this study we 
compared the effect of a low-frequency electromagnetic field, an electromagnetic field 
combined with an electric field, a sinusoidal electric field and a constant electric field on 
growth/growth inhibition of S. aureus. This germ was used as it is the predominating pathogen 
causing implant associated infections (9). These investigations admit results of the applied 
fields on fluid and gel-like medium under comparable conditions, conclusions about the mode 
of action can be drawn.  
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Our experiments with S. aureus on gel-like medium showed no significant influence of the 
applied electric and electromagnetic fields on bacterial growth. In contrast to these data all four  
applied fields revealed a significant effect on growth of S. aureus in fluid medium within the 
observation period of 24 hours. Depending on the applied field growth inhibition from 18 % 
using a sinusoidal electric field (470 mV/cm, 20 Hz) and 37 % using a constant electric field 
(588 mV/cm) could be observed (Table 1). These investigations demonstrated a reduction of S. 
aureus growth in fluid medium under field influence within 24 hours. Comparable effects 
could be shown by applying a direct current electric field and an electromagnetic field with 
additional electric field.  
 
Table 1. Reduction of S. aureus growth in fluid medium after 24 hours under the influence of electric and 
electro-magnetic fields. A) Low-frequency electro-magnetic field (5 mT, 20 Hz), B) Electro-magnetic field 
(5 mT, 20 Hz) combined with an additional electric field of 470 mV/cm, C) Sinusoidal electric alternating 
field (470 mV/cm, 20 Hz), D) Direct current field of 588 mV/cm. 
 
EMF ^= electromagnetic field, a.c. EF ^= alternating electrical field, d.c. EF ^= direct current electrical field 
 
electro-magnetic fields electric fields 
A) EMF 
(5 mT, 20 Hz) 
B) EMF + a.c. EF 
(5 mT, 470 mV/cm, 20 Hz) 
C) a.c. EF 
(470 mV/cm, 20 Hz) 
D) d.c. EF 
(588 mV/cm) 
Reduction of 
staphylococci 
concentration 
 
after 24 hours 
compared to reference 
29.2 % 
 
(p = 0.0376) 
36.9 % 
 
(p = 0.0044) 
18.6 % 
 
(p = 0.0676) 
37.3 % 
 
(p < 0.0001) 
 
 
In case of the application of the low-frequency electro-magnetic field, the sinusoidal electric 
alternating field and the direct current field, growth reduction were considered to be 
significant (P < 0.05). 
Observed growth inhibition effects in fluid medium and the fact that no impact of applied 
electric and magnetic field were assessed on gel-like medium are an indication that the 
unlimited mobility of ions is a basic requirement for field-induced effects. 
Detected effects in fluid medium corroborate clinical observations in the magnetic field 
therapy of infected pseudarthrosis (20, 21). In those patients under the influence of low-
frequency sinusoidal electromagnetic fields there is only in the beginning of the treatment an 
increase of the wound exudate which can be explained by our results in stimulating bacterial 
growth within the first eight hours of treatment. In clinical situation after 24 hours a 
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clarification of the exudate is observed corresponding to the decrease of bacterial growth as 
demonstrated in our experiments.  
The different kinds of fields have an effect on the growth on S. aureus and the effect on other 
pathogens is under elucidation. Whilst electrochemical effects give reason for the impact of 
electric fields, the underlying biochemical effects of electromagnetic fields have not been 
clarified until today (7). One assumption is that there is a bactericidal effect under the 
influence of electromagnetic fields. During the field treatment, a number of bacteria colony 
forming units are reduced. Even a small reduction in the number of bacteria, at the beginning 
of the growth process, greatly affects the geometrical progression of the growth process (11, 
32). Bacteriostatic effects induced by static magnetic fields may also be explained by radicals 
such as hydroxyl, chloride and hypochloride (18). The radical pair effect describes the 
generation of free radicals during high-energy photonic or electro-magnetic irradiation in 
biological systems due to the interaction of the magnetic field with unmatched electron spins.  
The formation of radicals leads to temporary damage of cell membranes and to a modification 
of the ionic channel conductivity which can result in cell death (24). Quantum 
electrodynamics predicts magnetic effects even with low energy stimulation as it occurs 
during the Kraus-Lechner procedure with frequencies between 10 and 30 Hz in the case that 
resonant stimulation conditions occur simultaneously (29). 
The "Ion cyclotron resonance" (ICR), primarily considered by Liboff predicts effects by small 
ions involved in biological processes, that occur in definite frequency- and intensity ranges 
("windows") of simultaneously impacting magnetic and electromagnetic fields related by a 
linear equation, which meanwhile is proven by a number of in vivo and in vitro experiments 
(22). 
Experiments carried out by Binhi have shown that frequencies to stimulate  ion or ion-protein 
complex to "swing" in a static magnetic field agree particularly well with those predicted for 
the biologically relevant ions – such as Ca2+, Ma2+ and Zn2+ – by means of the ion-cyclotron 
resonance formula (4). The resonance frequency for Ca2+ ions is in the range of extremely 
low-frequency fields which is an indication for a possible interaction of biological systems 
and applied electromagnetic fields. 
Obviously an interaction of radicals and electromagnetic fields cause damage to bacteria and 
these effects needs further investigation. 
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Described methodologies offer new perspectives in the treatment of device-related infections 
with pronounced biofilm formation. In the literature recent studies assessed an inhibiting 
effect of electric and electromagnetic fields on biofilm formation.  
Investigations by Perez-Roa et al. showed that low-voltage (0.5 V - 5 V) reduced the area of 
the electrodes covered by biofilm by 50 % (25). The exposure of bacterial biofilms to 
electrolysis resulted in killing (2.1-log reduction) and removal (4.0-log reduction) of viable 
cells within a few minutes (27). Van der Borden et al. described the advanced detachment and 
a decreased viability of staphylococci treated with 60 µA and 100 µA direct current (36). 
These in vitro investigations and the additional clinical observations show that there is high 
potential in the utilization of electric and electromagnetic fields to combat biofilms.  
 
5 Conclusions 
 
We conclude that a directed electromagnetic field to increase bone healing could offer new 
opportunities in the therapy of implant associated infections and infected non-unions. 
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7 Figure and Table Captions 
 
Figure 1. Experimental equipment A) Solenoid with cooling jacket to generate a sinusoidal 
electro-magnetic field (5 mT, 20 Hz), B) Electric field applicator with rod-like electrodes to 
expose bacterial suspensions, C) Electric field applicator for standard Petri dishes, D) 
Secondary coil to induce an additional electric field.  
 
Figure 2. Experimental setups to apply low-frequency electro-magnetic fields (20 Hz, 5 mT) 
and electro-magnetic fields with additional electric fields for S. aureus cultures on Mueller-
HintonII agar and in suspensions. 
 
Figure 3. Spatial distribution of the magnetic flux density inside the coil along the cross 
section beginning at the central axis. Measurements were carried out in each Petri dish layer 
to make sure that the cultures are exposed to a defined region of flux density.  
 
Figure 4. Experimental setups to apply sinusoidal and direct current electric fields for S. 
aureus cultures on Mueller-HintonII agar and suspensions. 
 
Figure 5. Gel-like medium containing S. aureus: Influence of electric and electro-magnetic 
fields on colony-forming units (cfu). 
 
Figure 6. Fluid medium containing S. aureus: Influence of electric and electro-magnetic fields 
on bacterial concentration (cfu/ml). 
 
Table 1. Reduction of S. aureus growth under the influence of electric and electro-magnetic 
fields. A) Low-frequency electro-magnetic field (5 mT, 20 Hz) in fluid medium, B) Electro-
magnetic field (5 mT, 20 Hz) combined with an additional electric field of 470 mV/cm in 
fluid medium, C) Sinusoidal electric alternating field (470 mV/cm, 20 Hz) in fluid medium, 
D) Direct current field of 588 mV/cm in fluid medium. 
 
 
90
Electromagnetic treatment of staphylococci  
_________________________________________________________________________________________________________________ 
 
 91
8 References 
 
1. Barton, A. J., R. D. Sagers, and W. G. Pitt. 1996. Bacterial adhesion to orthopedic 
implant polymers. J Biomed Mater Res 30:403-10. 
2. Bassett, C. A. 1988. Effects of a static magnetic field on fracture healing. Clin Orthop 
Relat Res:311-2. 
3. Bassett, C. A., S. N. Mitchell, and S. R. Gaston. 1982. Pulsing electromagnetic field 
treatment in ununited fractures and failed arthrodeses. Jama 247:623-8. 
4. Binhi, V. N., Y. D. Alipov, and I. Y. Belyaev. 2001. Effect of static magnetic field on 
E. coli cells and individual rotations of ion-protein complexes. Bioelectromagnetics 
22:79-86. 
5. Borsalino, G., M. Bagnacani, E. Bettati, F. Fornaciari, R. Rocchi, S. Uluhogian, 
G. Ceccherelli, R. Cadossi, and G. C. Traina. 1988. Electrical stimulation of human 
femoral intertrochanteric osteotomies. Double-blind study. Clin Orthop Relat 
Res:256-63. 
6. Capanna, R., D. Donati, C. Masetti, M. Manfrini, A. Panozzo, R. Cadossi, and M. 
Campanacci. 1994. Effect of electromagnetic fields on patients undergoing massive 
bone graft following bone tumor resection. A double blind study. Clin Orthop Relat 
Res:213-21. 
7. Cellini, L., R. Grande, E. Di Campli, S. Di Bartolomeo, M. Di Giulio, I. Robuffo, 
O. Trubiani, and M. A. Mariggio. 2008. Bacterial response to the exposure of 50 Hz 
electromagnetic fields. Bioelectromagnetics 29:302-11. 
8. Costerton, J. W., B. Ellis, K. Lam, F. Johnson, and A. E. Khoury. 1994. 
Mechanism of Electrical Enhancement of Efficacy of Antibiotics in Killing Biofilm 
Bacteria. Antimicrobial Agents and Chemotherapy 38:2803-2809. 
9. Darouiche, R. O. 2004. Treatment of infections associated with surgical implants. N 
Engl J Med 350:1422-9. 
10. Ellner, P. D., C. J. Stoessel, E. Drakeford, and F. Vasi. 1966. A new culture 
medium for medical bacteriology. Am J Clin Pathol 45:502-4. 
11. Fojt L., Strašák L., Vetterl V., and S. J. 2004. Comparison of the low-frequency 
magnetic field effects on bacteria Escherichia coli, Leclercia adecarboxylata and 
Staphylococcus aureus. Bioelectrochemistry - Proceedings of the XVIIth International 
Symposium on Bioelectrochemistry and Bioenergetics 63:337-341. 
12. Gerencser, V. F., M. F. Barnothy, and J. M. Barnothy. 1962. Inhibition of 
Bacterial Growth by Magnetic Fields. Nature 196:539-541. 
13. Gotz, F. 2002. Staphylococcus and biofilms. Mol Microbiol 43:1367-78. 
14. Gristina, A. G., C. D. Hobgood, L. X. Webb, and Q. N. Myrvik. 1987. Adhesive 
colonization of biomaterials and antibiotic resistance. Biomaterials 8:423-6. 
15. Grosman, Z., M. Kolar, and E. Tesarikova. 1992. Effects of static magnetic field on 
some pathogenic microorganisms. Acta Univ Palacki Olomuc Fac Med 134:7-9. 
16. Heckman, J. D., A. J. Ingram, R. D. Loyd, J. V. Luck, Jr., and P. W. Mayer. 
1981. Nonunion treatment with pulsed electromagnetic fields. Clin Orthop Relat 
Res:58-66. 
17. Kermanshahi R.K., and Sailani M.R. 2005. Effect of static electric field treatment 
on multiple antibiotic-resistant pathogenic strains of Escherichia coli and 
Staphylococcus aureus. J Microbiol Immunol Infect 38:394-398. 
18. Kohno M., Yamazaki M., Kimura I. I., and W. M. 2000. Effect of static magnetic 
fields on bacteria: Streptococcus mutans, Staphylococcus aureus, and Escherichia coli. 
Pathophysiology 7:143-148. 
91
Electromagnetic treatment of staphylococci  
_________________________________________________________________________________________________________________ 
 
 92
19. Kraus, W. 1992. The Treatment of Pathological Bone Lesion with Nonthermal, 
Extremely Low-Frequency Electromagnetic-Fields. Bioelectrochemistry and 
Bioenergetics 27:321-339. 
20. Lechner F., Ascherl R., and Uraus W. 1981. Treatment of pseudarthroses with 
electrodynamic potentials of low frequency range. Clin Orthop Relat Res:71-81. 
21. Lechner F., Oeller G., and Ascherl R. 1979. Treatment of infected pseudoarthroses 
with electrodynamic field therapy. Fortschr Med 97:943-9. 
22. Liboff, A. R. 1997. Electric-field ion cyclotron resonance. Bioelectromagnetics 
18:85-7. 
23. Pareilleux, A., and N. Sicard. 1970. Lethal effects of electric current on Escherichia 
coli. Appl Microbiol 19:421-4. 
24. Pazur, A. 2004. Characterisation of weak magnetic field effects in an aqueous 
glutamic acid solution by nonlinear dielectric spectroscopy and voltammetry. 
Biomagn Res Technol 2:8. 
25. Perez-Roa, R. E., D. T. Tompkins, M. Paulose, C. A. Grimes, M. A. Anderson, 
and D. R. Noguera. 2006. Effects of localised, low-voltage pulsed electric fields on 
the development and inhibition of Pseudomonas aeruginosa biofilms. Biofouling 
22:383-90. 
26. Piatti E., Albertini M.C., and F. D. Baffone W., Citterio B., Piacentini M.P., 
Dacha M., Vetrano F., Accorsi A. 2002. Antibacterial effect of a magnetic field on 
Serratia marcescens and related virulence to Hordeum vulgare and Rubus fruticosus 
callus cells. Comp Biochem Physiol B Biochem Mol Biol 132:359-65. 
27. Rabinovitch, C., and P. S. Stewart. 2006. Removal and inactivation of 
Staphylococcus epidermidis biofilms by electrolysis. Appl Environ Microbiol 
72:6364-6. 
28. Ramon C., Ayaz M., and S. D. D. Jr. 1981. Inhibition of growth rate of Escherichia 
coli induced by extremely low-frequency weak magnetic fields. Bioelectromagnetics 
2:285-9. 
29. Schulten, K. a. W., A. 1984. Magnetfeldeffekte in Chemie und Biologie. Die 
Umschau 25/26:779-783. 
30. Sharrard, W. J. 1990. A double-blind trial of pulsed electromagnetic fields for 
delayed union of tibial fractures. J Bone Joint Surg Br 72:347-55. 
31. Stiller, M. J., G. H. Pak, J. L. Shupack, S. Thaler, C. Kenny, and L. Jondreau. 
1992. A portable pulsed electromagnetic field (PEMF) device to enhance healing of 
recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trial. Br J 
Dermatol 127:147-54. 
32. Strašák L., Vetterl V., and S. J. 2002. Effects of low-frequency magnetic fields on 
bacteria Escherichia coli. Bioelectrochemistry 55:161-164. 
33. Strašák L., Vetterl V., and F. L. 2005. Effects of 50 Hz Magnetic Fields on the 
Viability of Different Bacterial Strains. Electromagnetic Biology and Medicine 
(formerly Electro- and Magnetobiology) 24:293 - 300. 
34. Stuhler, T., G. Kaiser, O. Meffert, and D. Strache. 1978. [The influence of low-
frequency DC (system Kraus-Lechner) on bone growth (author's transl)]. Arch Orthop 
Trauma Surg 91:297-303. 
35. Trock, D. H., A. J. Bollet, R. H. Dyer, Jr., L. P. Fielding, W. K. Miner, and R. 
Markoll. 1993. A double-blind trial of the clinical effects of pulsed electromagnetic 
fields in osteoarthritis. J Rheumatol 20:456-60. 
36. van der Borden, A. J., H. van der Werf, H. C. van der Mei, and H. J. Busscher. 
2004. Electric current-induced detachment of Staphylococcus epidermidis biofilms 
from surgical stainless steel. Appl Environ Microbiol 70:6871-4. 
92
Electromagnetic treatment of staphylococci  
_________________________________________________________________________________________________________________ 
 
 93
37. Zhang S., Wei W., and M. Y. Zhang J., Liu S. 2002. Effect of static magnetic field 
on growth of Escherichia coli and relative response model of series piezoelectric 
quartz crystal. Analyst 127:373-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93
Chapter 5
Augmentation of antibiotic efficacy by low-frequency electric and 
electro-magnetic fields examining Staphylococcus aureus
Abstract
Objectives: Systemic treatment of biomaterial-associated bacterial infections with high dosis 
of antibiotics is an established therapeutic concept. Electro-magnetic fields provoke growth 
inhibition on Staphylococcus aureus. The purpose of this in vitro study was to determine the 
influence  of  different  electric  and  electro-magnetic  fields  on  antibiotic  efficacy  using 
gentamicin.
Methods: Cultures of S. aureus in fluid and gel-like media in presence of gentamicin were 
exposed to a low-frequency electro-magnetic field, an electro-magnetic field combined with 
an additional electric field, a sinusoidal alternating electric field and a direct current electric 
field. 
Results: No significant  difference between sample  and reference was detected  in gel-like 
media.  In  presence  of  gentamicin,  each  of  the  four  applied  fields  showed  an  additional 
significant reduction of S. aureus concentration in fluid media after 24 hours of experiment. A 
direct current field decreased cfu/ml of over 91 percent.
Conclusions: An  augmentation  of  antibiotic  efficacy  is  a  promising  new  way  for  anti-
microbial chemotherapy. The application of electro-magnetic fields in the area of implant and 
bone infections could offer new perspectives in antibiotic treatment.
Keywords: Antibiotic efficacy, electro-magnetic fields, Staphylococcus aureus, gentamicin, 
infection
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1 Introduction 
 
Post-operative bone infections and biomaterial-associated infections are common and feared 
complications of bone fractures and artificial joint implantations (19). A treatment of bone 
and implant infections also means an administration of high systemic antibiotic concentrations 
as biofilms insulate pathogens from the host immune defence and antibiotic activity (5, 20). 
However, drug-induced side effects occur. In case of badly healing bone fractures like non-
unions, low-frequency sinusoidal athermic electro-magnetic field therapy according to Kraus-
Lechner is an established applied therapeutic procedure (10). This procedure is based on the 
interaction of sinusoidal electro-magnetic fields with bone and cartilage tissue. In case of 
infected non-unions, bone healing was observed with an infection palliation (11, 12). The 
purpose of this study was to investigate whether an application of different electro-magnetic 
fields could significantly improve antibiotic efficacy. 
 
2 Materials and Methods 
 
2.1 Test bacterium 
 
For in vitro studies, a clinical isolate of Staphylococcus aureus (strain ATTC 49230) was 
used. The test strain was susceptible to gentamicin at a minimal inhibitory concentration MIC 
of 0.5 µg/ml and cultured on columbia agar plates (No. 254071, BD Diagnostic Systems, 
Heidelberg, Germany) at 37 °C for 18 hours before testing. 
 
2.2 Growth curve 
 
In order to correlate the optical density at 600 nm of a S. aureus suspension with the colony 
forming units of the microorganism, a calibration curve was recorded. A bacterial suspension 
was produced by resuspending about 100 colonies of S. aureus from columbia agar plates in 
750 ml of sterile Mueller-Hinton broth (No. 275730, BD Diagnostic Systems, Difco™, 
Heidelberg, Germany). The homogeneous suspension was incubated at 37 °C for 24 hours. In 
time intervals of 60 minutes within the first eight hours and again after 24 hours both the 
optical density (GeneQuant pro, biochrom, Cambridge, UK) at 600 nm was measured and 
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different dilutions of each sample were plated on columbia agar plates. After incubating these 
agar plates for 24 hours at 37 °C the colony forming units were visually determined, 
extrapolated to the initial concentration in suspension and correlated to the measured value of 
optical density. This experiment was repeated three times and all values were combined as 
optical density values as well as cfu/ml can not be reproduced to defined values. A 
logarithmic regression curve with the formula OD=0.0741 Ln(cfu)–0.2066 and a correlation 
coefficient of 0.91 resulted. 
 
2.3 Antibiotic 
 
Gentamicin sulfate (No. FG0603020, Heraeus, Wehrheim, Germany) was used as antibiotic of 
choice. The minimal inhibitory concentration was determined according to the directive M7-
A6-MIC Testing M100-S15 Vol. 25 No.1 (Rules of Clinical and Laboratory Standards 
Institute CLSI) at 0.5 µg/ml. For experiments on gel-like medium, three diffusion discs 
(CT0998B, Oxoid, Hampshire, UK) with gentamicin sulfate concentrations of 4 MIC, 2 MIC 
and 1 MIC corresponding to 2 µg, 1 µg and 0.5 µg were placed on each sample and reference 
bacterial lawn on Mueller-HintonII agar plate (No. 221177 BD Diagnostic System, 
Heidelberg, Germany). For fluid medium experiments, 1 ml of a 6.25 µg/ml gentamicin 
sulfate stock solution was added to each sample and reference tube, resulting in an end 
concentration in 50 ml volume of 0.125 µg/ml corresponding to 0.25 MIC.  
 
2.4 Gentamicin test concentration  
 
The optimal gentamicin concentration in conjunction with applied electric and electro-
magnetic fields in fluid medium was elucidated in a preliminary experiment. 6 tubes were 
filled with 49 ml of bacterial suspension. In each tube 1 ml gentamicin sulfate solution of 
different concentrations was added, resulting in an end concentration of 0.125 MIC, 
0.25 MIC, 0.5 MIC, 1 MIC, 2 MIC and 4 MIC. Saline was used as blank. A growth curve was 
determined by measuring the optical density of bacterial suspension at 600 nm every 60 
minutes for 8 hours and again after 24 hours. Via a calibration curve, the optical density was 
converted in cfu/ml and correlated to time.  The three different  gentamicin concentrations  of 
4 MIC, 2 MIC and 1 MIC were used for experiments in gel-like medium.  
96
Augmentation of antibiotic efficacy by low-frequency electric and electro-magnetic fields  
_________________________________________________________________________________________________________________ 
 
 97
2.5 Bacteria on gel-like medium 
 
For experiments with pathogens on agar plates, bacterial cells were re-suspended in normal 
saline and adjusted to 1x108 cfu/ml by visual comparison with 0.5 McFarland standard. In 
each of the 7 sample and 7 reference Mueller-HintonII agar plates, 2 ml of this inoculum was 
added to receive a bacterial lawn. Three diffusion discs (CT0998B, Oxoid, Hampshire, UK) 
with gentamicin sulfate concentrations of 4 MIC, 2 MIC and 1 MIC were placed on each agar 
plate. Sample plates were then exposed to one of the four applied electro-magnetic fields in 
the sample incubator at 37 °C for 24 hours. The reference plates were placed in the reference 
incubator at 37 °C for 24 hours. After 24 hours the diameter of zones of inhibition between 
the corresponding diffusion plates of sample and reference were compared visually.  
 
2.6 Bacteria in fluid medium 
 
A S. aureus suspension as already described was produced for experiments in fluid medium. 
Four sterile 50 ml reference tubes and four sterile 50ml-sample tubes were filled with 49 ml 
of bacterial suspension. In each tube 1 ml of gentamicin sulfate solution was added, resulting 
in an end concentration of 0.25 MIC within the total volume of 50 ml in each tube. Samples 
were then exposed to one of the four applied electro-magnetic fields in the sample incubator 
at 37 °C within the first 8 hours. For that purpose, electro-magnetic fields were exposed in 40-
minute intervals following a 20 minute break within the first 8 hours. After 8 hours, samples 
were incubated at 37 °C for 16 more hours. References were placed in the reference incubator 
at 37 °C for 24 hours. A bacterial growth curve of sample and reference was determined by 
measuring the optical density at 600 nm of bacterial suspension within the first eight hours in 
a time interval of 60 min and again at 24 hours of incubation at 37 °C. Bacterial 
concentrations of sample and reference at different investigation points were compared with 
the aid of the recorded calibration curve. 
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Figure 1. Instruments: A) Solenoid with cooling jacket to generate a sinusoidal electro-magnetic field 
(5 mT, 20 Hz) and Petri dish holder, B) Electric field applicator with rod-like electrodes to expose 
bacterial suspensions, C) Secondary coil to induce an additional electric field, D) Electric field applicator 
for standard Petri dishes. 
 
2.7 Sinusoidal low-frequency electro-magnetic field  
 
A low-frequency electro-magnetic field was generated by a solenoid (FA-P6-K, Neue 
Magnetodyn, Munich, Germany) (Figure 1A) supplied with a frequency generator (M80, 
Neue Magnetodyn, Munich, Germany). This set-up is clinically licensed for magnetic-field 
therapies in bone fracture healing. Frequencies between 10 Hz and 30 Hz and magnetic field 
strengths of 0.5 mT to 10 mT can be applied. Vials containing bacteria in fluid medium as 
well as agar plates inoculated with bacteria were placed inside the solenoid. While running 
experiments, the coil was prevented from overheating by the use of a cooling jacket 
constructed surrounding the coil. In order to ensure a stable incubation temperature of the 
bacteria at 37° ± 0.1 °C, the coil was placed in an incubator (CB150, Binder, Tuttlingen, 
Germany). The cooling jacket was attached to a circulation water bath (F3, Haake, Vreden, 
Germany) including a thermostat to control the cooling liquid temperature. The temperature 
close to the bacterial culture was controlled by a calibrated temperature meter (VC306/K202, 
Conrad Electronic, Hirschau, Germany) and recorded online. To make sure that the reference 
incubator (CB150, Binder, Tuttlingen, Germany) was not influenced by the electro-magnetic 
field, the stray field of the coil was measured in x and z direction. The reference incubator 
was placed at a distance of 3 meters beyond the stray field. The homogeneity of the magnetic 
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field was assured by measuring the spatial distribution of the magnetic flux density inside the 
coil with a Gauss meter. A low-frequency electro-magnetic field with a frequency of 20 Hz 
and a flux density of 5 mT using a current of 1.2 A was examined for the following 
experiments (Figure 2A and 2 C).  
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Figure 2. Scheme of experimental setups to apply low-frequency electro-magnetic fields (20 Hz, 5 mT: 
only Solenoid) and electro-magnetic fields with additional electric fields for S. aureus cultures on Mueller-
HintonII agar and in suspensions. A sample incubator with a A) Low-frequency electro-magnetic field 
(5 mT, 20 Hz) in fluid medium, B) Electro-magnetic field (5 mT, 20 Hz) combined with an additional 
electric field of 470 mV/cm in fluid medium, C) Low-frequency electro-magnetic fields (5 mT, 20 Hz) 
exposed to gel-like medium and similar with D) Electro-magnetic field (5 mT, 20 Hz) combined with an 
additional electric field of 140 mV/cm on gel-like medium. 
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2.8 Electro-magnetic field combined with an additional electric 
alternating field  
 
The experimental set-up already described for low-frequency electro-magnetic fields was 
applied for generating a low-frequency electro-magnetic field. In order to establish an 
additional electric field, secondary coils (Neue Magnetodyn, Munich, Germany) (Figure 1C) 
were placed inside the primary coil. For agar plates, the lids of Petri dishes contained two 
plane electrodes dipping inside the agar (Figure 1D). The alternating magnetic field generated 
from the primary coil induces an alternating voltage which can be picked off at the secondary 
coil. The secondary coils supply up to seven Petri dishes. Running the primary coil with 
20 Hz and 5 mT, an additional voltage of 0.8 Veff is induced in the secondary coils, resulting 
in an additional alternating electric field strength of 140 mV/cm. This voltage is applied on 
the electrodes of each Petri dish.  
In fluid medium experiments, the secondary coils were made of surgical steel rods and placed 
inside the tubes attached to the lids (Figure 1B). A frequency of 20 Hz and a flux density of 
5 mT lead to an additional voltage of 0.8 Veff, resulting in an additional alternating electric 
field strength of 470 mV/cm (Figure 2B and 2D). 
 
2.9 Sinusoidal electric alternating field  
 
The effect of a sole sinusoidal alternating electric field on the number of bacterial colonies 
cultured on agar plates as well as in fluid medium was determined. For this, the electric field 
applicators already described as secondary coils were connected to a frequency generator (PM 
5131, Phillips, Hamburg, Germany) to generate a pure alternating electric field without using 
a primary coil. A comparable sinusoidal voltage of 0.707 Veff and a field density of 
124 mV/cm effective in case of agar plates as well as a sinusoidal voltage of 0.8 Veff and a 
field strength of 470 mV/cm in case of bacterial suspensions could be built up (Figure 1 and 
 3A, 3C). 
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Figure 3. Scheme of experimental setups to apply sinusoidal and direct current electric fields for S. aureus 
cultures on Mueller-HintonII agar and suspensions: A) Sinusoidal alternating electric field (470 mV/cm, 
20 Hz) in fluid medium, B) Direct current field of 588 mV/cm in fluid medium, C) Sinusoidal alternating 
electric field (124 mV/cm, 20 Hz) in gel-like medium, D) Direct current field of 175 mV/cm in gel-like 
medium. 
 
2.10 Direct current field  
 
Bacterial colonies on agar plates as well as in fluid medium were exposed to a direct current 
field by connecting the electrodes, as already described, to a frequency generator (PM 5131, 
Phillips, Hamburg, Germany). A direct current voltage of 1.0 V resulted in an electric field 
strength of 175 mV/cm affecting bacteria on agar plates and a field strength of 470 mV/cm 
affecting bacteria in fluid medium (Figure 1 and 3B, 3D). 
 
  
A B 
C D 
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2.11 Calculations and statistical methods  
 
Data from bacterial growth studies were compared for statistical significance using the 
student t-test with P < 0.05 considered significant. 
 
3 Results 
 
3.1 Bacteria on gel-like medium 
  
In gel-like medium, inhibition zones in the presence of gentamicin are shown to be dependent 
upon the MIC. However, the application of the four electric and electro-magnetic fields 
revealed no synergistic growth inhibitory effect, as seen in figure 4 for the application of the 
direct current field.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Median dimensions of inhibition zones [mm] of sample (n=7) and reference (n=7) from 
gentamicin loaded diffusion discs on S. aureus lawn cultured on Mueller-HintonII agar plate under the 
influence of a direct current fields of 175 mV/cm. 
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3.2 Bacteria in fluid medium 
 
3.2.1 Gentamicin test concentration 
 
In fluid medium growth, inhibition of the gentamicin concentrations chosen (0.125 MIC, 0.25 
MIC, 0.5 MIC, 1 MIC, 2 MIC and 4 MIC) is demonstrated in figure 5. For the experimental 
set-ups with electro-magnetic fields in fluid medium, 0.25 MIC was chosen. This moderate 
inhibition is in a range allowing detection of synergistic influences induced by electric and 
electro-magnetic fields. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Growth inhibition of S. aureus by different MICs of gentamicin in fluid medium within 24 
hours. 
 
3.2.2 Low - frequent electromagnetic field 
 
A marginal acceleration of bacterial growth within the first eight hours was detected when S. 
aureus suspensions in the presence of gentamicin (0.25 MIC) were esposed to a low frequent 
electromagnetic field (5 mT, 20 Hz). However, after 24 hours, the bacterial concentrations in 
the sample were significantly lower than in the reference. A significant reduction of S. aureus 
concentration of 32 % was demonstrated (Figure 6A). 
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Figure 6 A/B. Median cfu/ml of sample (n=4) and reference (n=4) from S. aureus cultured in sterile 
Mueller-Hinton broth in presence of gentamicin (0.25 MIC) under the influence of different electro-
magnetic-fields. A) A low frequent electromagnetic field (5 mT, 20 Hz), B) An electromagnetic field (5 mT, 
20 Hz) combined with an additional electric field of 470 mV/cm. 
 
EMF ^= electromagnetic field, a.c. EF ^= alternating electrical field, d.c. EF ^= direct current electrical 
field 
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Figure 6 C/D. Median cfu/ml of sample (n=4) and reference (n=4) from S. aureus cultured in sterile 
Mueller-Hinton broth in presence of gentamicin (0.25 MIC) under the influence of different electric fields. 
C) A sinusoidal alternating electric field (470 mV/cm, 20 Hz), D) A direct current fields of 588 mV/cm. 
 
EMF ^= electromagnetic field, a.c. EF ^= alternating electrical field, d.c. EF ^= direct current electrical 
field 
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3.2.3 Electro-magnetic field combined with an additional electric field  
 
The application of an electromagnetic field (5 mT, 20 Hz) combined with an additional 
electric field (470 mV/cm) to S. aureus already showed a decrease of cfu/ml after 7 hours of 
field exposure. After 24 hours of the experiment, a statistically significant reduction of 41 % 
of cfu/ml as compared to the reference was determined (Figure 6B).  
 
3.2.4 Sinusoidal alternating electric field 
 
Treatment of S. aureus with a sinusoidal alternating electric field (470 mV/cm, 20 Hz) 
revealed an increase of bacterial concentration during the first 8 hours of exposure time. 
However, in the following 16 hours of incubation at 37 °C, germ growth reduction was 
observed. Compared to bacterial growth in the presence of 0.25 MIC of gentamicin in 
reference investigations, an application of a sinusoidal alternating electric field demonstrated 
a statistically significant reduction of 43 % of cfu/ml (Figure 6C). 
 
3.2.5 Direct current field 
 
The influence of a direct current field (588 mV/cm) on bacterial suspensions in the presence 
of gentamicin already showed a significant reduction of bacterial concentration after 6 hours. 
A statistically significant decrease of 91.8 % of cfu/ml was observed after 24 hours (Figure 
6D). 
 
4 Discussion 
 
In the treatment of medical device infections, high concentrations of antibiotics are applied 
intravenously. Micro-organisms, mostly belonging to S. aureus and S. epidermidis, colonize 
implants and form a complex biofilm in conjunction with the patient`s own proteins such as 
fibronectin or albumin (1, 17). This biofilm encloses pathogens against the host immune 
defence (14) and increases antibiotic resistance (6, 15). Therefore, higher doses of antibiotics 
have to be applied, although mandatory long-term application increases side-effects. In 
patients suffering from implant infections, the eradication of pathogens is an important 
clinical necessity which could be supported by electro-magnetic field therapy. 
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As a result, improvement of antibiotic efficacy is an important consideration and could be 
supported by the use of electro-magnetic fields. 
Only few studies dealing with the enhancement of antibiotic activity by electric or 
electromagnetic fields are available in literature. Benson et al. (2) have investigated an 
enhancement of the activity of gentamicin against biofilm-forming P. aeroginosa adhered on 
different polymers by using magnetic fields between 5 and 20 Gauss. They report a reduction 
in the number of adhered bacteria when exposed to a 5 gauss magnetic field in the presence of 
gentamicin in a range of 86 %, independent of the colonized polymers. An improvement of 
antibiotic efficacy in orthopaedic implant infections has been found by Pickering et al. (16). 
They observed that a pulsed electronmagnetic field caused a reduction in the minimum 
biofilm concentration of gentamicin against five-day old biofilms of S. epidermidis. In 
contrast to this investigation, Stansell et al. (18) observed an increase of antibiotic resistance 
of E. coli when exposed to a static magnetic field. Grosman et al. (8) demonstrated no 
influence of a magnetic field on growth reduction of E. coli and S. aureus in a range of 0.5 to 
4 Tesla. Data on the impact of electric current on the activity of antibiotics are hardly 
available in literature. Caubet et al. (3) report an enhancement of antibiotic activity against 
bacterial biofilms when radio frequency electric current is used. They detected a bioelectric 
effect with a radio frequency alternating electric current of 10 MHz applied to E. coli biofilms 
with simultaneous gentamicin and oxytetracycline treatment. 
Our experimental set-up differs from previous studies. We have compared different types of 
electro-magnetic fields applied to a well-defined biofilm producing pathogen such as S. aureus 
(ATTC 49230) and simultaneous treatment with an antibiotic. Physical parameters of the 
applied fields were derived from the clinically established Magnetodyn® procedure to improve 
bone healing, as demonstrated in material and methods. Numerous data in literature concerning 
this magnetic field therapy are available as depicted by Kraus (9). A low-frequency electro-
magnetic field, an electro-magnetic field combined with an additional electric field, a 
sinusoidal electric alternating field and a direct current field were used. Gentamicin was 
selected as a clinically approved antibiotic in the treatment of S. aureus-induced soft tissue, 
bone and implant-associated infection (7). Our experiments showed no influence of the four 
applied fields on growth inhibition in the presence of gentamicin tested on gel-like medium.  
Low dose gentamicin application corresponding to 0.25 MIC under the influence of the four 
applied fields showed a statistically significant effect on growth inhibition in fluid medium. 
Depending on the type of field applied, an improvement of gentamicin efficacy from 32.4 % 
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using a clinically applied electromagnetic field (5 mT, 20 Hz) up to 91.8 % using a direct 
current field of 588 mV/cm was observed (Table 1). 
 
Table 1. Overview of pathogen reduction in synergism with 0.25 MIC gentamicin caused by different 
electro-magnetic fields: A) Low-frequency electro-magnetic field (5 mT, 20 Hz) in fluid medium, B) 
Electro-magnetic field (5 mT, 20 Hz) combined with an additional electric field of 470 mV/cm in fluid 
medium, C) Sinusoidal alternating electric field (470 mV/cm, 20 Hz) in fluid medium, D) Direct current 
field of 588 mV/cm in fluid medium.  
 
EMF ^= electromagnetic field, a.c. EF ^= alternating electrical field, d.c. EF ^= direct current electrical 
field 
 
 
electro-magnetic field 
 
 
 
electric field 
A) EMF 
(5 mT, 20 Hz) 
B) EMF + a.c. EF 
(5 mT, 470 mV/cm, 20 Hz) 
C) a.c. EF 
(470 mV/cm, 20 Hz) 
D) d.c. EF 
(588 mV/cm) 
pathogen 
reduction 
after 24 h in [%] 
 
(relative to 
gentamicin without 
field-influence) 32.4 %  
(p = 0.0002) 
41.7 % 
 
(p = 0.0332) 
43.9 % 
 
( p = 0.0004) 
91.8 % 
 
(p < 0.0001) 
 
In general, we have been able to demonstrate an additional statistically significant reduction 
of S. aureus growth in the presence of gentamicin under the influence of all applied fields in 
fluid medium. The strongest effect of augmented gentamicin efficacy could be shown by the 
application of the direct current field. We assume that this effect is caused by electrolysis-
induced radicals. Formed hydroxyl and oxygen radicals are known to destroy cell membranes 
of bacteria. This so-called bioelectric effect (2, 4, 13, 16) may facilitate the penetration of 
antibiotic drugs and could be an explanation for the detected efficacy augmentation of 
gentamicin. The effect of various antibiotics and antiseptics depending on charged and non-
charged compounds in the presence of the four fields are under investigation to shed light on 
the underlying mechanism. 
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5 Conclusions 
 
In this study we have demonstrated that a combination of electro-magnetic fields with the 
antibiotic gentamicin improves efficacy against S. aureus in vitro. These results corroborate 
clinical observations that the application of electro-magnetic fields according to Kraus and 
Lechner in infected non-unions improves bone healing and induces infection palliation. We 
conclude that the combination of antibiotic treatment with low-frequency electro-magnetic 
fields could offer new opportunities in biomaterial-associated infection therapy. 
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7 Figure and Table Captions 
 
Figure 1. Instruments: A) Solenoid with cooling jacket to generate a sinusoidal electro-
magnetic field (5 mT, 20 Hz) and Petri dish holder, B) Electric field applicator with rod-like 
electrodes to expose bacterial suspensions, C) Secondary coil to induce an additional electric 
field, D) Electric field applicator for standard Petri dishes. 
 
Figure 2. Scheme of experimental setups to apply low-frequency electro-magnetic fields 
(20 Hz, 5 mT: only Solenoid) and electro-magnetic fields with additional electric fields for S. 
aureus cultures on Mueller-HintonII agar and in suspensions. A sample incubator with a A) 
Low-frequency electro-magnetic field (5 mT, 20 Hz) in fluid medium, B) Electro-magnetic 
field (5 mT, 20 Hz) combined with an additional electric field of 470 mV/cm in fluid medium, 
C) Low-frequency electro-magnetic fields (5 mT, 20 Hz) exposed to gel-like medium and 
similar with D) Electro-magnetic field (5 mT, 20 Hz) combined with an additional electric 
field of 140 mV/cm on gel-like medium. 
 
Figure 3. Scheme of experimental setups to apply sinusoidal and direct current electric fields 
for S. aureus cultures on Mueller-HintonII agar and suspensions: A) Sinusoidal alternating 
electric field (470 mV/cm, 20 Hz) in fluid medium, B) Direct current field of 588 mV/cm in 
fluid medium, C) Sinusoidal electric alternating field (124 mV/cm, 20 Hz) in gel-like 
medium, D) Direct current field of 175 mV/cm in gel-like medium. 
 
Figure 4. Median dimensions of inhibition zones of sample (n=7) and reference (n=7) from 
gentamicin-loaded diffusion discs on S. aureus lawn cultured on Mueller-HintonII agar plate 
under the influence of a direct current fields of 175 mV/cm.
 
Figure 5. Growth inhibition of S. aureus by different MICs of gentamicin in fluid medium 
within 24 hours. 
 
Figure 6. Median cfu/ml of sample (n=4) and reference (n=4) from S. aureus cultured in 
sterile Mueller-Hinton broth in presence of gentamicin (0.25 MIC) under the influence of 
different electro-magnetic-fields.  
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Table 1. Overview of pathogen reduction in synergism with 0.25 MIC gentamicin caused by 
different electro-magnetic fields. 
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Chapter 6 
 
 
Magnetic drug targeting for biomaterial infections  
 
Abstract 
Objectives: Biomaterial-associated infections present a challenging problem in surgery. 
Increased antibiotic resistance of pathogens in biofilms requires high drug concentrations in 
the area of infection. The present work presents a novel strategy to concentrate high antibiotic 
doses at the surface of vascular grafts using newly developed antibiotic-functionalized 
nanoparticles directed by a magnetic drug targeting system.  
Methods: Magnetic nanoparticles were ionically and covalently functionalized with 
gentamicin. Drug release kinetics within 90 minutes was studied in phosphate buffered saline 
at 37 °C. Anti-infective characteristics were determined by measuring the change in optical 
density of Staphylococcus aureus suspensions charged with coated ferrofluids within 24 
hours. A cell proliferation assay was performed to assess the degree of cytotoxicity. The 
enrichment of ferrofluids at the surface of model tubes in circulatory experiments was 
investigated. 
Results: A technology for the antimicrobially equipment of magnetic nanoparticles could be 
generated. All gentamicin-functionalized nanoparticles did not show drug release within 90 
minutes. Selected coated nanoparticles reduced bacterial growth even beyond pathologically 
relevant concentrations within 24 hours. Excellent concentration-independent 
biocompatibility was assessed for ferrofluids of choice. Magnetic nanoparticles could be 
concentrated on the surface of model grafts. 
Conclusions: The development and in vitro studies of described magnetic drug targeting 
system present a new perspective in the treatment of vascular graft infection. With the help of 
a strong external magnetic field drug-functionalized nanoparticles can be enriched at the 
surface of infected grafts ensuring high drug levels to fend off biofilm embedded pathogens. 
 
Keywords: Magnetic nanoparticles, drug targeting, gentamicin, infection, Staphylococcus 
aureus 
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1 Introduction 
 
Biomaterial-associated infections present a challenging problem for patients and surgeons (24, 
27). Synthetic vascular grafts like PTFE prostheses are easily accessible to pathogens because 
of their porous structure (4). These pathogens, mostly belonging to Staphylococcus aureus 
and Staphylococcus epidermidis, colonize the implant by adhering to the patients own 
proteins located on the surface of the graft and forming a biofilm (9, 15, 19). Once a biofilm 
has established, there is an essential need for surgical intervention with the objective of 
vascular graft replacement because of a high risk of sepsis associated with a high amputation 
rate or mortality (6, 28). In many cases these life-essential replacements can not be performed 
because of the high risk of the surgical intervention itself due to the age structure of patients 
with vascular implants (29). A standard treatment with high doses of intravenous antibiotics  
is the result and mandatory long-term application increases side-effects (13). It is therefore 
essential to find new ways to locally concentrate antibiotics in the area of infected grafts, 
thereby minimizing side effects (25). In the last few years, nanotechnology moved into the 
focus of scientific interest (17, 18, 20). Drugs like chemotherapeutics can be ionically or 
covalently bound to magnetic nanoparticles and concentrated with the help of a magnetic drug 
targeting system in the target area (2, 21, 22). In the present study, a technology for the 
development of gentamicin-functionalized magnetic nanoparticles was generated (Figure 1), 
and developed particles were analyzed for drug release, antibacterial characteristics and 
biocompatibility. Furthermore, the enrichment of magnetic nanoparticles on the surface of 
modified model grafts in circulatory experiments in vitro was investigated with a magnetic 
drug targeting system.     
 
 
 
 
 
 
Figure 1. TargetMAG with ionically coupled gentamicin. The electrostatic attraction is based on the 
interaction between positively charged tertiary ammonium groups of gentamicin and negatively charged 
phosphate groups of the organic shell surrounding the magnetic iron core (Chemicell GmbH archives). 
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2  Materials and methods 
 
2.1 Nanoparticles 
 
Six different magnetic nanoparticle types consisting of a magnetite core and an organic shell 
were used for coating experiments (Table 1 A/B). Four different types of ferrofluids were 
chosen, that are potentially useful to prepare ionic adsorption complexes with the antibiotic 
gentamicin. S13, S21 and S26 were kindly provided by the University Hospital Munich 
(Klinikum r. d. Isar, Institut für Experimentelle Onkologie und Therapieforschung, Munich, 
Germany), TargetMAG was kindly provided by Chemicell (Chemicell GmbH, Berlin, 
Germany). The nanoparticle types FluidMAG and SiMAG (Chemicell GmbH, Berlin, 
Germany) were chosen for a covalent gentamicin binding (Table 1A/B). 
 
Table 1A. Overview of individual nanoparticle types used for ionic or covalent gentamicin coupling.   
 
 S13 S21 S26 
Composition Aqueous dispersion of palmitoyl-
dextran-coated magnetic 
nanoparticles 
Aqueous dispersion of 
palmitic acid-coated 
magnetic nanoparticles 
Aqueous dispersion of 
dihexadecylphosphate-
coated magnetic 
nanoparticles 
functional 
group 
Hydroxyl Carboxyl Phosphate 
Binding type ionic ionic Ionic 
Particle Size 
hydrodynamic 
diameter [nm] 
175 231 10 
Mean  
magnetite 
crystallite size 
<d> (nm) 
4,0 12,8 10,0 
ξ-potential 
(mV) 
-31.4 23.5 31.4 
Iron 
concentration, 
mg Fe/ml 
9,2 20,0 5,0 
 
 
 
 
 
 
 
117
Magnetic drug targeting for biomaterial infections 
_________________________________________________________________________________________________________________
  
 
 118 
Table 1B. Overview of individual nanoparticle types used for ionic or covalent gentamicin coupling. 
 
 TargetMAG FluidMAG SiMAG 
Composition Aqueous dispersion of starch 
polymer-coated magnetic 
nanoparticles particles 
Aqueous dispersion of 
polysaccharide-coated 
magnetic nanoparticles 
Aqueous dispersion of 
magnetic silicea 
particles 
functional 
group 
Phosphate Glucuronic acid -
Carboxyl 
Carboxyl 
Binding type ionic covalent Covalent 
Particle Size 
hydrodynamic 
diameter [nm] 
250 250 500 
Mean 
magnetite 
crystallite size 
<d> (nm) 
60.0 60.0 60.0 
ξ-potential 
(mV) 
-35.1 -38.1 -40.9 
Iron 
concentration, 
mg Fe/ml 
30.0 25.0 50.0 
 
2.2 Particle size and zeta potential 
 
The median particle size as well as the zeta potential of individual nanoparticle types was 
determined by dynamic light scattering (Zetasizer Nano SZ, Malvern Instruments, Malvern 
UK) (Table 1A/B). Therefore nanoparticles were suspended in distilled water at 10 µg/ml.  
 
2.3 Drug loading 
 
For ionically bound gentamicin on magnetic nanoparticles the optimal ratio for coating 
procedure between gentamicin sulfate (Heraeus Kulzer GmbH, Werheim, Germany) and 
magnetic nanoparticles was assessed. Therefore different gentamicin concentrations were 
combined with a defined ferrofluid concentration. S13, S21 and S26 and TargetMAG 
nanoparticle suspensions were diluted with distilled water to a concentration of 1 mg Fe/ml. 
Gentamicin sulfate was dissolved at 1 mg/ml in distilled water and diluted to concentrations 
of 200 µg/ml, 100 µg/ml, 75 µg/ml, 50 µg/ml, 25 µg/ml and 10 µg/ml. 500 µl of the ferrofluid 
suspension (1mg/ml) was incubated with 500 µl gentamicin sulphate solution of the 
respective concentration at 37 °C for 30 minutes at 1400 rpm (Eppendorf Thermomixer, 
Eppendorf AG, Hamburg, Germany). Drug ferrofluid suspension was placed in a permanent 
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magnet field (NdFeB Magnet 80x40x10 mm, Neotexx, Berlin, Germany) for 30 minutes to 
achieve segregation between drug solution and nanoparticles. 500 µl of the supernatant were 
removed. A reference was established by adding 500 µl distilled water to 500 µl of 
gentamicin sulfate solutions. Gentamicin was analyzed by the Innofluor Gentamicin assay 
system (Opus Diagnostics, Fort Lee, USA). Gentamicin concentrations assessed in the 
supernatant of respective ferrofluid suspensions were compared to reference gentamicin 
concentrations. The ratio between the difference of sample concentrations and the reference 
concentration is defined as the loading capacity.  
 
2.4 Coating Technology 
 
For further experiments S13, S21 and S26 were diluted with distilled water to a 
concentration of 1mg Fe/ml. Gentamicin sulfate was diluted to the optimal coating 
concentration of 100 µg/ml. 500 µl of the obtained ferrofluid suspension was then incubated 
with 500 µl of 100 µg/ml gentamicin sulfate at 37 °C for 30 minutes at 1400 rpm (Eppendorf 
Thermomixer, Eppendorf AG, Hamburg, Germany). A reference was established by adding 
500 µl distilled water to 500 µl of 100 µg/ml gentamicin sulfate solution. TargetMAG 
particles were coated with a one to five ratio between gentamicin and iron content. In order to 
assess the loading capacity, ferrofluid suspensions with covalently bound gentamicin were 
placed in a permanent magnetic field (NdFeB Magnet 80x40x10 mm, Neotexx, Berlin, 
Germany), for 30 minutes to achieve a segregation between drug solution and nanoparticles. 
500 µl of the supernatant were removed and analyzed for gentamicin concentration by the 
Innofluor Gentamicin assay system. Subsequently the loading capacity of used nanoparticles 
was assessed. Gentamicin was covalently coupled to FluidMAG and SiMAG nanoparticles by 
the carboiimide method (7, 8). Thereby, carboiimides react with the terminal carboxylate-
groups from the magnetic beads to highly reactive O-acylisourea derivatives which bind the 
amino-groups of gentamicin via an amide bond. 
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2.5 Antibacterial characteristics 
 
2.5.1 Test bacterium 
 
For in vitro studies, a clinical isolate of Staphylococcus aureus (strain ATCC
®
 49230) was 
used. The test strain was susceptible to gentamicin (MIC 0.5 mg/l). Staphylococcus aureus 
was cultured on columbia agar plates (Becton Dickinson GmbH, Heidelberg, Germany) at 
37 °C for 18 hours before testing.  
 
2.5.2 Calibration curve 
 
In order to correlate the optical density at 600 nm of a S. aureus suspension with the colony 
forming units of the microorganism, a calibration curve was recorded. A bacterial suspension 
was produced by resuspending about 100 colonies of S. aureus from columbia agar plates in 
750 ml of sterile Mueller-Hinton broth (No. 275730, BD Diagnostic Systems, Difco™, 
Heidelberg, Germany).  The homogeneous suspension was incubated at 37 °C for 24 hours. 
The optical density (GeneQuant pro, biochrom, Cambridge, UK) at 600 nm was measured at 
time intervals of 60 minutes within the first eight hours and again after 24 hours. Different 
dilutions of each sample were also plated on columbia agar plates. After incubating these agar 
plates for 24 hours at 37 °C the colony forming units were visually determined, extrapolated 
to the initial concentration in suspension and correlated to the measured value of optical 
density. This experiment was repeated three times and all values were combined since optical 
density values as well as cfu/ml can not be reproduced to defined values. A logarithmic 
regression curve with the formula OD=0.0741 Ln(cfu)–0.2066 and a correlation coefficient of 
0.91 resulted.  
 
2.5.3 Antimicrobial potential 
 
In order to investigate the antimicrobial potential of drug-carrier-coated grafts, a hundredfold 
concentration of the commonly observed pathological concentration (1 x 10
4
 cfu/ml) was 
chosen. Bacterial cells from columbia agar plates were resuspended in Müller-Hinton broth to 
form a bacterial suspension. 1 ml of gentamicin coated TargetMAG (TargetMAG-Genta) 
suspension (1 mg/ml) or 1 ml gentamicin coated S13 (S13-Genta) suspension (1 mg/ml) was 
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added to 49 ml of Staphylococcus aureus suspensions to determine their anti-infective 
efficiency. The optical density was measured after certain time intervals and plotted against 
time. With the aid of the calibration curve, bacteria concentrations of sample and reference at 
different points in time could be compared. A reference was established using TargetMAG 
and S13 suspensions. 
 
2.5.4 Pathologically relevant bacterial concentrations 
 
In order to assess antibiotic efficacy at pathologically relevant bacterial concentrations (12), 
bacterial suspensions with concentrations of 1 x 10
2
, 1 x 10
3
, 1 x 10
4
 cfu/ml were prepared 
and incubated in partes aequales with gentamicin coated S13 and TargetMAG-Genta particles 
as well as non-coated S13 and TargetMAG particles of 2 mg/ml iron concentration suspended 
in NaCl 0.9 % for 24 hours in 37 °C. A reference was established by incubating individual 
bacterial suspensions with pure NaCl 0.9 %. 200 ml of each sample was plated out and colony 
forming units on blood agar plates were determined for each sample and reference. 
 
2.5.5 Gentamicin efficacy 
  
In a continuing experiment, the influence of individual gentamicin concentrations on S. 
aureus growth in fluid media was elucidated. Therefore, tubes filled with 49 ml of bacterial 
suspension were incubated with 1 ml gentamicin sulfate solution of different concentrations 
resulting in a gentamicin end concentration of 0.665 µg/ml, 1.330 µg/ml, 6.650 µg/ml and 
66.500 µg/ml. Saline was used as a blank. A growth curve was determined by measuring the 
optical density of bacterial suspension at 600 nm every 60 minutes for 8 hours and again after 
24 hours. Via a calibration curve, the optical density was converted in cfu/ml and correlated to 
time. 
 
2.6 Gentamicin release from nanoparticles 
 
The supernatant of coated S13 and TargetMAG ferrofluids was completely removed; particles 
were washed twice with purified water and 1ml PBS was added to nanoparticles. Drug 
ferrofluid suspensions were then placed in a permanent magnetic field and at time points  
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5, 10, 15, 30, 60 and 180 minutes 100 µl of supernatant were analyzed for gentamicin 
concentration by an Innofluor Gentamicin assay system. Released gentamicin concentrations 
were plotted against time in order to gain a release curve. 
 
2.7 In vitro cytotxicity studies 
 
2.7.1 Cell culture 
 
Human umbilical vein endothelial cells (HUVEC) were maintained in endothelial cell growth 
medium (PromoCell, Heidelberg, Germany) supplemented with SupplementMix, 10 % fetal 
bovine serum, penicillin and streptomycin (100 U/ml and 0.1 mg/ml, respectively), partricin 
(50 µg/ml) and stable glutamine at 37 °C in a humidified atmosphere containing 5 % CO2. 
Cells were washed with PBS-Dulbecco (Biochrom AG, Berlin, Germany) and trypsinized 
with Trypsin/EDTA-Solution (Biochrom AG, Berlin, Germany). 
 
2.7.2 Ferrofluid toxicity 
 
Cytotoxicity tests were carried out with different concentrations of coated and uncoated 
magnetic nanoparticles. Human umbilical vein endothelial cells were cultured in a 96 well 
plate until subconfluence, TargetMAG, and S13 both blank and Gentamicin loaded ferrofluids 
were added in concentrations of 2000 µg/ml, 1000 µg/ml, 500 µg/ml, 100 µg/ml, 60 µg/ml 
and 10 µg/ml and cells were cultured for 10 hours at 37 °C. Resovist
®
 served as reference, as 
it is an already established and licensed radiopaque material. After ferrofluid incubation cells 
were washed with PBS and metabolic activity of viable cells was measured with the Roche 
cell proliferation reagent WST-1 (Roche Diagnostics GmbH, Mannheim, Germany).  
 
2.7.3 Gentamicin toxicity 
 
In order to analyze the toxicity of gentamicin, cells were cultured in 96-well microplates in 
presence of different  concentrations of gentamicin (1.33 µg/ml, 6.65 µg/ml, 33.25 µg/ml, 
66.5 µg/ml, 133 µg/ml) until subconfluence followed by a Roche cell proliferation reagent 
WST-1 test. 
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2.8 Circulatory experiments 
 
A closed circuit was built up as a model for bloodstream in a ratio of one to one hundred to 
physiological conditions (Figure 2). TargetMAG was chosen as a model ferrofluid. A flexible 
synthetic tube (target tube) of 8 mm diameter, 1.6 mm wall thickness and 10 cm length 
(Tygon® R3603, Ismatec Laboratoriumstechnik GmbH, Wertheim-Mondfeld, Germany) was 
placed between two plugs and placed in the centre of a Bruker Magnet (Bruker, Karlsruhe, 
Germany). Three different tip-target distances, the distance between the symmetry axis of the 
target tube and the magnet tip, at 0 mm, 15 mm and 30 mm were chosen. The plugs of the 
target tube were attached to two flexible tubes of 7 mm diameter (silicone tube, I:5 x A:7 mm, 
neoLab, Heidelberg, Germany). One tube was connected directly to a sealable reservoir 
containing 50 ml of an aqueous 1 mg/ml TargetMAG suspension, the second tube was 
directed via a peristaltic pump (VC380, ISMATEC Laboratoriumstechnik GmbH, Wertheim-
Mondfeld, Germany) to the 50 ml ferrofluid reservoir. The peristaltic pump assured a flow 
rate of 260 ml/min, similar to physiological blood stream conditions for vascular grafts (in the 
range of 400 ml/min for sane veins and 150 ml/min to 200 ml/min for vascular grafts). Before 
starting the circulatory experiment, the ferrofluid suspension was shaken for 2 minutes until a 
homogenous distribution was achieved and 500 µl of the ferrofluid suspension were taken out 
for iron content analysis. The circulatory experiment was started by opening all valves in flow 
direction and starting the pump. At time points 15 min and 30 min, 500 µl samples were 
abstracted for further iron content analysis to allow ferrofluid saturation in the closed circuit. 
After ferrofluid saturation, the Bruker Magnet was operated for 30 minutes with a direct 
current of 30 A and 120 V creating a magnetic field strength of 1.7 Tesla at the vertex of the 
magnet (14). During magnetic field application after 15 minutes and 30 minutes 500 µl 
samples were abstracted for further iron content analysis. Ferrofluid agglomeration was 
studied with naked tubes as well as with tubes surrounded by a wire netting consisting of 0.8 
mm nealed and oxidized Mumetal with a diameter of 0.8 mm, a length of 5 cm and a flank 
lead of 2 mm (Vacuum Schmelze Hanau, Germany). The wire netting was constructed in 
order to distort the field gradient and therefore the magnetic forces in a way that magnetic 
nanoparticles are forced to adsorb at the inner-surface of the PTFE graft as shear forces 
prevent particles from accumulating in the area of the graft. 
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Figure 2. Closed circuit built up as a model for bloodstream in a ratio of one to one hundred to 
physiological conditions (total volume 50 ml ferrofluid suspension).  
 
2.9 Iron content determination 
 
Iron content analysis for determination of the nanoparticle concentration was based on 
turbidity measurements and was performed by visual spectroscopy (ELISA-reader sunrise, 
Tecan, Crailsheim, Germany). A calibration curve was recorded by correlating the optical 
density at 490 nm with iron concentrations between 5 µg/ml and 500 µg/ml. The iron content 
of samples for different time points was assessed and compared among each other. 
 
 
 
 
 
 
 
 
 
Peristaltic Pump
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50 ml
Siltube
d= 7 mm
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aequos suspension
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3 Results 
 
3.1 Loading of magnetic nanoparticles with gentamicin 
 
For S13 and S26 loading curves could be generated, whereas for S21 particles, no difference 
between gentamicin concentrations in sample supernatant and reference supernatant during 
the loading process was observed indicating no particle loading. For S13 and S26 particles an 
increasing loading capacity with the application of higher gentamicin concentrations was 
observed (Figure 3A/B). 
 
 
Figure 3 A/B. Loading of magnetic nanoparticles with gentamicin: A. S13 particles and B. S26 particles. 
 
The maximal loading capacity of S13 ferrofluids was achieved at a gentamicin concentration 
of 10 % (c/c) referring to the total iron concentration resulting in 6.6 % (m/m) loading. For 
S26 particles, the maximal loading capacity was also achieved at the same gentamicin to iron 
ratio of 1:10 resulting in 1.4 % (m/m) antibiotic loading. For TargetMAG particles the 
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maximal loading capacity was achieved at an applied gentamicin concentration of 20 % of 
used iron concentration resulting in 15.0 % (m/m) drug loading.  
The covalent equipment of FluidMAG and SiMAG with gentamicin was performed 
successfully, however the maximal loading capacity could not be determined. As S21 and S26 
particles did not show enough drug loading at their surface, they were excluded from further 
experiments. 
 
3.2 Antibacterial characteristics 
 
Pathogen growth in suspensions at pathologically relevant bacterial concentrations (10
2
 – 10
4
 
cfu/ml) incubated with gentamicin coated S13 and TargetMAG particles at 1 mg/ml was 
completely inhibited. Suspensions with uncoated nanoparticles or saline reference 
demonstrated the formation of bacterial lawns on agar plates. Bacterial growth in highly 
concentrated bacterial suspensions of 2 x 10
6
 cfu/ml could be reduced by ionically bound 
gentamicin coated ferrofluids TargetMAG-Genta. In contrast, magnetic nanoparticles coated 
with covalent coupled gentamicin, like FluidMAG (FluidMAG-Genta) and SiMAG (SiMAG-
Genta), showed a growth stimulating effect of S. aureus cultures in fluid media (Figure 4). 
 
Figure 4. Staphylococcus aureus growth cultured in sterile Mueller-Hinton broth without adjuvant (pure 
bacteria), in presence of gentamicin coated nanoparticles (TargetMAG-Genta, FluidMAG-Genta, 
SiMAG-Genta), uncoated nanoparticles (TargetMAG, FluidMAG, SiMAG). 
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TargetMAG-Genta showed a S. aureus growth inhibition resulting in a colony reduction after 
24 hours of over 99 % compared to reference (Figure 5). Coated S13 particles reduced 
bacterial growth by over 85 %, whereas the phenomena of a growth stimulating effect already 
observed for FluidMAG-Genta and SiMAG-Genta particles was also detected for uncoated 
S13 particles. Applying gentamicin concentrations between 0.665 µg/ml up to 66.500 µg/ml 
resulted in a S. aureus growth inhibiting effect of approximately 85 % to 88 % independent of 
concentration. As S21 and S26 particles did not show enough drug loading at their surface, 
they were excluded from experiments. As FluidMAG and SiMAG particles did not show 
antimicrobial potential, they were excluded from further experiments. 
 
 
Figure 5. Staphylococcus aureus growth cultured in sterile Mueller-Hinton broth without adjuvant (pure 
bacteria), in presence of gentamicin coated nanoparticles (TargetMAG-Genta), uncoated nanoparticles 
(TargetMAG). 
 
Analyses of drug release for all six coated nanoparticle types incubated in PBS at 37 °C and 
pH 7.4 for release showed no measurable gentamicin release from the surface of investigated 
magnetic nanoparticles. 
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3.3 Percent surface coverage 
 
The percentage of S13 particle surface covered by gentamicin after the loading procedure can 
be estimated as performed. As 1 µg iron contains 7.9 x 10
12
 S13 particles and the gentamicin 
load per 1 µg iron averaged at 0.066 µg, 8.3 x 10
-15
 g gentamicin (^= 10.5 x 10
6
 molecules) is 
bound per 1 S13 particle. Based on the fact that one particle has a surface area of  
1.3 x 10
-15
 m
2
, 6.6 g gentamicin, corresponding to 13.8 mmol gentamicin, or 8.4 x 10
21
 
gentamicin molecules are bound per one square meter particle surface. According to this 
calculation 8400 gentamicin molecules are bound to one square nanometer S13 surface. 
 
3.4 In vitro cytotoxicity studies 
 
The WST-1 assay shows high metabolic activity of HUVEC in the presence of magnetic 
nanoparticles at the concentration used in circulatory experiments of 1 mg/ml for Resovist
® 
(150 % of reference cell proliferation), followed by TargetMAG-Genta particles (122 % of 
reference cell proliferation), and uncoated TargetMAG-NC particles (91 % of reference cell 
proliferation) (Figure 6A). Metabolic activity of HUVEC in presence of S13 particles was 
assessed at 95 % for S13-Genta and 101 % for S13 particles (Figure 6B). Under the influence 
of individual gentamicin concentrations, the metabolic activity ranged from 96 % up to 102 % 
compared to reference (Figure 6C).  
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Figure 6 A-C. Metabolic activity of HUVEC incubated with different concentrations of A) TargetMAG 
and TargetMAG-Genta, B) S13 and S13-Genta and C) different gentamicin concentrations. 
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3.5 Circulatory experiments 
 
The operation of the Bruker Magnet with 30 A and 120 V for 30 minutes resulted in an 
enrichment of the magnetic nanoparticles TargetMAG at the surface of the target tube when 
keeping a maximal tip-target distance of 15 mm, independent of the application of an 
additional wire netting. TargetMAG particles were used as they showed superior anti-
infective and biocompatible characteristics towards all other developed nanoparticles. The 
nanoparticle fixation with indirect touch with the tip could already be visually observed. A 
setting with a tip-target distance larger than 15 mm did not result in any measurable ferrofluid 
agglomeration. The surface-adhered iron rate (RS) is defined as the ratio in percent between 
the iron content of adhered ferrofluids at the inner surface of the target tube after the magnetic 
field application of a certain time t and the total iron content in the circuit at t = 0. Differences 
between RS30 and RS15 values describing the influence of different application times of the 
magnetic field on the amount of ferrofluid accumulation were observed. RS15 values of 
experiments with a tip-target distance of 0 cm, with or without wire netting, ranged 
considerably below corresponding RS30 values. RS15 without wire netting averaged at 19.6 % 
± 2.8 % according to a total iron amount of 9.8 mg ± 1.4 mg, whereas under the influence of 
the wire netting RS15 averaged at 14.6 % ± 4.9 % according to a total iron amount of 7.3 mg ± 
2.5 mg. Increasing the tip-target distance to 15 mm showed an assimilation of corresponding 
RS15 and RS30 values. RS15 without wire netting averaged at 2.6 % ± 0.8 % according to a 
total iron amount of 1.3 mg ± 0.4 mg, whereas under the influence of the wire netting RS15 
averaged at 3.3 % ± 0.5 % according to a total iron amount of 1.6 mg ± 0.2 mg. The highest 
amount of ferrofluids at the surface of the target tube after 30 minutes was assessed with a tip-
target distance of 0 cm without the influence of the wire netting (Table 2). Thereby RS30 
averaged at 31.5 % ± 3.3 % according to a mean total iron amount of 15.8 mg ± 1.6 mg. The 
additional application of the wire netting at the same tip-target distance of 0 cm resulted in an 
average RS30 of 24.7 % ± 1.4 % and an iron content of 12.4 mg ± 0.7 mg. Increasing the tip-
target distance to 15 mm resulted in a decreased accumulation of ferrofluids at the inner 
surface of the target tube. RS30 in the presence of the wire netting averaged at 3.3 % ± 0.6 % 
according to a total iron amount of 1.7 mg ± 0.2 mg, whereas without the influence of a wire 
netting RS30 averaged at 2.4 % ± 1.6 % according to a total iron amount of 1.2 mg ± 0.8 mg.  
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Table 2 A/B. RS values/ absolute iron/ absolute gentamicin adhered on the target tube surface assessed A. 
without wire netting B. with wire netting. 
 
 
 
After magnetic field application, measured nanoparticle accumulations dispersed within 
several seconds and the ferrofluid concentration, represented by the iron content in the circuit, 
increased to the initial value (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tip-target distance
176.3 ± 122.0191.3 ± 58.32365.0 ± 245.41467.5 ± 210.2Absolute gentamicin [µg]
1175.0 ± 813.21275.0 ± 388.9 15766.7 ± 1635.89783.3 ± 1401.2Absolute iron [µg]
2.4 ± 1.62.6 ± 0.831.5 ± 3.319.6 ± 2.8RS [%]
15 mm15 mm 0 mm0 mm
30 min15 min30 min15 minMagnetic field application
time
A
Tip-target distance
247.5 ± 42.5243.8 ± 37.11852.5 ± 106.11095.0 ± 367.7Absolute gentamicin [µg]
1650.0 ± 282.81625.0 ± 247.5 12350.0 ± 707.17300.0 ± 2451.5Absolute iron [µg]
3.1 ± 0.63.3 ± 0.524.7 ± 1.4 14.6 ± 4.9RS [%]
15 mm15 mm 0 mm0 mm
30 min15 min30 min15 minMagnetic field application
time
B
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Figure 7. Change of the total iron content in µg over experimental time measured in the closed circuit 
using a tip-target distance 0 mm without wire netting. 
 
4 Discussion 
 
In the present work new antimicrobially equipped ultra-small superparamagnetic iron oxides 
were developed and studied. These particles usually consist of an iron oxide (Fe3O4) core 
surrounded by an organic shell consisting e.g. of dextrans, fatty acids or starch (11). The 
antibiotic gentamicin was ionically and covalently linked to the organic shell. The 
antimicrobial equipment of magnetic nanoparticles presents the possibility to accumulate high 
antibiotic concentrations on the surface of vascular grafts with the help of a magnetic drug 
targeting system.  
Magnetic drug targeting has been performed in several in vitro and in vivo studies. Inada et al. 
applied urokinase-magnetide complexes for in vitro investigation of localized fibrinolysis 
(16). Viroonchaptan et al. showed that it is possible to release incorporated calcein from 
thermosensitive magnetoliposomes by temperature increase above 40 °C (30). Mykhaylyk et 
al. reports the development and utilization of magnetic nanoparticles with high DNA binding 
capacity for high transfection efficiencies (23). Particularly in oncology, where the selective 
application of chemotherapeutics is an important column for a successful treatment, magnetic 
drug targeting systems moved into focus. Alexiou et al. demonstrated the in vitro 
accumulation of ferrofluids in the intracellular space of HeLa-cells by an external magnetic 
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field at room temperature (3). In the same study the treatment of VX2 tumor-bearing rabbits 
with mitoxantrone labelled magnetic nanoparticles revealed a higher chemotherapeutic 
concentration in the tumor region compared to systemic chemotherapy. The first clinical 
approach in human patients was performed with epirubicin-loaded ferrofluids for advanced 
and unsuccessfully pre-treated cancer or sarcoma (21). A successful accumulation of drug-
loaded ferrofluids in one half of the patients was assessed. These successful advances show 
that the combination of drug-loaded magnetisable nanoparticles and a magnetic drug targeting 
system is not just a futuristic vision, but becomes an established method to obtain high drug 
levels in a target area of the body.  
A major risk associated with implants like vascular grafts is the development of device-related 
infections (5, 10). The key events on the way to biomaterial infection are the adherence of 
pathogens and a subsequent biofilm formation as a consequence of a genetic switch and a 
change of the planctonic phenotype into the biofilm phenotype (26). This genetic switch leads 
to an increased host defence and antibiotic resistance which is the major barrier for a 
successful treatment. While post-operative infections can widely be avoided by anti-infective 
graft coatings, this time limited protection becomes less important in terms of infections 
caused years after surgical placement. An increase of the intravenous antibiotic application is 
also limited due to arising side-effects. The accumulation of high antibiotic concentrations in 
the area of infection on demand via a magnetic drug targeting system is therefore of high 
interest. 
In the present work, gentamicin-functionalized nanoparticles were developed and studied in 
vitro for drug release, biocompatibility and anti-infective characteristics. The coverage of a 
broad spectrum of pathogens and the application for implant infection therapy were crucial 
factors for the choice of gentamicin (27). Loading capacity and anti-infective experiments 
demonstrated that only Target-MAG-Genta and S13-Genta meet the demands for applicable 
anti-infective nanoparticles. Loading capacities at 6.6 % (m/m) for S13 and 15 % (m/m) for 
TargetMAG particles showed that a successful coating technology was performed resulting in 
highly equipped nanoparticles concerning the drug amount on the nanoparticle surfaces.  
The installation of a computer-aided model for a better understanding of the surface loading 
of nanoparticles with gentamicin was taken into consideration. However due to too many 
variables such as different gentamicin composition, individual conformations within one 
composition and various possible binding sites for one gentamicin molecule,this project was 
not pursued.  
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TargetMAG-Genta and S13-Genta demonstrated no drug release within 90 minutes, however 
high anti-infective characteristics were assessed. This phenomenon needs further prove as in 
previous works concerning magnetic drug targeting for tumor treatment, the release of 
chemotherapeutics from similar nanoparticles was the basic requirement for the effectiveness 
of developed particles. Alexiou et al. demonstrated a mitoxantrone release within 60 minutes 
(1) and based the effectiveness of developed particles on this drug release. We assume that a 
pH shifting of the bacterial growth medium Mueller-Hinton broth due to metabolic activity of 
bacteria from originally pH 7.3 ± 0.1 to a lower pH might result in a drug release, however 
this requires further investigation.  
In pathologically relevant bacterial concentrations, as demonstrated by Elek and Conen (12), 
TargetMAG-Genta and S13-Genta at a concentration of 1 mg/ml achieved a bacterial 
eradication rate of 100 %. This shows a highly effective potency against S. aureus growth. 
Even at a concentration hundredfolds beyond maximal pathologically relevant bacterial 
concentration, S. aureus growth could highly be reduced after 24 hours by TargetMAG-Genta 
and S13-Genta. Thereby TargetMAG-Genta showed a significantly higher growth inhibition 
effect than S13-Genta. TargetMAG, TargetMAG-Genta, S13 and S13-Genta, as well as in situ 
expected gentamicin concentrations, did not show cytotoxic potentials with regard to the 
metabolic activity of human umbilical vein endothelial cells. In circulatory experiments, the 
optimal parameters for a maximal iron accumulation, and therefore gentamicin 
concentrations, at the surface of the model tube were assessed. The magnetic field strength as 
well as the flow rate were held steady in consideration of the physiological blood flow at 150 
ml/min up to 200 ml/min in a vascular graft of 7 mm diameter. The application time of the 
external magnetic field, the distance between target tube and magnet tip, and the utilization of 
an additional wire netting surrounding the target tube are important parameters that should be 
taken into consideration. 
The application of an additional wire netting to distort the field gradient, which is meant to 
force nanoparticles to adsorb at the inner-surface of the PTFE graft, did not show the desired 
effects. A tip-target distance of 0 cm without a wire netting and 30 minutes field application 
represent the optimal choice of parameters resulting in an iron accumulation of 15767 µg ± 
1636 µg corresponding to 2365 µg ± 245 µg gentamicin at the surface of the model graft. For 
in vivo experiments the tip-target distance has to be increased as replaceable vessels are 
situated at about 2 cm to 7 cm distance from the body surface. As shown in our experiments, 
nanoparticle enrichment on the tube surface with the described system is strongly reduced 
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with an increasing tip-target distance. The application of a stronger magnetic field and the 
influence of a higher viscosity of blood on the particle enrichment at a PTFE surface are the 
objectives of future investigations.  
 
5 Conclusions 
 
In this study we could demonstrate the development and selective enrichment of antibiotic-
functionalized nanoparticles consisting of ultra-small superparamagnetic iron oxides 
surrounded by starch or palmitoyl-dextran with ionically bound gentamicin. Selected 
nanoparticles TargetMAG-Genta and S13-Genta completely inhibited the proliferation of S. 
aureus in pathologically relevant concentrations while preserving biocompatible 
characteristics. In in vitro circulatory experiments we further demonstrated that it is possible 
to accumulate high gentamicin concentrations on the surface of a model tube. If these results 
can be confirmed in vivo, developed magnetic drug targeting system could have be of high 
interest for the treatment of vascular graft infections. 
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7 Figure and Table Captions 
 
Figure 1. TargetMAG with ionically coupled gentamicin.  
 
Figure 2. Closed circuit built up as a model for bloodstream in a ratio of one to one hundred 
to physiological conditions (total volume 50 ml ferrofluid suspension).  
 
Figure 3A/B. Loading of magnetic nanoparticles with gentamicin: A. S13 particles and B. 
S26 particles. 
 
Figure 4. Staphylococcus aureus growth cultured in sterile Mueller-Hinton broth without 
adjuvant (pure bacteria), in presence of gentamicin coated nanoparticles (TargetMAG-Genta, 
FluidMAG-Genta, SiMAG-Genta), uncoated nanoparticles (TargetMAG, FluidMAG, 
SiMAG). 
 
Figure 5. Staphylococcus aureus growth cultured in sterile Mueller-Hinton broth without 
adjuvant (pure bacteria), in presence of gentamicin coated nanoparticles (TargetMAG-Genta), 
uncoated nanoparticles (TargetMAG). 
 
Figure 6A-C. Metabolic activity of HUVEC incubated with different concentrations of A. 
TargetMAG and TargetMAG-Genta, B. S13 and S13-Genta and C. different gentamicin 
concentrations. 
 
Figure 7. Change of the total iron content in µg over experimental time measured in the 
closed circuit.  
 
Table 1A/B. Overview of individual nanoparticle types used for ionic or covalent gentamicin 
coupling. 
 
Table 2A/B. RS values/ absolute iron/ absolute gentamicin adhered on the target tube surface 
assessed A. without wire netting, B. with wire netting. 
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Chapter 7 
 
Functional neurotoxicity of individual antibiotics investigated 
with mammalian neuronal networks grown on microelectrode 
neuroarrays  
 
Abstract 
Objectives: The prevention of infections in the central nervous system demonstrates a life 
essential requirement in neurosurgery. In many cases antibiotics are locally applied and 
mingle directly with neuronal brain cells. The present work investigates the functional 
neurotoxicity of individual antibiotics using neuronal networks on microelectrode 
neuroarrays.  
Methods: Penicillin G, streptomycin, penicillin/streptomycin, gentamicin and vancomycin 
were studied for functional neurotoxic effects. Compounds were added to mammalian frontal 
cortex networks cultivated on microelectrode neuroarray. Neuronal activity was recorded and 
suppression of action potential production regarding dose response curves and IC50 levels, the 
determination of different burst parameter and the drop out of individual cells were 
investigated and compared among each other. 
Results: A step-wise activity decrease under the influence of studied antibiotics was 
observed. The IC50 averaged between 37 µM for streptomycin and 2371 µM for gentamicin. 
The investigation of burst parameters focusing on burst frequency, burst period and spikes in 
bursts corroborate the different characters of used antibiotics regarding functional toxicity. 
The drop out of individual cells and the comparison between active neurons and bursting 
neurons under compound influence unsheathe a higher loss of bursting neurons than active 
neurons under IC50 concentrations of streptomycin and vancomycin. IC50 concentrations of 
pen/strep and gentamicin caused a higher level of bursting neurons compared to the level of 
active neurons. The application of penicillin G in IC50 concentrations led to a slight loss of 
bursting neurons while the number of active neurons slightly increased.  
Conclusions: The in vitro investigation of the impact of individual antibiotics on mammalian 
neuronal clusters cultured on microelectrode neuroarray provided useful data regarding the 
functional toxicity in particular the signal activity suppression, dose response and IC50 
concentrations.  
Keywords: Antibiotics, microelectrode neuroarray, neurosurgery, functional toxicity, frontal 
cortex 
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1 Introduction 
 
In neurosurgery, antibiotics are locally applied in order to prevent or treat infection. Kala and 
Houdek evaluated patients treated with and without an antibiotic for cerebral abscess and 
demonstrated a beneficial effect of local antibiotic administration for cerebral abscess 
treatment (11). Kharitonova et al. described the preclinical and clinical application of gelatin 
sponges with kanamycin and gentamicin as a reliable anti-infective protection in neurosurgery 
(12). Broggi et al. achieved a recovery from deep brain abscesses in four patients by 
stereotactic implantation of a chronic intracavitary catheter connected to a subcutaneous 
reservoir to allow local antibiotic irrigations (1). Klein et al. applied neomycinsulfate 
intracerebral, epidural or intramuscular during neurosurgical operations and observed an 
infection rate below 1 % (10). In consideration of all these prosperities, very little data of 
neuronal toxicity of antibiotics is described in the literature. Side effects give a possible hint 
for toxic reactions in neuronal cells caused by antibiotics reaching from paralysis from 
neuromuscular blockage caused by streptomycin to irreversible ototoxicity occuring in 
patients treated with gentamicin (9, 14). Further studies are important in order to optimize as 
well as standardize applied doses to ensure a safer use of these drugs and to identify their 
influence on neuronal behaviour. Different in vitro models like microfluid techniques can be 
used for such investigations (8), however whole functional neuronal ensembles provide more 
physiologically relevant information (2, 4). Electrical signal patterns of a cluster of neurons 
on multielectrode neurochips were first described by Gross et al. (7). Different improvements 
in this technique lead to a stable and reliable method with the possibility to study the effects 
of transmitters, receptors, specific compounds, or drugs (3, 5, 15). The aim of this study was 
to test different antibiotics for their influence, used either for cell culture or in brain trauma 
surgery, on the electrical activity measured from neuronal networks on microelectrode arrays.  
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2 Materials and Methods 
 
2.1 Compounds 
 
The antibiotics penicillin G (1663 units penicillin G base per mg, Sigma Aldrich, St. Louis, 
USA), streptomycin (Sigma Aldrich, St. Louis, USA), pen/strep (GIBCO Laboratories, NY, 
USA), gentamicin (Sigma Aldrich, St. Louis, USA) and vancomycin (Sigma Aldrich, St. 
Louis, USA) were studied. Stock solutions were prepared for penicillin G (6.68 mg/ml), 
streptomycin (0.5 mg/ml), pen/strep (10000 units penicillin G and 10 mg streptomycin per 
ml), gentamicin (4.7 mg/ml) and vancomycin (14.49 mg/ml). Solutions were filtered with a 
0.22 µm filter (Acrodisc® Syringe Filter, Pall Corporation, Ann Arbor, USA) under aseptic 
conditions and stored at 4 °C. Before compound application, solutions were brought to room 
temperature and a defined volume was added to the recording chamber with a pipette by 
lifting up the cap, adding the test solution in small droplets to the periphery of the medium in 
the chamber and mixing twice with a syringe through a Luer entry portal in the chamber.  
  
2.2 Microelectrode Arrays (MEAs) 
 
The MEAs were manufactured at the Center for Network Neuroscience (CNNS) at the 
University of North Texas. These are 50 · 50 x 1 mm glass plates with a 1 mm2 central 
recording matrix containing 64 passive electrodes of thin film indium tin oxide conductors. 
The basic glass plate consists of a soda lime glass base and two films, a coating of sputtered 
silicon dioxide with 90 % optical transmission and a thickness of 1200 Å and a 1400 Å thick 
conductive coating of sputtered indium tin oxide (ITO). The glass is cut into plates, cleaned 
and baked at 200 °C for drying. Subsequently the ITO surface is coated with a thin layer of 
photoresist, which is softly baked (95 °C) to drive off excess solvent. In order to cover the 
areas that will later be electrodes, a clean chrome photo mask is fixed to the photoresist 
coated plate. Thereafter the plate is briefly exposed to UV light, which modifies the exposed 
photoresist in a way that it can be dissolved with solvents. Photoresist areas under the masked 
regions are protected against UV light and therefore stay intact during the following 
development and etching steps. After UV exposure, glass plates are developed in 0.8 % KOH 
solution, which leads to a removal of the UV light exposed photoresist revealing the ITO 
underneath. In order to increase the adhesion of the remaining photoresist, plates are “hard” 
baked (115 °C). Subsequently the plates are submerged in an acid etching solution comprised 
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of HCl, HNO3 and H2O, which etches the exposed ITO metal, but does not affect the ITO 
under the photoresist. Each plate is now cut into four individual MMEPs for further 
processing (6). 
The edges of each MMEP need to be sanded to fit in the CNNS base plate with 0.5 mm total 
play at the top and bottom. Furthermore any ITO tool marks have to be sanded off to avoid a 
possible electrode coupling upon zebra strip attachment. Before the cleaning step, the MMEPs 
need to be checked for electrode coupling. If coupling occurs, electrodes have to be separated 
using a diamond- tipped engraver or a laser. The MMEPs are then first soaked in 100 % EtOH 
for three hours before being scrubbed in a 10 % Contrad solution with a camelhair brush. 
Subsequently, MMEPs are boiled for 30 minutes in a 10 % H2O2 solution, rinsed with ultra 
pure water and 100 % EtOH, finally stored in.  
The following step in fabrication contains insulation and curing. Therefore part of the 
polysiloxane stock insulation must be evaporated at room temperature for 8 hours until a final 
volume of 50 % of the stock is obtained. The edge electrodes for the zebra strip contacts are 
now taped before the MMEPs are placed on the spinner which is started at a speed of 1500 – 
2500 rotations per minute and approximately 2 ml of polysiloxane solution are applied on the 
center of the MMEP. The  spinner is stopped thirty  seconds later and MMEPs are cured at 
150 °C for 8 minutes. For deinsulation, the electrode sites in the recording matrix are 
deinsulated separately with a near UV laser. After that, all 64 deinsulated electrodes are 
electroplated simultaneously with a citrate potassium gold cynide (CPGC) solution, MMEPs 
are assembled on a non-conducting base plate with zebra conductors and a conducting top 
plate connected to a pulse generator. A gold wire anode is placed in the GPGC electroplating 
solution (3.1 g Au2+/l) which saturates the 64 ITO cathodes. The pulse generator supplies the 
system with 1200 mV at 1.0 µA for two minutes.  
 
2.3 Cell culture 
 
MMEPs were prepared for cell seeding by autoclaving for 25 minutes at 121 °C and exposing 
the hydrophobic polysiloxane insulation material to a butane flame to create a hydrophilic 
surface. After flaming, MMEPs are fitted with greased silicone gaskets and 50 µl of a sterile 5 
mg/l poly-L-lysine solution (PLL, Sigma Aldrich, St. Louis, USA) is applied to the flamed 
matrices of each MMEP for 24 hours in an incubator under 10 % CO2 and 95 % relative 
humidity. The PDL is then rinsed with ultra-pure water and removed with a sterile pipette. 
  143143
Functional neurotoxicity of individual antibiotics 
_________________________________________________________________________________________________________________ 
Each MMEP is transferred to a Petri dish and each matrix is incubated with 60 µl of a 2 µg/ml 
laminin solution for 45 minutes. 
Frontal cortex tissue is harvested from one time-pregnant ICR mouse (Harlan Sprague 
Dawley, Inc.) at embryonic day sixteen. After anesthesia with chloroform and sacrifice via 
cervical dislocation, the uterus is removed under sterile conditions. The obtained embryos in a 
usual quantity of twelve to fourteen are immediately immersed for further dissection in an 
anaesthetic bath of D1SGH at a pH of 7.35 and an osmolarity of 320 miliosmoles at 4 °C. 
With the aid of a pair of fine-tipped forceps and a stereoscopic microscope, embryos are 
decapitated and the skull revealed by removing skin and muscle tissue. The skull is carefully 
removed from the dorsal side working rostrally to caudally. The intact brain is then lifted 
from the skull cavity. In order to reveal the cerebral cortex, the meninges are removed from 
each brain and the frontal lobe is dissected in a trapezoidal pattern. After isolating the frontal 
cortex from each embryonic brain, it is stored in a separate bath of D1SGH. After aspirating 
the DSGH from the Petri dish, the frontal cortex tissue is minced with two sterile scalpel 
blades and enzymatically dissociated with the addition of 3 ml of 1:14 papain:DSGH solution. 
After 5 minutes incubation at 37 °C and 5 minutes at 22 °C, papain is removed via 
centrifugation with 50 µl DNAse I in 5 ml DMEM5/5 at 900 rpm for four minutes. By adding 
DNAse I, cell clumping during seeding induced by free DNA, released by proteolytic activity 
of papain is avoided (Huettner & Baughman, 1986). The supernatant is removed and the cell 
pellet is suspended in 50 µL DNAse I in 5 ml DMEM5/5 solution. With the help of a 
cytometer, the cell density is adjusted to 100000 cells/ml and cells are seeded onto the 
recording matrix area of each MMEP. Thereafter laminin is removed from the recording 
matrix area with a fine-bore plastic pipette and 100 µL cell suspension is seeded onto each 
matrix. After 2 hours of incubation at 38 °C, cell adhesion is evaluated and cells are fed with 
1 ml of DMEM 5/5. A full medium change is performed after 24 hours with DMEM 5/5 in 
order to remove any DNAse and non-adhered cells respectively cell debris. To eliminate 
remaining fetal bovine serum from the medium, a full medium change with DMEM 5 is 
performed three days later. Onto the matrix of each MMEP, a monolayer neuronal network 
atop a confluent glial carpet layer develops. Cell cultures could be maintained in an incubator 
at 37 °C under 10 % CO2 and 95 % relative humidity for up to six months without addition of 
antibiotics or fungicides by bi-weekly half medium changes into DMEM 5. Cultures are ready 
for use usually three weeks to three months after seeding. 
 
  144144
Functional neurotoxicity of individual antibiotics 
_________________________________________________________________________________________________________________ 
Networks developed from a mixture of different types of postmitotic neurons and glia cells. 
The glia cells have the important auxiliary function for metabolism and to supply neurons 
with ions and nutrients. They also influence synaptogenesis. By culturing neurons in 
combination with glia cells, stability over many months is ensured. After approximately two 
days in vitro spontaneous electrical activity develops (3). Random spiking at first stabilized 
after two weeks in culture into more coordinated activity. This activity is composed of 
coordinated main burst patterns and interburst spiking. These networks showed a high 
interculture repeatability (5) and remained spontaneously active and pharmacologically 
responsive for more than six months. For this study cultures between 25 and 40 days in vitro 
were used. 
 
Figure 1. Preparation procedure of the neuronal cell cultures (CNNS archives). 
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2.4 Experimental Setup 
 
2.4.1 Recording station 
 
The signal amplifier systems at the CNNS are manufactured by Plexon Inc., Dallas, USA. The 
experimental setup consists of different parts described in the following. The edge connectors 
at either side of the MEA plate contact the matched preamplifier circuit board via flexible 
zebra strips. Thereby original signals of 50 – 800 µV are amplified by a gain of 100. Any 
frequency components lower than 100 Hz and higher than 8000 Hz are filtered out. From the 
preamplifiers, signals are transferred to the MAP-box (Multichannel Acquisition Processor) 
and become amplified again (10x – 100x) and A/D converted. The DSP board contains four 
(32-channel board) digital signal processors. Each DSP receives eight channels of A/D 
converted data from a signal board. On each channel, up to four action potential waveforms 
can be discriminated in real time. From the DSP board, the signals are first transferred to a 
GPIB or MXI bus board and further to a workstation, where data analysing is performed. For 
a better differentiation between noise and real activity signals, two oscilloscopes (HM 407, 
HAMEG Instruments GmbH, Mainhausen, Germany) are attached to the MAP box showing 
the analog signal of the current channel and the signal of the last DSP selected in the 
Sortclient software (Plexon, Inc, Dallas, TX USA). For further control, selected analog 
signals are transferred to a loudspeaker array (CNNS, Denton, USA) of up to sixteen 
speakers, making selected signals audible.  
 
2.4.2 Chamber Setup 
 
A MMEP with a greased gasket and DMEM 5 for cell life supply was placed under aseptic 
conditions onto a base plate with a rubber separator as a spacer between glass and steel 
(Figure 2B). Part of the cell medium was removed with a syringe leaving behind a thin film of 
medium covering the matrix, the gasket was removed with forceps and a stainless steel 
chamber was fixed with set screws at the base plate in a way that the cell matrix was kept in 
the middle of the chamber. Removed cell medium was given into the chamber through a 
chamber entry portal and a cap (Figure 2B) was fixed on top of the chamber to create an 
enclosed system and connected to the chamber by a wire. The cell chamber was deposited on 
a microscope stage, connected to the preamplifiers of the recording station and grounded 
Figure 3C). During experiment, osmolarity in the chamber was maintained constant at about 
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320 milliosmoles by adding ultra-pure water via a pump system (Pump 11, Harvard 
apparatus, Holliston, USA) through an entry portal in the chamber and controlling it with an 
osmometer ( 5500 vapor pressure osmometer, Wescor, Inc., Logan USA). In order to maintain 
the pH at 7.4, the  chamber was  supplied by a constant  flow of a mixture of 10 % CO2 and 
90 % air (AFC 2600 Pro, Mass Flow Controller, Aalborg Instruments, USA) at 5–10 ml⁄min 
through a side entry portal in the cap that sat on top of the chamber. In order to maintain a 
constant temperature at 37 °C inside the cell chamber, two heating systems were used. A 
constant 12 V voltage source (Micronta Radio shack, Forth) was connected to four 3 Ώ power 
resistors attached to the microscope stage (Axiovert 100, Zeiss, Göttingen, Germany) to heat 
up the plate to approximately 30 °C. The base plate contained a second set of power resistors. 
Temperature was controlled by a regulated heater (CN 9000 A, Omega Engineering, Inc., 
Stamford, USA) which was connected to the base plate (see Figure 2) and assured a stable 
temperature of 37 °C ± 1 °C. 
 
B C
A
 
Figure 2. Experimental setup to study neuronal networks on microelectrode arrays: A) Segment of a 
frontal cortex network grown on an array for 21 days in vitro. B) Chamber setup: A MMEP with DMEM 
5 for cell life supply is placed under aseptic conditions onto a base plate with a rubber cushion between 
glass and metal. C) Recording station. The edge connectors of the MMEPs are in contact with zebra 
strips, which make contact to the preamplifiers (CNNS archives).  
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2.4.3 Data recording  
 
Recording was performed with a computer-controlled 64-channel amplifier system from 
Plexon, Inc., Dallas, USA, the so-called Multichannel Acquisition Processor System. This 
system provides programmable amplification, filtering, switching, and digital signal 
processing of multielectrode signals. A template-matching algorithm in real time provided 
spike identification and separation and delivered single neuron spike data online. For 
recording neuronal activity, the programs Sortclient (Plexon, Inc., Dallas, USA) and Vernac 
(CNNS, Denton, USA) were used. Vernac averages all sorted time stamps from the Sort client 
and plots minute mean values of the total spike and burst production in real time. It allows the 
user to get an overview of the previous and current conditions of the cell culture and the 
impact of compounds added. Data for further analysis is provided by the program Sortclient 
which records time stamps and waveforms of the selected units and provides values of 
different parameters describing the activity of identified action potentials (Figure 3). 
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Figure 3. Summary of data acquisition and display: A) MEA showing 32 edge connectors on either side of 
the 5x5 cm glass plate. B) Central recording area with 64 microelectrodes. The network seeding area (red 
circle) is generally larger than the 1 mm2 recording matrix. C) Computer display of electrode matrix 
geometry, showing assignment of DSPs to specific channels (yellow boxes) and assignment of speaker 
outputs (blue boxes). D) Selected channel display showing three action potentials recorded and separation 
via template matching. E. Raster plot of time stamps generated when discriminated action potentials cross 
threshold (40 s window). All discriminated action potentials (32 DSP system) are also shown to the right of 
the raster display. 
 
2.4.4 Data analysis 
 
Eight parameters were selected to describe the changes in activity in response to successively 
increasing concentrations of antibiotics. Most represent mean values from averaging all 
channels per minute (usually called “Minute Means”). In some cases “Total Activity” is 
plotted to eliminate artifactual increases at very low channel counts. All data was extracted 
from the Plexon time stamp files. The parameters are: (1) the spike and burst activity, (2) 
burst duration, (3) burst period (time between beginning on one burst to the beginning of the 
next burst), (4) the burst amplitude (integrated burst value representing maximum spike 
frequencies in a burst), (5) the number of spikes in a burst, (6) the mean spike frequency in a 
burst, (7) the number of bursting neurons. No universally accepted mathematical definitions 
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of bursts exist (16). Bursts were identified operationally by digital RC integration with rise 
time constants of 100-150 ms. A lower threshold was set to determine the start and stop times 
for the burst and a higher threshold served to confirm that the integrated profile was above the 
noise level (Figure 4). A gap rule of 100 ms devoid of spikes was used to separate burst 
events into two bursts (13). T1 and T2 were set by inspection during off line data analysis 
with the intent to capture major bursts and ignore singlets or doublets. Raster displays 
showing spiking and bursting were viewed with the Neuroexplorer program (NEX 
Technologies) and thresholds were set to mimic the burst count in initial segments of the 
native activity. If thresholds are not changed during one experiment, such an operational 
definition allows quantitative comparisons of burst patterns within the same culture. 
 
Figure 4. Time stamp sequence of a discriminated unit and 
mathematically simulated RC integration. Threshold 1 (T1) 
identifies start and stop times of bursts, whereas T2 is set to 
select only major bursts and eliminate noise. 
For further statistical analysis activity was measured in bins of 
60 seconds. That way minute mean values for action potential 
production and the significant burst parameters were 
calculated. 
 
T2
T1
F
BA (Burst Amplitude) 
 
2.4.5 Dose Response curves 
 
Changes in burst levels and spike levels were specific for each compound. Spike activity was 
plotted as a function of the log of test substance concentration and fitted with a sigmoidal 
function. Curve fitting, calculation of IC50 and fitting quality values were performed using 
Origin 6.0 software. IC50 values represent the concentration required for a 50 % inhibition of 
spike activity.  
 
2.5 Experimental design 
 
The aim of this study was to investigate the effect of different antibiotics on the spontaneous 
electrical activity of neuronal networks. Experiments were carried out as acute application of 
test substances to the 2 ml constant volume culture medium. The initial spontaneous activity 
of each network or a subsequent time period under bicuculline served as reference (baseline 
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activity) and was recorded at the beginning of each experiment for at least 30 minutes. This 
baseline activity was used as an absolute reference and all activity changes were determined 
as a percent change from this activity. Consequently, networks need to attain a stable 
reference state that was determined by a horizontal minute mean display in the VerNac 
window. A minute mean fluctuation of ± 10 % was preferred, although not always attained. 
Larger fluctuations were accepted as long as the minute-by-minute activity trace remained 
horizontal. For stabilization and activity increase 40 uM bicuculline was added to cultures. 
When such spike activity displayed by Vernac 0.6 was stable in time, compounds were 
applied in increasing concentrations approximately every 30 min. After each compound 
application, the network was allowed to seek a new stable state with relatively horizontal 
activity plateaus. Within each experiment, these stable activity plateaus were used for data 
analysis. The data set consisted of: For streptomycin and vancomycin three experiments and 
for pen/strep and gentamicin two experiments each were used for data analysis. For penicillin, 
three experiments under bicuculline and one experiment without bicuculline were performed 
and analysed.  
 
3 Results 
 
3.1 Suppression of action potential production  
 
3.1.1  Dose-response curves 
 
A step-wise decrease in action potentials (spikes) and bursts after compound addition was 
detected with each of the applied antibiotics. Figure 5 demonstrates the progression of minute 
mean spike and burst values of a neuronal network under increasing penicillin G/streptomycin 
(pen/strep) concentrations. Spike and burst rates showed an overall decrease in activity with 
increasing pen/strep concentrations. At the beginning of the experiment not under the 
influence of pen/strep, the mean activity was 52 spikes/min (S/min), the burst rate/min 
(B/min) was 2. By adding bicuculline, the mean activity was stabilized and raised to 80 S/min 
and 9 B/min, respectively (Figure 5). Adding pen/strep in nine concentration steps of 90 µM/ 
85 µM resulted in a decline of activity to a level of 10 S/min and 0 B/min at a final 
concentration of 2415 µM/ 2320 µM pen/strep. A full medium change recovered the activity 
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of the neuronal network to 70 S/min and 2 B/min, respectively in the recorded window. From 
the high recovery and activity slope at 420 min, the pen/strep influence was considered 
reversible.  
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Figure 5. Step-wise decrease of spike rates and burst rates (n= 69 units) under increasing pen/strep 
concentrations with reversibility after medium change. Volume of pen/strep solutions added to a total 
bath volume of 2000 µl ranged from 20 µl to 100 µl. 
3.1.2 IC50 Determination 
 
Dose Response curves were developed resulting in different IC50 values for each test 
compound (Table 1). The IC50 for streptomycin (Figure 6) averaged 37 µM ± 16 µM (n=4) 
and for pen/strep (Figure 7) 775 µM (n=2). Gentamicin (Figure 8) showed two differing IC50 
values of 2371 µM (n=2). The IC50 value of vancomycin (Figure 9) averaged 1322 µM ± 75 
µM (n=3). In one experiment under vancomycin, an IC50 value of 2519 µM was assessed, 
however this experiment was regarded as unreliable. Under penicillin, cultures did not show a 
significant activity pattern change, and dose response curves could not be generated (Figure 
10A - D). However in an internal control without bicuculline, an activity decrease caused by 
penicillin G was observed with an IC50 value of 1205 µM (Figure 10D). For further analysis 
of burst parameters this IC50 value is used.  
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Table 1. IC50 values of individual antibiotics.
Antibiotic IC50 Values [µM]
Streptomycin(n=3) 37 ± 16 
Pen/Strep (n=2) 775 
Gentamicin (n=2) 2371
Vancomycin (n=3) 1322 ± 75 
Penicillin (n=1, without bicuculline) 1205 
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Figure 6A – 6D. Dose response curves of streptomycin generated in four individual experiments.
IC50 values are: A) 40 µM, B) 32 µM, C) 18 µM, D) 57 µM.
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Figure 7 A/B. Dose response curves of pen/strep generated in two individual experiments.  
IC50 values are: A) 1065 µM, B) 484 µM. 
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Figure 8 A/B. Dose response curves of gentamicin generated in two individual experiments.  
IC50 values are: A) 4007 µM, B) 734 µM. 
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Figure 9A – 9D. Dose response curves of vancomycin generated in four individual experiments.  
IC50 values are: A) 1236 µM, B) 1354 µM, C) 1375 µM, D) 2519 µM.  
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Figure 10A – 10D. Concentration/activity change dependence under penicillin G in four individual 
experiments: 10A) – 10C) under bicuculline, 10D) without bicuculline. 
IC50 value are: 10A) – 10C) no curve fitting, 10D) 1205 µM. 
 
3.2 Burst Parameter 
 
The influence of the five antibiotics on burst rate, burst period and number of spikes in bursts 
was quantified according to the following procedure. The values of the respective burst 
parameters at IC50 concentration of each compound were divided by the values under native 
conditions and multiplied by 100 to obtain the percentage of change value (Table 2). The 
application of IC50 concentrations to frontal cortex networks led to a slight increase of burst 
rate level under pen/strep to 103 % and under penicillin G to 101 %. A burst rate level 
decrease was observed under streptomycin to 86 % and gentamicin to 71 %. The application 
of vancomycin at IC50 concentrations showed no change in burst rate values. Burst period 
levels showed an increase under the five tested compounds The application of pen/strep raised 
the burst period level to 115 % while the application of gentamicin led to an average burst 
period level of 126 %. Streptomycin, penicillin G and vancomycin increased burst period 
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levels to 153 %, 160 % and 185 %, respectively. No change of spikes in burst level was 
detected under vancomycin while penicillin G and gentamicin decreased the spikes in burst 
level to 98 % and 70 % respectively. The application of streptomycin and pen/strep led to an 
increase of spikes in burst level to 104 % under streptomycin and 120 % under pen/strep. 
 
Table 2. Levels of burst rate, burst period and spikes in burst of individual antibiotics defined as the ratio 
in percent under spike IC50 concentrations and values under native DMEM 5 medium and bicuculline.  
 
Antibiotic Burst Rate Level 
 [%] 
Burst Period Level 
 [%] 
Spikes in Burst Level 
[%] 
Penicillin G (n=3) 101 ± 2 160 ± 41 98 ± 4 
Streptomycin (n=3) 86 ± 24  153 ± 53 104 ± 47 
Pen/Strep (n=2) 103 (76/129) 115 (168/62) 120 (104/136) 
Gentamicin (n=2) 71 (45/97) 126 (118/135) 70 (25/114) 
Vancomycin (n=3) 100 ± 4  185 ± 55 100 ± 5 
 
Figure 11 shows a typical development of spikes in burst rate under pen/strep. Values 
averaged under reference conditions at 160 Hz and increased after the addition of bicuculline 
to a level of 280 Hz. The step-wise addition of the compound pen/strep resulted in a decline 
of frequency to an average of 175 Hz under the influence of 626.5 µM/ 602 µM pen/strep. 
Higher drug concentrations caused an irregular frequency pattern which was stabilized at 90 
Hz after full medium change.  
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Figure 11. The change of mean spike frequencies in bursts values under the influence of pen/strep 
followed by a media change. 
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3.3 Drop out of individual cells 
 
3.3.1  Bursting neurons 
 
The application of individual antibiotics affected the amount of bursting and active neurons in 
frontal cortex neuronal networks. Table 3 shows the level of bursting neurons and active 
neurons defined as the ratio in percent of the measured values under IC50 concentrations and 
the reference values under native DMEM 5 medium. While penicillin G, vancomycin and 
streptomycin in IC50 concentrations caused a decrease in the number of bursting neurons 
ranging from 98 % for penicillin G to 73 % under streptomycin, gentamicin and pen/strep led 
to an increase in the number of bursting neurons to 106 % and 125 %, respectively. 
 
Table 3. Levels of bursting neurons and active neurons of individual antibiotics defined as the ratio in 
percent of bursting neuron or active neuron values under IC50 concentrations and values under native 
DMEM 5 medium and bicuculline. 
 
Antibiotic Level of bursting neurons [%] Level of active neurons [%] 
Penicillin G (n=3) 98 ± 6 102 ± 2 
Streptomycin (n=3) 73 ± 4 89 ± 7 
Pen/Strep (n=2) 125 (68/182) 104 (81/126) 
Gentamicin (n=2) 106 (112/100) 100 (103/98) 
Vancomycin (n=3) 87 ± 9 96 ± 7 
 
3.3.2 Active neurons 
 
A different tendency was observed investigating the number of active neurons. The level of 
active neurons defined as the ratio in percent of the measured values under IC50 
concentrations and the reference values under native DMEM 5 medium is demonstrated in 
Table 3. The application of gentamicin IC50 concentrations did not change the level of active 
neurons while streptomycin and vancomycin lead to a decrease in the number of active 
neurons to 89 % under streptomycin and 96 % under vancomycin. Penicillin G and pen/strep 
in IC50 concentrations led to a slight increase in the level of active neurons to 102 % under 
penicillin and 104 % under pen/strep. 
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3.3.3 Active neurons versus bursting neurons  
 
A typical recording of the amount of bursting neurons and active neurons per minute is shown 
in Figure 12. After a medium change with DMEM 5, bicuculline was added to stabilize 
activity pattern in the culture. A continuous addition of streptomycin lead to a decrease of 
active and bursting neurons resulting in a nearly complete loss of burst activity at 77 µM 
streptomycin. Although burst had ceased, uncoordinated spike activity remained. After a 
medium change with DMEM 5 a recover of both parameters to a stable reference level was 
observed.  
 
Bursting Neurons
 
Figure 12. Number of active neurons versus bursting neurons per minute (n=50) under the influence of 
different streptomycin concentrations in [µM] and intermittent media changes. Volume of streptomycin 
solutions added ranged from 20 µl to 100 µl to a total bath volume of 2000 µl. 
 
A comparison between the level of active neurons and the level of bursting neurons after 
addition of an antibiotic provided information about the grade of functional toxicity of applied 
compound. The application of streptomycin and vancomycin in IC50 concentrations showed a 
higher loss of bursting neurons than active neurons. IC50 concentrations of pen/strep and 
gentamicin caused a higher level of bursting neurons compared to the level of active neurons. 
The application of penicillin G in IC50 concentrations led to a slight loss of bursting neurons 
while the number of active neurons slightly increased (Table 3). 
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4 Discussion 
 
The utilization of mammalian neuronal networks on microelectrode arrays is an emerging 
method to screen new compounds, investigate their impact on neuronal networks and define 
therapeutic windows in vitro, as a first step for further animal studies. An optimization and 
standardization of applied doses ensures a safer use of these drugs. 
The screening of well-established compounds like antibiotics seems to be unessential at first 
glance as they are already widely applied in neurosurgery. Thereby the intravenous or local 
administration of antibiotics is part of the prophylactic, peri-operative and post-operative 
therapy. However a differentiation between cytotoxicity and functional toxicity has to be 
drawn. Neuronal networks only operate effectively when the inter-cellular transmittance of 
electrical signals is assured. Action potentials are generated in the axon hillock forwarded to 
the synaptic gap where released neurotransmitter result in a depolarization or 
hyperpolarization potential in the dendrite of the target cell. This simplified description is the 
basic mechanism for signal transmittance between neurons within a neuronal network and is 
the foundation for the maintenance of body functions. Cytotoxicity of drugs implicates the 
damage of cells and can be measured by, for instance, the MTT, WST or NRU-Test. 
Experiments with mammalian neuronal networks on microelectrode arrays have clearly 
shown that while the cytotoxic concentration of applied compounds is not yet reached, there 
is a concentration range where neurons loose their ability to generate action potentials and to 
transmit information within the network. This loss of neuronal functionality is a grey area 
which needs to be further investigated as the local application of antibiotics in neurosurgery is 
a common practice following therapeutic doses which are not neurotoxic yet, but might bear 
the risk of functional toxicity.  
In the present work the antibiotics penicillin G, pen/strep, streptomycin, gentamicin and 
vancomycin were studied for functional toxicity on mammalian neurons being part of a 
neuronal network. These neuronal ensembles cultured on microelectrode arrays reflect more 
relevant physiological information than conventional in vitro pharmacological models. 
Studied antibiotics showed conformity in suppressing the action potential production during 
concentration increase observed by a step-wise decrease in spikes and bursts after compound 
addition. Obtained dose response curves corroborate this observation, demonstrating a 
decrease of percent mean spike activity under rising compound concentrations. Identified IC50 
values demonstrated that a differentiation of applied antibiotics in terms of dose response has 
to be drawn. While the IC50 is already reached at 37 µM under streptomycin, gentamicin is 
well tolerated in terms of neuronal activity showing an IC50 value of 2371 µM. The average 
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IC50 value of the combination of penicillin and streptomycin at 775 µM corroborates the IC50 
value identification of the two separate studied compounds as penicillin G shows an IC50 
value at 1205 µM. The expectation of an IC50 value in the middle of those of streptomycin and 
penicillin was fulfilled. Vancomycin showed an average IC50 value similar to penicillin G at 
1322 µM. 
The impact of individual antibiotics on the burst parameters of cultures in particular the 
change of burst rate, burst period and spikes in burst under IC50 concentrations compared to 
untreated cultures showed a complex pattern. An overall tendency of burst period increase 
and spikes in burst increase apart from gentamicin and penicillin G was observed whereas the 
burst rate apart from investigations under streptomycin and gentamicin maintained quite 
stable.  
The gap between levels of active neurons and levels of bursting neurons is an important 
consideration when studying the functional toxicity of compounds. The number of neurons 
being active does not automatically give information about the condition of these neurons in 
regard to their functionality. The addition of compounds can rather lead to the loss of 
functionality in regard to information transmittance while conserving life functions. Common 
life/death assays do not provide information about this phenomenon. Concentrations 
considered to be non toxic may turn out to be suppressive against information transmittance 
within the neuronal network and therefore knock out important downstream body functions.  
While streptomycin and vancomycin showed a higher gap under IC50 concentrations between 
the level of bursting neurons maintained and the level of active neurons maintained, pen/strep 
and gentamicin demonstrated the opposite effect. By contrast penicillin G showed no explicit 
impact on the relation between the level of bursting neurons and the level of active neurons. 
Referred to individual IC50 values, streptomycin and vancomycin showed the highest 
functional toxicity followed by penicillin G, gentamicin and pen/strep. 
 
5 Conclusions 
 
In this study we demonstrated an approach to in vitro characterize individual antibiotics for 
functional neurotoxicity. The utilization of mammalian neuronal networks on microelectrode 
arrays was therefore a good method for the investigation of compounds close to physiological 
conditions. New data on dose response, IC50 concentrations and the impact on the neuronal 
activity pattern could be obtained for an advanced understanding of how antibiotics influence 
the information transmittance in neuronal ensembles. This in vitro microelectrode recording 
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system  could  be  used  for  the  investigation  of  the  impact  of  analgesics,  anaesthetic  and 
narcotics on neuronal clusters, which is an interesting subject for future studies.
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7 Appendix 
7.1 Activity pattern of antibiotics 
7.1.1 Penicillin G 
Figure 13. Change of spike rates and burst rates (n=68 units) under increasing penicillin G 
concentrations. Volume of penicillin G solutions added averaged for each step at 40 µl to a total bath 
volume of 2000 µl.  
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Figure 14A – 14F. Change of burst parameters: A) burst amplitude, B) burst duration, C) bursting 
neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of penicillin G (n=68 
units). Volume of penicillin G solutions added averaged for each step at 40 µl to a total bath volume of 
2000 µl. All variables are mean values derived from averaging all burst measurement per minute across 
all units. 
 
1^= refererence, 2^= bicuculline, 3^= 400 µM penicillin G, 4^= 800 µM penicillin G, 5^= 1200 µM 
penicillin G, 6^= 1600 µM penicillin G, 7^= 2000 µM penicillin G, 8^= 2400 µM penicillin G, 9^= 2800 µM 
penicllin G, 10^= 3200 µM penicillin G, 11^= 3600 µM penicillin G 
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7.1.2 Penicillin G/Streptomycin 
 
 
Figure 15. Step-wise decrease of spike rates and burst rates (n=69 units) under increasing pen/strep 
concentrations with reversibility after medium change. Volume of pen/strep solutions added ranged from 
20 µl to 100 µl to a total bath volume of 2000 µl.  
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Figure 16A – 16F. Change of burst parameters: A) burst amplitude, B) burst duration, C) bursting 
neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of pen/strep (n=69 units) 
followed by a medium change. Volume of pen/strep solutions added ranged from 20 µl to 100 µl to a total 
bath volume of 2000 µl. All variables are mean values derived from averaging all burst measurement per 
minute across all units. 
 
1^= 90 µM pen G/ 85 µM strep, 2^= 180 µM pen G/ 170 µM strep, 3^= 270 µM pen G/ 260 µM strep, 4^= 
360 µM pen G/ 345 µM strep, 5^= 450 µM pen G/ 430 µM strep, 6^= 540 µM pen G/ 515 µM strep, 7^= 
625 µM pen G/ 600 µM strep, 8^= 1520 µM pen G/ 1460 µM strep, 9^= 2415 µM pen G/ 2320 µM strep 
 
7.1.3 Streptomycin 
 
Figure 17. Change of spike rates and burst rates (n=16 units) under increasing streptomycin 
concentrations with reversibility after medium change. Volume of streptomycin solutions added ranged 
from 20 µl to 100 µl to a total bath volume of 2000 µl. 
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Figure 18A – 18F. Change of burst parameters: A) burst amplitude, B) burst duration, C) bursting 
neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of streptomycin (n=16 
units) followed by a medium change. Volume of streptomycin solutions added ranged from 20 µl to 100 µl 
to a total bath volume of 2000 µl. All variables are mean values derived from averaging all burst 
measurement per minute across all units. 
 
1^=reference under bicuculline, 2^= 43 µM streptomycin, 3^= 86 µM streptomycin, 4^= medium change, 
5^= bicuculline, 6^= 8.6 µM streptomycin, 7^= 17.2 µM streptomycin, 8^= 25.8 µM streptomycin, 9^= 
34.4 µM streptomycin, 10^= medium change, 11^= bicuculline 
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7.1.4 Gentamicin 
 
 
Figure 19. Change of spike rates and burst rates (n=27 units) under increasing gentamicin concentrations 
with reversibility after medium change. Volume of gentamicin solutions added ranged from 20 µl to 40 µl 
to a total bath volume of 2000 µl. 
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Figure 20A – 20F. Change of burst parameters: A) burst amplitude, B) burst duration, C) bursting 
neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of pen/strep (n=27 units) 
followed by a medium change. Volume of gentamicin solutions added ranged from 20 µl to 40 µl to a total 
bath volume of 2000 µl. All variables are mean values derived from averaging all burst measurement per 
minute across all units. 
 
1^= reference under bicuculline, 2^= 200 µM gentamicin, 3^= 400 µM gentamicin, 4^= 600 µM 
gentamicin, 5^= 800 µM gentamicin, 6^= 1000 µM gentamicin, 7^= 1200 µM gentamicin, 8^= medium 
change, 9^=1000 µM gentamicin, 10^= 2000 µM gentamicin, 11^= medium change 
 
7.1.5 Vancomycin 
 
 
Figure 21. Change of spike rates and burst rates (n=23 units) under increasing vancomycin concentrations 
followed by a medium change. Volume of vancomycin solutions added averaged at 60 µl to a total bath 
volume of 2000 µl. 
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Figure 22A – 22F. Change of burst parameters: A) burst amplitude, B) burst duration, C) bursting 
neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of vancomycin (n=23 
units) followed by a medium change. Volume of vancomycin solutions added averaged at 60 µl to a total 
bath volume of 2000 µl. All variables are mean values derived from averaging all burst measurement per 
minute across all units. 
 
1^= 300 µM vancomycin, 2^= 600 µM Strep, 3^= 900 µM vancomycin, 4^= 1200 µM vancomycin, 5^= 
1500 µM vancomycin, 6^= 1800 µM vancomycin, 7^= 2100 µM vancomycin, 8^= 2400 µM vancomycin, 
9^= 2700 µM vancomycin, 10^= 3000 µM vancomycin, 11^= 3300 vancomycin, 12^= medium change 
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8 Figure and Table Captions 
 
Figure 1. Preparation procedure of the neuronal cell cultures 
 
Figure 2. Experimental setup to study neuronal networks on multielectrode neurochips. 
 
Figure 3. Activity pattern change of frontal cortex network. Each action potential is 
represented by a vertical tick.  Several neurons can be recorded by one electrode and 
separated online by a software. Action potentials generated by a 64 electrode recording matrix 
21 days in vitro. 
 
Figure 4. Time stamp sequence of a discriminated unit and mathematically simulated RC 
integration.   
 
Figure 5. Change of spike rates and burst rates (n= 68 units) under increasing penicillin G 
concentrations. Volume of penicillin G solutions added averaged at 40 µl to a total bath 
volume of 2000 µl.  
 
Figure 6A – 6C. Dose Response curves of streptomycin generated in three individual 
experiments.  
 
Figure 7A/B. Dose Response curves of pen/strep generated in two individual experiments. 
 
Figure 8A/B. Dose Response curves of gentamicin generated in two individual experiments.  
 
Figure 9A – 9D. Dose Response curves of vancomycin generated in four individual 
experiments.  
 
Figure 10A – 10D. Concentration/activity change dependence under penicillin in four 
individual experiments: 10 A) – 10 C) under bicuculline, 10 D) without bicuculline. 
 
Figure 11. The change of burst frequency values under the influence of pen/strep followed by 
a media change. 
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Figure 12. Number of active neurons versus bursting neurons per minute (n=50) under the 
influence of different streptomycin concentrations in [µM] and intermittent media changes. 
Volume of streptomycin solutions added ranged from 20 µl to 100 µl to a total bath volume of 
2000 µl.  
 
Figure 13. Change of spike rates and burst rates (n= 68 units) under increasing penicillin G 
concentrations. Volume of penicillin G solutions added averaged at 40 µl to a total bath 
volume of 2000 µl.  
 
Figure 14A – 14F. Change of burst parameters: A) burst amplitude, B) burst duration, C) 
bursting neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of 
penicillin G (n= 68 units). Volume of penicillin G solutions added averaged at 40 µl to a total 
bath volume of 2000 µl. All variables are mean values derived from averaging all burst 
measurement per minute across all units. 
 
Figure 15. Step-wise decrease of spike rates and burst rates (n= 69 units) under increasing 
pen/strep concentrations with reversibility after medium change. Volume of pen/strep 
solutions added ranged from 20 µl to 100 µl to a total bath volume of 2000 µl.  
 
Figure 16A – 16F. Change of burst parameters: A) burst amplitude, B) burst duration, C) 
bursting neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of 
pen/strep (n= 69 units) followed by a medium change. Volume of pen/strep solutions added 
ranged from 20 µl to 100 µl to a total bath volume of 2000 µl. All variables are mean values 
derived from averaging all burst measurement per minute across all units. 
 
Figure 17. Change of spike rates and burst rates (n= 16 units) under increasing streptomycin 
concentrations with reversibility after medium change. Volume of streptomycin solutions 
added ranged from 20 µl to 100 µl to a total bath volume of 2000 µl. 
 
Figure 18A – 18F. Change of burst parameters: A) burst amplitude, B) burst duration, C) 
bursting neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of 
pen/strep (n= 16 units) followed by a medium change. Volume of pen/strep solutions added 
ranged from 20 µl to 100 µl to a total bath volume of 2000 µl. All variables are mean values 
derived from averaging all burst measurement per minute across all units. 
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 Figure 19. Change of spike rates and burst rates (n= 27 units) under increasing gentamicin 
concentrations with reversibility after medium change. Volume of gentamicin solutions added 
ranged from 20 µl to 40 µl to a total bath volume of 2000 µl. 
 
Figure 20A – 20F. Change of burst parameters: A) burst amplitude, B) burst duration, C) 
bursting neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of 
pen/strep (n= 27 units) followed by a medium change. Volume of gentamicin solutions added 
ranged from 20 µl to 40 µl to a total bath volume of 2000 µl. All variables are mean values 
derived from averaging all burst measurement per minute across all units. 
 
Figure 21. Change of spike rates and burst rates (n= 23 units) under increasing vancomycin 
concentrations followed by a medium change. Volume of vancomycin solutions added 
averaged at 60 µl to a total bath volume of 2000 µl. 
 
Figure 22A – 22F. Change of burst parameters: A) burst amplitude, B) burst duration, C) 
bursting neurons, D) spikes in bursts, E) burst period, F) Burst Hz - under the influence of 
vancomycin (n= 23 units) followed by a medium change. Volume of vancomycin solutions 
added averaged at 60 µl to a total bath volume of 2000 µl. All variables are mean values 
derived from averaging all burst measurement per minute across all units. 
 
Table 1. IC50 values of individual antibiotics.  
 
Table 2. Levels of burst rate, burst period and spikes in burst of individual antibiotics defined 
as the quotient between burst rate, burst period or spikes in burst values under IC50 
concentrations and values under medium change.  
 
Table 3. Levels of bursting neurons and active neurons of individual antibiotics defined as the 
quotient between bursting neuron or active neuron values under IC50 concentrations and 
values under medium change.  
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Chapter 8 
 
 
Summary of the thesis 
 
1 General introduction 
 
The objective of this thesis was to study new strategies to prevent post-operative medical 
device-associated infections and new concepts for the on demand treatment of already 
manifested medical device-associated infections. Chapter 1 provides a general introduction 
into the classification of biomaterials with the focus on vascular grafts and surgical sutures. 
The complex process of infection is highlighted and in particular, post-operative, neuronal 
and medical device-associated infections are discussed. The key events initiating biomaterial-
associated infection are the adherence of pathogens like Staphylococcus aureus or 
Staphylococcus epidermidis on the surface of biomaterials and the subsequent biofilm 
formation triggered by quorum sensing signals controlling the complex structure of biofilm 
communities. Biofilm phenotypic pathogens show an increased antibiotic and host defence 
resistance presenting a major challenge for a successful treatment of device-related infections. 
Today graft explantation in combination with the pre-, peri and postoperative administration 
of antibiotics and antiseptics is surgical goldstandard.  
 
2 The anti-infective equipment and characterization of 
PTFE grafts for the prevention of post-operative infection 
 
In chapter 2 commercially available PTFE grafts were equipped with various biodegradable 
drug delivery systems and characterized for drug release, anti-infective potency, 
biocompatibility and haemocompatibility. PTFE grafts with a diameter of 6 mm were coated 
with gentamicin and teicoplanin incorporated in different lipid-like carriers under aseptic 
conditions with a dipping method. Poly-D, L-lactic acid, tocopherol acetate, the diglyceride 
Softisan®649 and the triglyceride Dynasan®118 were used as drug carriers. All coatings 
showed an initial drug burst followed by a low continuous drug release within 96 hours. 
Release kinetics depended on the carrier used. In pathologically relevant bacterial 
concentrations, the developed drug-carrier coatings achieved a bacterial eradication rate of 
100 %. This shows a highly effective potency against S. aureus colonization. Even in a 
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concentration hundredfolds beyond maximal pathologically relevant bacterial concentration, 
S. aureus growth could strongly be reduced after 24 hours by each of the developed drug-
carrier coatings. Coatings with incorporated teicoplanin showed an insignificant smaller 
growth inhibition effect than coatings with gentamicin. Bacterial adhesion after 24 hours of 
incubation in a 2 x 106 cfu/ml S. aureus suspension could effectively be reduced by drug-
carrier-coated prostheses compared to uncoated ones. Different cytotoxic levels investigated 
with the cell proliferation assay WST 1 with fibroblasts L929 from mouse connective tissue 
could be observed bringing up tocopherol acetate as the most promising biocompatible 
carrier. Tests with oil red O reagent show that the diglyceride Softisan®649 is incorporated in 
the cell soma which apparently leads to cell death. In order to assess haemocompatibility, 
tromboelastography studies, ELISA assays and an amidolytic substrate assay to detect 
markers of the activated coagulation and complement system were carried out. Excellent 
haemocompatible characteristics of all coatings were assessed. The development and in vitro 
studies of described biodegradable drug delivery systems highlighted the most important 
requirements for an effective as well as compatible anti-infective equipment of PTFE grafts. 
Through continuous local release, high drug levels can be obtained at only the targeted area, 
demonstrating that bacterial proliferation can completely be inhibited while at the same time 
biocompatibility as well as haemocompatibility can be ensured. 
 
3 Anti-infective coatings of surgical sutures based on a 
combination of antiseptics and fatty acids  
 
The anti-infective equipment of commercially available PGA surgical sutures was subject of 
chapter 3. Synthetic absorbable PGA surgical sutures were antimicrobially equipped with one 
type of chlorhexidine dipalmitate coating, two types of chlorhexidine dilaurate coatings and 
two types of octenidine hydrochloride coatings. For octenidine hydrochloride the fatty acid 
palmitic acid was used as drug carrier. Within one coating type, coatings differed only in the 
drug weight per unit length. Suture coating was performed by dip-coating procedures. 
Individual anti-infective coatings were characterized by drug release, anti-infective 
characteristics and biocompatibility studies. Drug release studies showed a continuous drug 
release in PBS at 37 °C within 96 hours which is a basic requirement for an effective anti-
infective protection. The gap between the amount of released drug after 96 hours and the 
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remaining drug amount on the surface of developed sutures revealed a high potential for a 
long-term anti-infective protection in the body. 
A reduction of the number of adhered pathogens on the suture surface as well as the inhibition 
of S. aureus growth in suspension was assessed by all investigated coating types. All 
chlorhexidine and octenidine coated sutures showed superior anti-infective characteristics in 
comparison to the clinically well-established Vicryl Plus®. Biocompatibility studies revealed 
a higher cytotoxic potential of developed suture coatings than Vicryl Plus®.  
We conclude that developed anti-infective suture coatings consisting of lipid based drug 
delivery systems in combination with antiseptics are highly effective against bacterial 
colonization in vitro, however antiseptic doses have to be adjusted to comply with 
biocompatibility. 
 
4 Growth inhibition of Staphylococcus aureus induced by 
low-frequency electric and electro-magnetic fields 
 
In many areas of medicine as for example in the magnet resonance tomography or the magnetic 
stimulation of brain areas strong magnetic fields are applied. In therapeutic procedures 
magnetic field therapy is often used for the improvement of bone fracture healing. The so-
called Kraus-Lechner procedure is based on the interaction of low-frequency nonthermal 
sinusoidal electro-magnetic fields with bone and cartilage tissue and it is often applied to badly 
healing bone fractures of non-unions. Clinical observations have shown that in infected 
pseudarthrosis this technology improves bone healing and decreases bone infections. 
Nowadays there are no data of low-frequent electromagnetic fields based on the Kraus-Lechner 
techniques and similar electric fields on the influence on bacterial growth. Methodical 
investigations of the effect of different kinds of applied fields on bacterial growth have not 
been elucidated before as previous studies mostly focused on one specific electric or 
electromagnetic field effect. 
The study of chapter 4 focused on the impact of different electric and electromagnetic fields 
on the growth of S. aureus by in vitro technologies as a new perspective for the treatment of 
device-associated infections. Cultures of S. aureus in fluid and gel-like media were exposed to 
a low-frequency electromagnetic field, an electromagnetic field combined with an additional 
electric field, a sinusoidal electric field and a static electric field. 
In gel-like media no significant difference between colony-forming units of exposed samples 
and non-exposed references was detected. In contrast to these data, all four applied fields 
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revealed a significant effect on growth of S. aureus in fluid media within the observation 
period of 24 hours. Depending on the applied field growth inhibition from 18 % using a 
sinusoidal electric field (470 mV/cm, 20 Hz) and 37 % using a constant electric field 
(588 mV/cm) could be observed. These investigations demonstrated a reduction of S. aureus 
growth in fluid media under field influence within 24 hours. Observations about the influence 
of low-frequency electromagnetic fields on bacterial growth corroborate data in clinical 
situations of bone infections during magnetic field therapy and is of high interest for the 
treatment of medical device-associated infections. 
 
5 The investigation of the influence of low-frequency 
electromagnetic fields on antibiotic susceptibility of 
Staphylococcus aureus 
 
The aim of chapter 5 was to increase antibiotic susceptibility of S. aureus by the application of 
low-frequency electromagnetic fields as a new perspective for the on demand treatment of 
already manifested medical device-associated infections. Cultures of S. aureus in fluid and 
gel-like media in presence of gentamicin were exposed to a low-frequency electro-magnetic 
field, an electro-magnetic field combined with an additional electric field, a sinusoidal 
alternating electric field and a direct current electric field.  
No significant difference between sample and reference was detected in gel-like media. Low 
dose gentamicin application corresponding to 0.25 MIC under the influence of the four applied 
fields showed a statistically significant bacterial growth inhibition effect in fluid media. 
Depending on the type of field applied, an improvement of gentamicin efficacy from 32 % 
using a clinically applied electromagnetic field (5 mT, 20 Hz) up to 92 % using a direct current 
field of 588 mV/cm was observed. 
In general, we have been able to demonstrate an additional statistically significant reduction 
of S. aureus growth in the presence of gentamicin under the influence of all applied fields in 
fluid media. The strongest effect of augmented gentamicin efficacy could be shown by the 
application of the direct current field. We assume that this effect is caused by electrolysis-
induced radicals. Formed hydroxyl and oxygen radicals are known to destroy cell membranes 
of bacteria. This so-called bioelectric effect may facilitate the penetration of antibiotic drugs 
and could be an explanation for the detected efficacy augmentation of gentamicin. We 
conclude that the combination of antibiotic treatment with low-frequency electro-magnetic 
fields could offer new therapeutic strategies in biomaterial-associated infection therapy. 
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6 Magnetic drug targeting for biomaterial infections 
 
In chapter 6 new antimicrobially equipped ultra-small superparamagnetic iron oxides 
(USPIO) were developed and characterized. The antimicrobial equipment of USPIOs 
institutes the possibility to enrich high antibiotic concentrations on the surface of vascular 
grafts with the help of a magnetic drug targeting system. These USPIOs usually consist of an 
iron oxide (Fe3O4) core surrounded by an organic shell like dextrans, fatty acids or starch 
molecules. The antibiotic gentamicin was ionically and covalently linked to the organic shell. 
Individual USPIOs were characterized and compared among each other. All gentamicin-
functionalized nanoparticles did not show drug release in PBS at 37 °C within 90 minutes. 
Selected coated nanoparticles reduced S. aureus growth even beyond pathologically relevant 
concentrations within 24 hours. Excellent concentration-independent biocompatibility was 
assessed for ferrofluids of choice. The enrichment of developed USPIOs at the surface of 
model tubes in circulatory experiments under physiologically comparable conditions was 
investigated. Magnetic nanoparticles could be concentrated on the surface of model grafts 
under optimized parameters. The development and in vitro studies of described magnetic drug 
targeting system presented a new perspective in the treatment of vascular graft infection. With 
the help of a strong external magnetic field drug-functionalized nanoparticles can be 
concentrated at the surface of infected grafts ensuring high drug levels to fend off biofilm 
embedded pathogens. 
7 Functional neurotoxicity of individual antibiotics 
investigated with mammalian neuronal networks grown 
on microelectrode neuroarray  
 
In order to elucidate the local application of antibiotics in combination with biomaterials used 
in brain surgery, the functional neurotoxicity of individual antibiotics applied in neurosurgery 
was investigated with mammalian neuronal networks grown on microelectrode neuroarrays. 
In chapter 7 frontal cortex tissue was harvested from time-pregnant ICR mice at embryonic 
day sixteen. Obtained embryos were decapitated and the frontal lobe of the extracted brains 
was dissected in a trapezoidal pattern. After various preparations, cells were seeded onto the 
recording matrix area of microelectrode neuroarrays. Cultures were ready for use usually 
three weeks to three months after seeding. Networks developed from a mixture of different 
types of postmitotic neurons and glia cells.  
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Penicillin G, streptomycin, penicillin/streptomycin, gentamicin and vancomycin were studied 
for functional neurotoxic effects. Compounds were added to mammalian frontal cortex 
neuronal networks cultivated on microelectrode neuroarrays. Neuronal activity was recorded 
and suppression of action potential production regarding dose response curves and IC50 levels, 
the determination of different burst parameter and the drop out of individual cells were 
investigated. A step-wise activity decrease under the influence of studied antibiotics was 
observed. The IC50 averaged between 37 M for streptomycin and 2371 M for gentamicin. 
The investigation of burst parameters focusing on burst frequency, burst period and spikes in 
bursts corroborate the different characters of used antibiotics regarding functional toxicity. 
The drop out of individual cells and the comparison between active neurons and bursting 
neurons under compound influence unsheathe a higher loss of active neurons than bursting 
neurons under streptomycin and vancomycin. A vice versa effect is observed under pen/strep 
and gentamicin while penicillin G does not influence this balance. In this study we 
demonstrated an approach to in vitro characterize individual antibiotics for functional 
neurotoxicity. The utilization of mammalian neuronal networks on microelectrode 
neuroarrays was therefore a good method for the investigation of compounds close to 
physiological conditions. New data on dose response, IC50 concentrations and the impact on 
the neuronal activity pattern could be obtained for an advanced understanding of how 
antibiotics influence the information transmittance in neuronal ensembles. 
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